

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Can traditional risk factors explain the higher risk of cardiovascular disease in South Asians compared to Europeans in Norway and New Zealand? Two cohort studies

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-016819
Article Type:	Research
Date Submitted by the Author:	13-Mar-2017
Complete List of Authors:	Rabanal, Kjersti; Nasjonalt folkehelseinstitutt, Domain for Mental and Physical Health Meyer, Haakon; Norwegian Institute of Public Health, Epidemiology Tell, Grethe; University of Bergen, Department of Global Public Health and Primary Care Igland, Jannicke; Faculty of Medicine and Dentistry, University of Bergen, Global Public Health and Primary Care Pylypchuk, Romana; University of Auckland, Epidemiology and Biostatistics, School of Population Health Mehta, Suneela; University of Auckland, Epidemiology and Biostatistics, School of Population Health Kumar, Bernadette; Oslo University Hospital, Norwegian Center for Minority Health Research Jenum, Anne; University of Oslo, Selmer, Randi; Norwegian Institute of Public Health, Department of Pharmacoepidemiology Jackson, Rod; University of Auckland, Epidemiology and Biostatistics
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Cardiovascular medicine, Public health
Keywords:	cardiovascular disease, risk factors, South Asians, ethnicity, prospective, cohort

SCHOLARONE™
Manuscripts

1
2
3
4
5
6 **Can traditional risk factors explain the higher risk of cardiovascular disease in South Asians compared to Europeans in Norway and New**
7 **Zealand? Two cohort studies**
8

9 Kjersti S Rabanal^a, Haakon E Meyer^{a,b}, Grethe S Tell^{c,d}, Jannicke Igland^d, Romana Pylypchuk^e, Suneela Mehta^e, Bernadette Kumar^f, Anne Karen
10 Jenum^g, Randi M Selmer^a, Rod Jackson^e
11

12
13
14 ^a Domain for Mental and Physical Health, Norwegian Institute of Public Health, Oslo, Norway

15 ^b Department of Community Medicine, Institute of Health and Society, University of Oslo, Oslo, Norway

16 ^c Domain for Health Data and Digitalisation, Norwegian Institute of Public Health, Bergen, Norway

17 ^d Department of Global Public Health and Primary Care, University of Bergen, Norway

18 ^e School of Population Health, University of Auckland, Auckland, New Zealand

19 ^f Norwegian Center for Minority Health Research, Oslo, Norway

20 ^g Institute of Health and Society, Faculty of Health and Society, University of Oslo, Oslo, Norway
21
22
23
24
25
26
27
28

29 **Corresponding author**

30 Kjersti S Rabanal

31 Address: Norwegian Institute of Public Health, P.O. Box 4404, Nydalen, 0403 Oslo, Norway

32 Telephone number: +47 22078118

33 E-mail: kjersti.stormark.rabanal@fhi.no, kjersti.rabanal@hotmail.com
34
35

36 Wordcount, abstract: 297

37 Wordcount, manuscript text: 4137
38
39

40 Keywords: cardiovascular disease, risk factors, South Asians, ethnicity, prospective, cohort
41
42
43
44
45

ABSTRACT

Objectives The objective was to prospectively examine potential differences in the risk of first cardiovascular disease (CVD) events between South Asians and Europeans living in Norway and New Zealand, and to investigate whether traditional risk factors could explain any differences.

Methods We included participants (30-74 years) without prior CVD in a Norwegian (n=16 606) and a New Zealand (n=129 449) cohort. Ethnicity and cardiovascular risk factor information was linked with hospital registry data and cause of death registries to identify subsequent CVD events. We used Cox proportional hazards regression to investigate the relationship between risk factors and subsequent CVD for South Asians and Europeans, and to calculate age-adjusted hazard ratios (HRs) for CVD in South Asians versus Europeans in the two cohorts separately. We sequentially added the major CVD risk factors (blood pressure, lipids, diabetes and smoking) to study their explanatory role in observed ethnic CVD risk differences.

Results South Asians had higher total cholesterol (TC)/high density lipoprotein (HDL) ratio and more diabetes at baseline than Europeans, but lower blood pressure and smoking levels. South Asians had increased age-adjusted risk of CVD compared to Europeans (87-92% higher in the Norwegian cohort and 42-75% higher in the New Zealand cohort) and remained with significantly increased risk after adjusting for all major CVD risk factors. Adjusted HRs for South Asians versus Europeans in the Norwegian cohort were 1.57; 95% CI 1.19-2.07 in men and 1.76; 95% CI

1
2
3
4
5 1.09-2.82 in women. Corresponding figures for the New Zealand cohort were 1.64; 95% CI 1.43-1.88 in men and 1.39; 95% CI 1.11-1.73 in
6
7 women.

8
9
10 **Conclusion** Differences in TC/HDL ratio and diabetes appear to explain some of the excess risk of CVD in South Asians compared to Europeans.
11
12 Preventing dyslipidaemia and diabetes in South Asians may help reduce their excess risk of CVD.
13
14

15 16 17 18 19 **Strengths and limitations of this study**

- 20
21 • This is one of few prospective investigations of cardiovascular disease and its risk factors in South Asian populations living in Western
22 countries.
23
- 24
25 • A special feature is the inclusion of prospective data from two different countries enhancing the external validity of the findings.
26
27
- 28
29 • The two cohorts differed in how participants were recruited and how information about risk factor levels was collected at baseline.
30
- 31
32 • A limited number of South Asians in the Norwegian cohort and short follow up time in the New Zealand cohort restricted the statistical
33 power in our analyses.
34
35
36
37
38
39
40
41
42
43
44
45

INTRODUCTION

Immigrants from South Asia (countries in the Indian subcontinent such as India, Pakistan, Sri-Lanka and Bangladesh) who have settled in Western countries have increased risk of cardiovascular disease (CVD) compared to their host populations of European origin[1]. This excess risk has been documented in several countries, especially the increased risk of coronary heart disease (CHD)[2-4]. We recently found that South Asian immigrants in Norway had more than two-fold higher risk of acute myocardial infarction (AMI) than ethnic Norwegians and an increased risk of stroke (26% higher in men and 58% higher in women)[5]. Collaborators in New Zealand found a higher risk of CVD in Indians compared to the European New Zealand population[6].

The mechanisms underlying the increased risk of CVD in South Asian populations are mostly unknown[1]. Few studies have examined the prospective relationship between CVD risk factors and subsequent CVD among South Asians[4, 7-9], and there are few cohort studies including ethnic minority groups in Europe[10]. The two large and multinational case-control studies, Interheart[11] and Interstroke,[12] indicate that different populations share the same risk factors and that the relationship between risk factors and CVD is similar in different populations around the world. The Interheart study also concluded that the earlier age of AMI in South Asians can be largely attributed to higher risk factor levels at younger ages[13]. In both Norway and New Zealand, South Asians have been found to have similar or higher mean total cholesterol (TC) to high density lipoprotein (HDL) ratio and higher prevalence of diabetes compared to the European majority populations[14-17]. However, they also have lower levels of smoking (especially in women) and mean systolic blood pressure (SBP) than the European majority

1
2
3
4
5 populations. Whether the higher risk of CVD among South Asians in Norway and New Zealand is due to higher levels of certain risk factors have
6
7 not previously been studied.
8

9
10 Due to the dearth of prospective data on the relationship between risk factors and CVD among South Asians, we aimed to prospectively
11
12 examine possible differences in the risk of a first CVD event between South Asians and Europeans using cohort studies from Norway and New
13
14 Zealand, and to examine whether traditional CVD risk factors could explain such differences. Since the two cohorts differ in several aspects we
15
16 do not intend to compare the two cohorts directly, but mainly focus on within-country comparisons.
17
18

19 20 21 **MATERIAL AND METHODS**

22 23 **The New Zealand PREDICT-CVD cohort**

24
25 We used data from the PREDICT-CVD cohort, collected through use of the PREDICT web-based decision support program in New Zealand for
26
27 the assessment and management of CVD risk during primary health care consultations[18]. The study methods and data definitions are
28
29 described in detail elsewhere[18, 19]. In short, the software has been integrated with commonly used primary care management systems, and
30
31 allows systematically coded CVD risk data to be automatically and anonymously extracted from patients' electronic medical records and
32
33 augmented where required by primary care staff[18, 19]. The cardiovascular profile data was subsequently linked, using an encrypted national
34
35 health identifier number to national and regional health datasets with information about hospitalisations, deaths, publicly funded drug
36
37 dispensing and laboratory test claims and results[19].
38
39
40
41
42
43
44
45
46
47
48
49

1
2
3
4
5 The PREDICT software is used in around 35% of New Zealand primary care practices mainly in the Auckland and Northland regions,[19] which
6
7 serve around 1.7 million people, representing around 37 % of the New Zealand population[20]. Any patient with their CVD risk assessed by a
8
9 general practitioner (GP) or practice nurse into online PREDICT-CVD forms are included in the PREDICT cohort.
10
11

12
13 New Zealand CVD risk management guidelines recommend that all men over 45 years and all women over 55 years have a regular CVD risk
14
15 assessment[21]. Specified high-CVD risk groups, including those of South Asian ethnicity, are recommended to undergo a risk assessment ten
16
17 years earlier than the general population.
18
19

20
21 We used PREDICT data from August 2002 until September 2012. Members of the cohort were enrolled and examined continuously throughout
22
23 this period via their contact with the primary health care. We included individuals aged 30 to 74 years since the dataset was comprised of
24
25 people undergoing a risk assessment based on a Framingham risk score intended for people in this age group[22]. Using information from the
26
27 GP, hospital discharges and medication dispensing, we excluded persons with a history of CVD (CHD (including angina), stroke, TIA, peripheral
28
29 vascular disease (PVD), percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)), or atrial fibrillation at baseline
30
31 (n=24 537), and people with overt renal disease, those who had eGFR \leq 29 and those with prior hospitalisations for congestive heart failure or
32
33 who were on loop diuretics at baseline (n=1582). Only subjects with European or Indian background were included. The risk factor
34
35 measurements in the PREDICT cohort were extracted from a standardised electronic template that primary care practitioners completed. The
36
37 SBP was based on the mean of the last two recordings done by the GP or practice nurse, in most cases with a manual mercury
38
39
40
41
42
43
44
45
46
47
48
49

1
2
3
4
5 sphygmomanometer. Blood lipid and glucose or HbA1c measurements were carried out in the community laboratories routinely used by
6
7
8 general practitioners and smoking status and other risk factor data was measured using a standard questionnaire completed by a primary care
9
10 practitioner.

11 12 13 **Cohort of Norway**

14
15 We included participants from three surveys conducted during 2000-2002 in Oslo, Norway; The Oslo Health Study (HUBRO), The Oslo
16
17 Immigrant Health Study (I-HUBRO) and The Romsås in Motion study (MoRo II) (n=26 709), which are part of the Cohort of Norway
18
19 (CONOR)[23]; a collection of health data and blood samples from several Norwegian health surveys. Participation rates for the three studies
20
21 were 40-46%[23].
22
23

24
25 All CONOR surveys followed the same standard procedure for collection of data from self-administered questionnaires, physical measurements
26
27 and blood samples. The CONOR questionnaire provided information on self-reported diabetes, smoking, use of blood pressure and/or lipid
28
29 lowering medication and family history of CVD. All participants attended a clinical examination and non-fasting venous blood samples were
30
31 drawn. SBP was measured by an automatic device (DINAMAP, Criticon, Tampa, FL,USA) after 2 minutes of seated resting. Three recordings
32
33 were made at 1-min intervals. For the analyses we used the average of the second and third SBP measurements. The blood samples were
34
35 subsequently measured for total cholesterol (TC) and HDL cholesterol[23].
36
37
38
39
40
41
42
43
44
45

1
2
3
4
5 Using an 11-digit personal identifier, CONOR data were linked to hospitalizations and deaths in the Cardiovascular Disease in Norway (CVDNOR)
6
7 project, 1994-2009[24,25]. This enabled us to follow CONOR participants for CVD outcomes (hospitalizations or deaths) occurring after CONOR
8
9 examination through December 31st 2009.
10

11
12 We included participants aged 30-74 years old at baseline (n=3 871 excluded) to ensure comparable samples between the Norwegian and New
13
14 Zealand data. We excluded participants not born in Norway or South Asia (n=5 651 excluded), pregnant women (n=197), and participants with
15
16 prior CVD ((coronary heart disease (CHD), cerebrovascular disease, atherosclerotic disease, transient ischemic attack (TIA) and heart failure
17
18 (HF)) (n=353) or atrial fibrillation (n=31) registered in the hospital data before screening.
19
20
21

22 23 **Outcomes**

24
25 In both cohorts, we identified the first CVD event (non-fatal and fatal) using main or secondary diagnoses from hospital discharge data or the
26
27 underlying cause of death from national mortality statistics. The International Classification of Diseases (ICD) codes (versions 9 and/or 10) were
28
29 used to define outcome variables. New Zealand hospitals used an Australian modification of the ICD-10 classification called ICD10-AM[26].
30
31

32
33 CVD in the Norwegian cohort included the codes: ICD9: 410-414, 428, 430-438, 440, 441 except 441.7, 442, 443.9, 444; ICD10:I20-I25, I50, I60-
34
35 I69, I70-I79, G45. The CVD variable in the New Zealand PREDICT cohort also included some additional ICD10-codes (I469, J81, G460-G468, Z951,
36
37 Z955, Z958, Z959) plus a list of procedure codes (too many to be listed here). The PREDICT CVD outcome has been described elsewhere[19].
38
39
40
41
42

Ethnicity

Ethnicity in the New Zealand PREDICT data was based on two sources: 1) the PREDICT template filled in by the GP and 2) the National Health Index dataset, both according to pre-defined categories. A prioritising algorithm was used to agree on one ethnicity in case of multiple ethnicities recorded. The system for coding ethnicity in New Zealand enables identification of Indian people, who account for approximately 90% of South Asian people living in New Zealand. The remaining South Asian ethnic groups are classified as part of the “Other Asian” ethnic group in national health data and so could not be included here. Indian people can include both immigrants and individuals who have been born in New Zealand with parents (or older generations) who have immigrated. The majority of this group are immigrants since 76.5% of the people who identified themselves with the Indian ethnic group in New Zealand in 2013 were born overseas[27].

For the Norwegian cohort, we used country of birth merged into larger world regions to define ethnicity[28]. We defined South Asians as individuals who migrated to Norway from Bangladesh, Myanmar, Sri Lanka, Pakistan, India or Nepal[28]. The largest share of South Asians in this dataset (95%) came from the HUBRO or the I-HUBRO study. HUBRO and I-HUBRO combined included 1145 Sri Lankans and 780 Pakistanis,[29] indicating that about 50% of the South Asian group (n=2206) in the present study are Sri Lankans and 35% are Pakistanis.

1
2
3
4
5 In general, we refer to the ethnic groups as South Asians (South Asians in Norway and/or Indians in New Zealand) and Europeans (ethnic
6
7
8 Norwegians and/or New-Zealanders with ethnic European origin). Most European New Zealanders are of British and Irish ancestry, of whom
9
10 about three quarters were born in New Zealand.

11 12 13 **Statistical analysis**

14
15 Baseline characteristics are reported as mean values with standard deviations for continuous variables and fractions for categorical variables.
16
17 We tested the differences between the ethnic groups adjusted for age by analysis of covariance. We used Cox regression models to examine
18
19 the prospective relationship between baseline risk factors (blood pressure, lipids, diabetes and smoking) and time until subsequent first CVD
20
21 event. People were censored if they died from other causes. Cox regression was also used to calculate hazard ratios (HRs) for CVD in South
22
23 Asians versus Europeans using ethnicity as the exposure variable and adjusting for risk factors. Proportional hazards assumptions were tested
24
25 using scaled Schoenfeld residuals[30]. All analyses were stratified by sex and ethnicity. Only complete cases were included in the analyses.
26
27
28
29 Stata 14 was used for analyses in the Norwegian data and Stata 11 for analysis in the New Zealand data.

30
31
32 To check whether the use of BP medication at baseline would impact the analyses where SBP were included, we repeated the Cox regression
33
34 analyses excluding people using antihypertensive medication at baseline. Correspondingly, we also repeated the Cox-regression analyses for
35
36
37 TC/HDL ratio without people using lipid lowering medication at baseline.
38
39
40
41
42
43
44
45

Ethics

The current project was approved by the Regional Committee for Medical Research Ethics, Health Region West. Each individual CONOR study was approved by the Norwegian Data Inspectorate and evaluated by the Regional Committee for Medical Research ethics[31]. The PREDICT study was approved by the Northern Region Ethics Committee Y in 2003 (AKY/03/12/134), and later annually approved by the National Multi Region Ethics Committee since 2007 (MEC07/19/EXP)[19]. Both datasets contained anonymized data.

RESULTS

Baseline characteristics

The final study sample from the New Zealand cohort consisted of 129 449 individuals (43% women) of European (87%) or Indian ethnicity (13%) with no history of CVD, atrial fibrillation or renal disease. Correspondingly for the Norwegian cohort, the final study sample consisted of 16 606 individuals (54% women) born in either Norway (87%) or South Asia (13%) with no history of CVD or atrial fibrillation.

At baseline, the Norwegian cohort was younger than the New Zealand cohort, and New Zealand women were older than New Zealand men (Table 1). In both cohorts, South Asians were younger than Europeans.

Table 1. Baseline characteristics (unadjusted) of the Norwegian and New Zealand participants. Participants free of prior CVD.

	<i>Norwegian cohort</i>		<i>Women</i>	
	<i>Norwegian</i>	<i>South Asian</i>	<i>Norwegian</i>	<i>South Asian</i>
<i>N</i>	6 385	1 239	8 015	967
<i>Age (years)</i>	43.7 (11.2)	41.4 (7.8)	43.9 (10.9)	40.3 (7.9)
<i>Age range</i>	30.0 – 70.1	30.0 - 67.8	30.0 – 74.9	30.0 - 65.5
<i>TC (mmol/L)</i>	5.60 (1.1)	5.48 (1.0)	5.41 (1.0)	4.98 (0.9)
<i>HDL cholesterol (mmol/L)</i>	1.31 (0.3)	1.07 (0.2)	1.62 (0.4)	1.24 (0.3)
<i>TC/HDL ratio</i>	4.55 (1.4)	5.33 (1.4)	3.52 (1.1)	4.22 (1.2)
<i>SBP (mmHg)</i>	132.6 (14.4)	126.6 (13.2)	124.0 (15.7)	119.1 (15.6)
<i>Diastolic blood pressure (mmHg)</i>	77.6 (10.8)	76.9 (9.8)	71.5 (10.3)	70.0 (10.1)
<i>Hypertension[†] (%)</i>	30	22	19	16
<i>Diabetes (%)</i>	1.6	8.7	1.4	10.9
<i>Former smokers (%)</i>	28	16	26	2
<i>Current smokers (%)</i>	26	25	31	1
<i>Family history of heart disease* (%)</i>	33	24	37	27
<i>Family history of stroke[#] (%)</i>	11	3	13	4
<i>Antihypertensive treatment (%)</i>	6	8	6	9
<i>Lipid lowering treatment (%)</i>	4	6	3	6
<i>Follow-up time (years)</i>	8.44 (1.4)	7.65 (1.4)	8.54 (1.2)	7.88 (1.1)
		<i>Men</i>		<i>Women</i>
		<i>European</i>		<i>Indian</i>
<i>N</i>	63 319	9 997	49 094	7 039
<i>Age (years)</i>	55.0 (9.3)	47.4 (9.7)	58.7 (8.7)	52.9 (8.5)
<i>Age range</i>	30.0 - 74.0	30.0 - 74.0	30.0 - 74.0	30.0 - 74.0
<i>TC (mmol/L)</i>	5.36 (1.1)	5.09 (1.1)	5.68 (1.1)	5.04 (1.0)
<i>HDL cholesterol (mmol/L)</i>	1.29 (0.4)	1.14 (0.3)	1.59 (0.5)	1.30 (0.3)
<i>LDL cholesterol (mmol/L)</i>	3.3 (1.0)	2.9 (1.0)	3.4 (1.1)	2.8 (0.9)
<i>TC/HDL ratio</i>	4.35 (1.3)	4.60 (1.3)	3.68 (1.1)	3.93 (1.1)
<i>SBP (mmHg)</i>	131.5 (16.3)	125.3 (16.1)	131.6 (17.4)	126.1 (17.4)

Diastolic blood pressure (mmHg)	80.5 (10.0)	79.1 (10.4)	78.8 (9.7)	77.4 (9.8)
Hypertension [†] (%)	40	34	44	39
Type 2 diabetes [§] (%)	9	24	9	29
Former smokers (%)	19	6	16	1
Current smokers (%)	12	9	10	1
Family history of CVD [§] (%)	12	8	15	10
Antihypertensive treatment (%)	24	26	30	32
Lipid lowering treatment (%)	18	27	18	27
Follow-up time (years)	2.94 (2.3)	2.93 (2.0)	2.92 (2.3)	2.83 (1.9)

Data are mean values (SD) for continuous variables and prevalence (%) for categorical variables. [†]Hypertension is defined as having systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg or using blood pressure medication.

HDL, high density lipoprotein; LDL, low density lipoprotein; SBP, systolic blood pressure, TC, total cholesterol. *Parents or siblings have had heart attack or angina pectoris (self-report).

[#]Parents or siblings have had stroke (self-report). [§]The diabetes variable in the New Zealand data includes people with diabetes of unknown type (5%) and type 2 diabetes (95%), while in the Norwegian data we could not differentiate between different types of diabetes. [§]Family history of CVD in the New Zealand data: self-reported familial history of ischemic heart disease or ischemic stroke occurring in a father or brother <55 years of age, or a mother or sister <65 years of age

South Asians had lower levels of TC and HDL and higher mean levels of TC/HDL ratios than Europeans in both Norway and New Zealand. South Asians also had the lowest SBP levels (Table 1). These differences persisted after adjustment for age ($p < 0.05$ for differences between ethnic groups – results not shown).

The diabetes baseline prevalence was higher among South Asians compared to Europeans in both cohorts (Table 1). The difference in diabetes were the same after adjustment for age ($p < 0.001$). Antihypertensive and lipid lowering treatments were generally more prevalent among South Asians than Europeans, and more prevalent in the New Zealand cohort compared to the Norwegian cohort. Cigarette smoking was more

1
2
3
4
5 common among Europeans than South Asians, and practically none of the South Asian women smoked. Mean follow up time was significantly
6
7 longer in the Norwegian cohort than in the New Zealand cohort (Table 1).
8

9 10 **CVD events**

11
12 During follow-up, we observed 743 new CVD events among the 16 606 individuals in the Norwegian cohort (139 470 person-years) and 2 654
13
14 CVD events among 129 446 individuals in the New Zealand cohort (378 874 person-years). The overall crude rates were 533 per 100 000
15
16 person-years in the Norwegian cohort and 700 per 100 000 person-years in the New Zealand cohort. Ethnic specific rates and age-adjusted
17
18 HRs, for men and women in the two cohorts are shown in the Appendices (tables A1-A4).
19
20
21
22

23 **Prospective associations between risk factors and CVD**

24
25 Increasing age was significantly associated with risk of CVD in both ethnic groups in both cohorts (Table 2). The age effect was very similar
26
27 within the countries for both ethnic groups and gender, but was stronger in the Norwegian cohort compared to the New Zealand cohort. After
28
29 adjustment for age, the traditional CVD risk factors were positively associated with CVD in both ethnic groups, across gender and country.
30
31 Whereas all the risk factor-CVD event associations were statistically significant in Europeans, the 95% CIs were wider and the results not always
32
33 statistically significant among South Asians. The relationship between SBP, TC/HDL ratio, smoking and subsequent CVD appeared to be weaker
34
35 in Indian men compared to European men in the New Zealand cohort. The prospective association between the risk factors and CVD changed
36
37 little after adjusting for the other risk factors in addition to age (results not shown). In the sensitivity analyses where we excluded people using
38
39
40
41
42
43
44
45
46
47
48
49

BP- and lipid lowering medication at baseline, the estimates for the prospective associations between risk factors and CVD were similar as in the main analyses. However, for women in the New Zealand cohort, after excluding people on lipid-lowering medication, the HR for TC/HDL ratio changed to 1.12; 95% CI 0.91-1.39 for Indian women and to 1.20; 95% CI 1.12-1.27 for European women.

Table 2. Age-adjusted hazard ratios for first CVD event after baseline for selected risk factors in men and women aged 30-74 years with no history of CVD, stratified by cohort, ethnicity and gender.

MEN							
	N events/N[‡]	Age (one year)	SBP (10 mm/Hg)	DBP (10 mm/Hg)	TC/HDL ratio (one unit)	Diabetes (yes/no)	Current smoking (yes/no)
<i>New Zealand cohort</i>		HR (95%CI)	HR (95%CI)	HR (95%CI)	HR (95%CI)	HR (95%CI)	HR (95%CI)
European men	1518/63316	1.07 (1.06-1.07)	1.15 (1.12-1.18)	1.16 (1.10-1.22)	1.20 (1.16-1.23)	1.92 (1.68-2.19)	2.29 (2.02-2.59)
Indian men	273/9997	1.06 (1.05-1.07)	1.05 (0.98-1.13)	1.02 (0.91-1.14)	1.08 (0.98-1.19)	1.72 (1.34-2.20)	1.45 (0.99-2.11)
<i>Norwegian cohort</i>							
Norwegian men	379/6385	1.10 (1.09-1.11)	1.15 (1.08-1.22)	1.19 (1.08-1.30)	1.22 (1.15-1.30)	3.15 (2.14-4.65)	1.86 (1.51-2.29)
South Asian men	79/1239	1.11 (1.08-1.14)	1.17 (1.01-1.35)	1.21 (0.97-1.51)	1.23 (1.05-1.42)	1.61 (0.90-2.86)	1.43 (0.88-2.30)
WOMEN							
	N events/N[‡]	Age (one year)	SBP(10 mm/Hg)	DBP (10 mm/Hg)	TC/HDL ratio (one unit)	Diabetes (yes/no)	Current smoking (yes/no)
<i>New Zealand cohort</i>		HR (95%CI)	HR (95%CI)	HR (95%CI)	HR (95%CI)	HR (95%CI)	HR (95%CI)
European women	757/49094	1.06 (1.05-1.07)	1.09 (1.05-1.13)	1.13 (1.05-1.22)	1.14 (1.09-1.21)	1.93 (1.59-2.35)	2.74 (2.30-3.27)
Indian women	106/7039	1.06 (1.03-1.08)	1.27 (1.16-1.39)	1.25 (1.03-1.50)	1.21 (1.03-1.41)	2.29 (1.55-3.37)	2.60 (0.64-10.59)
<i>Norwegian cohort</i>							
Norwegian women	259/8015	1.10 (1.09-1.12)	1.20 (1.12-1.28)	1.32 (1.18-1.47)	1.30 (1.19-1.43)	2.79 (1.52-5.11)	2.22 (1.73-2.84)
South Asian women	26/967	1.14 (1.09-1.19)	1.06 (0.86-1.30)	1.07 (0.74-1.55)	1.04 (0.77-1.39)	2.74 (1.21-6.22)	†

[‡]The numbers of events and people included in the analyses may differ due to missing risk factor data. Few were missing in the NZ cohort. [†] Not calculated due to no exposed cases.

DBP, diastolic blood pressure; HDL, high density lipoprotein; SBP, systolic blood pressure; TC, total cholesterol.

Ethnic difference in CVD

South Asians of both genders in Norway and New Zealand had increased risk of CVD compared to the European majority populations (Table 3), being respectively 92% and 87% higher in South Asian men and women in Norway, and 75% and 42% higher in South Asian men and women in New Zealand. After adjustment for TC/HDL ratio and diabetes, the HRs for South Asians versus Europeans were reduced and no longer significant in women. Additional adjustments for SBP and smoking increased the hazard ratios again so that South Asians in both countries had significantly increased risk of CVD compared to Europeans. In the Norwegian cohort, South Asians had 57% and 76% higher risk than Europeans in men and women respectively after adjustment for age, TC/HDL ratio, diabetes, SBP and smoking. The corresponding excess risk after full adjustment was 64% for men and 39% for women in South Asians vs Europeans in the New Zealand cohort.

Table 3. Hazard ratios (95% CI) for first CVD event in South Asian groups compared to ethnic European groups in Norway and New Zealand.

	Men		Women	
	South Asians vs. Norwegians*	Indian vs. European NZ*	South Asians vs. Norwegians*	Indian NZ vs. European NZ*
<i>N events/N Adjusted for</i>	436/7387	1791/73308	264/8558	8631/56126
Age	1.92 (1.48-2.49)	1.75 (1.53-2.00)	1.87 (1.21-2.87)	1.42 (1.16-1.75)
Age, TC/HDL ratio	1.66 (1.27-2.16)	1.77 (1.55-2.02)	1.52 (0.98-2.36)	1.41 (1.14-1.73)
Age, TC/HDL ratio, diabetes	1.42 (1.08-1.87)	1.49 (1.30-1.71)	1.30 (0.82-2.04)	1.15 (0.92-1.42)
Age, TC/HDL ratio, diabetes, SBP	1.53 (1.16-2.01)	1.57 (1.37-1.80)	1.31 (0.83-2.07)	1.19 (0.96-1.47)
Age, TC/HDL ratio, diabetes, SBP, smoking	1.57 (1.19-2.07)	1.64 (1.43-1.88)	1.76 (1.09-2.82)	1.39 (1.11-1.73)

HDL, high density lipoprotein; NZ, New Zealand; SBP, systolic blood pressure; TC, Total cholesterol.

All had complete information on the risk factors

1
2
3
4
5 After excluding people using lipid lowering medication in the sensitivity analyses for table 3, the HRs were more attenuated when adding
6
7 TC/HDL ratio to the age-adjusted model than before the exclusion, especially for men in the New Zealand cohort (HRs: 1.61; 95%CI 1.36-1.91 in
8
9 men and 1.38; 95% CI 1.06-1.79 in women).

12 13 **DISCUSSION**

14
15 This study confirmed that the traditional risk factors SBP, TC/HDL ratio, diabetes and smoking are all positively associated with risk of CVD in
16
17 South Asians as well as in Europeans. The present study also confirmed that South Asians had an increased risk of CVD compared to Europeans
18
19 and that ethnic differences in the distribution of TC/HDL ratio and type 2 diabetes appear to explain some of this excess risk.

20
21 The main strengths of this study are the prospective study design, and inclusion of data from two countries. Unfortunately, we lacked
22
23 information about duration of stay for the immigrants and the ethnic groups that we studied are heterogeneous.

24
25
26
27
28 Strengths of CONOR data are the standardized measurements of risk factors, the linkage with disease outcomes from comprehensive national
29
30 health registers and the standardized way of defining ethnicity using country of birth. A validation study examining the Oslo Health study,
31
32 showed that participants with a non-western background had a lower participation rate than others[32]. This may reflect self-selection which
33
34 can work both ways; healthy and resourceful people have the energy and motivation to participate or less healthy people who think their
35
36 health could benefit from participating do so. Self-selection is unlikely to influence associations between risk factors and subsequent disease,
37
38 but could influence the ethnic comparisons if the mechanisms were systematically different for the ethnic groups. The South Asian group in the
39
40
41
42

1
2
3
4
5 Norwegian cohort was relatively small, which reduced the precision of the estimates and limited the statistical power. Another limitation in the
6
7 CONOR data is missing information on some of the risk factors (see tables A1-A2 in the appendices for numbers of missing).
8
9

10 Strengths of the PREDICT cohort are the large sample size and the completeness of risk factors included in the risk-assessment. Furthermore,
11
12 comprehensive national health registers were used to identify and exclude people with prior CVD and to determine cardiovascular outcomes.
13
14 In the New Zealand cohort, some recruitment bias is likely since risk assessment was initially prioritized for high-risk patients. The
15
16 representativeness of the source population is, however, improving as PREDICTs coverage increases. In this study, follow-up extended to 2012
17
18 when PREDICT included 50% of guideline-eligible patients in the practices where the PREDICT software is used[33]. We did not assume that the
19
20 cohorts were representative of the general populations in the two countries, but that the ethnic groups within the two cohorts should be
21
22 comparable. Results from the two cohorts showed approximately the same regarding ethnic differences, which is a strength concerning the
23
24 external validity of these results. A limitation in the New Zealand data is short follow-up time restricting the statistical power. Another
25
26 limitation is the lack of standardized BP measurements since recorded BP can easily be affected by a range of factors including the type of
27
28 device used[34].
29
30
31
32
33
34

35 In both cohorts, the endpoints are based on register data, including both hospital and mortality data, which enables almost complete
36
37 ascertainment of CVD events. In New Zealand, more than 95% of patients with an acute CVD event are managed by government-funded health
38
39 services[19]. However, CVD events occurring among participants who travelled outside of New Zealand, those who emigrated after the index
40
41
42
43
44
45

1
2
3
4
5 CVD risk assessment or among participants treated in private hospitals would not be captured in the national hospital and mortality
6 registers[19]. We have no information about possible emigration for the New Zealand cohort, but for the Norwegian cohort we know that few
7
8 people have emigrated (about 1% of the ethnic Norwegians and <3% of the South Asians who participated in the Oslo health studies had
9
10 emigrated by the end of follow-up).
11
12
13

14
15 Our finding that the traditional major CVD risk factors contribute to the development of CVD in South Asians as in Europeans was an expected,
16
17 yet important, finding since most knowledge about CVD prevention is based on studies in populations of European descent, and some have
18
19 questioned whether these risk factors apply worldwide[11, 35]. This finding is in line with the large INTERHEART and INTERSTROKE case-control
20
21 studies[11, 12], which reported that 90% of the population attributable risk for AMI and stroke worldwide was accounted for by respectively
22
23 nine and ten (similar) risk factors, including those included in the present study. We are only aware of two other prospective studies reporting
24
25 HRs for the prospective relationship between major CVD risk factors and subsequent CVD in South Asians[7, 36]. One of these studies included
26
27 only men,[7] and the other showed estimates for men and women combined and did not include blood lipids[36]. These studies generally agree
28
29 with our findings that traditional risk factors contribute to the development of CVD in South Asians as in Europeans[7, 36]. Also, consistent with
30
31 previous reports[5, 6], we found that South Asians in both Norway and New Zealand have a higher risk of CVD compared to the European
32
33 majority populations. By including all the measured risk factors (BP, TC/HDL ratio, diabetes and smoking) as adjustment variables in one
34
35
36
37
38
39
40
41
42
43
44
45

1
2
3
4
5 statistical model, we could not explain the higher risk of CVD in South Asians. However, the increased risk was attenuated when we only
6
7 included the risk factors more prevalent in South Asians than in Europeans (TC/HDL ratio and diabetes).
8
9

10 The excess risk of CVD among South Asians compared to Europeans in the Norwegian cohort was almost two-fold. This is comparable to what
11 we reported previously when studying the total Norwegian population[5]. The South Asians in the New Zealand cohort had 42-75% higher risk
12 of CVD compared to European New Zealanders which also agrees with previous New Zealand studies [6]. In both the Norwegian and New
13 Zealand data, South Asians had higher baseline levels of dyslipidemia indicated by the TC/HDL ratio and higher diabetes prevalence compared
14 to the European majority populations, which is in general agreement with previous knowledge from these countries[14-16]. Attenuation of the
15 excess risk in South Asians versus Europeans was best achieved in the Cox model only including diabetes and TC/HDL ratio as covariates in
16 addition to age. The same was found in both cohorts, clearly indicating that the unfavorable distribution of blood lipids and type 2 diabetes
17 explains some of the higher risk of CVD in South Asians. South Asians generally have a high prevalence of metabolic risk factors related to
18 insulin resistance, often clustered so that they match the concept of the metabolic syndrome[37-40]. A British cohort study that tested
19 whether traditional risk factors could account for the high mortality of CHD among South Asian men compared to European men, reported that
20 adjusting for insulin resistance, dyslipidemia and hyperglycemia in South Asians did not explain their higher risk[7]. However, they also adjusted
21 for smoking and total cholesterol, which were both less prevalent/lower among South Asian men compared to European men.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

1
2
3
4
5 It is unclear why the traditional risk factors do not completely explain the excess risk of CVD in South Asians. This could be related to
6
7 incomplete adjustments; due to either imprecise measurement of risk factors or that other important risk factors were not included (e.g. waist
8
9 measurement, length of time since diabetes diagnosis). A number of non-conventional risk factors are also thought to partially account for the
10
11 high risk of CVD in South Asians, including dysfunctional HDL, C-Reactive Protein, thrombogenic risk factors, telomere length, high
12
13 homocysteine levels and low birth weight[41, 42]. Socioeconomic factors could probably also explain some of the differences in risk between
14
15 the ethnic groups, but we did not have such variables. Another possibility is that risk factors work cumulatively over time in the development of
16
17 atherosclerosis, and some risk factors may also work at specific and crucial time points during the life course. Measurements taken on single
18
19 occasions may also lead to an underestimation of the strength between the *usual* levels of the risk factors and later disease, known as the
20
21 regression dilution bias[43]. Consequently, it is unlikely that the ethnic differences would disappear completely by adjusting for selected risk
22
23 factors measured once in midlife.
24
25
26
27
28

29 Although South Asians seem to have an underlying susceptibility for metabolic diseases, traditional and modifiable risk factors are important
30
31 for preventing disease. Our analyses indicate that it is important to focus on the prevention of type 2 diabetes and dyslipidaemia when aiming
32
33 to reduce the burden of CVD among South Asians. The additional effect of abdominal obesity for the risk of CVD among South Asians in Norway
34
35 and New Zealand has, however, not yet been studied although we know that the prevalence is high in this ethnic group[38, 44]. In both
36
37 Norway[45, 46] and New Zealand,[47] intervention studies targeting immigrants from South Asia have been carried out with some promising
38
39
40
41
42
43
44
45

1
2
3
4
5 results. A UK-study that prospectively examined the influence from four health behaviors on the risk of CVD in South Asian immigrants and UK
6
7 Europeans found an important potential for disease prevention among South Asians if they adhered to healthy behaviors[8].
8
9

10 11 12 **CONCLUSION**

13
14 Ethnic differences in distribution of TC/HDL ratio and type 2 diabetes explained some, but not all, the excess risk of CVD in South Asians
15
16 compared to Europeans in Norway and New Zealand. Smoking and elevated BP were less prevalent among South Asians and thus could not
17
18 explain any of the observed differences in risk of CVD. Targeted diabetes and dyslipidaemia management among South Asians, including
19
20 support for healthy lifestyle choices, should be a priority if the high burden of CVD in these ethnic populations is to be reduced.
21
22
23
24
25
26
27

28 **Acknowledgements**

29
30 The authors thank Tomislav Dimoski at the Norwegian Knowledge Centre for Health Services, Oslo, Norway for his contribution by developing
31
32 software necessary for obtaining data from Norwegian hospitals, conducting the data collection and quality assurance of data in this project.
33
34 We also wish to thank Dr. Geeta Gala and Dr Roshini Peiris-John, members of the South Asian governance group for the University of Auckland
35
36 VIEW research team, for reviewing the paper and giving us their feedback.
37
38
39
40
41
42
43
44
45
46
47
48
49

1
2
3
4
5 **Competing interests:** All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf. Dr. Jackson and Dr.
6
7 Mehta both report grants from Health Research Council of New Zealand. All other co-authors declare to have no competing interests.
8

9
10 **Funding:** This work was supported by the Norwegian Extra-Foundation for Health and Rehabilitation (grant number 2012-2-0129).
11

12
13 **Contributors:** HEM, RJ and GST contributed to the conception and design of the work. RJ, BK, AKJ and GST contributed to the collection of data.
14
15
16 JI, RP and SM contributed to data preparations and definition of endpoints. KRS drafted the paper and carried out the data analyses. All authors
17
18 contributed to the interpretation of data as well as critical reading and revision of the draft.
19

20
21 **Data sharing statement:** No additional data are available.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

REFERENCES

1. Zaman MJ, Bhopal RS. New answers to three questions on the epidemic of coronary mortality in south Asians: incidence or case fatality? Biology or environment? Will the next generation be affected? *Heart* 2013;99(3):154-8.
2. Bo A, Zinckernagel L, Krasnik A et al. Coronary heart disease incidence among non-Western immigrants compared to Danish-born people: effect of country of birth, migrant status, and income. *Eur J Prev Cardiol* 2015;22(10):1281-9
3. Hedlund E, Lange A, Hammar N. Acute myocardial infarction incidence in immigrants to Sweden. Country of birth, time since immigration, and time trends over 20 years. *Eur J Epidemiol* 2007;22(8):493-503.
4. Tillin T, Hughes AD, Mayet J, et al. The Relationship Between Metabolic Risk Factors and Incident Cardiovascular Disease in Europeans, South Asians, and African Caribbeans: SABRE (Southall and Brent Revisited)—A Prospective Population-Based Study. *J Am Coll Cardiol*. 2013;61(17):1777-1786.
5. Rabanal KS, Selmer RM, Iglund J et al. Ethnic inequalities in acute myocardial infarction and stroke rates in Norway 1994-2009: a nationwide cohort study (CVDNOR). *BMC Public Health* 2015;15:1073.
6. Ministry of Health, *Asian Health Chart Book 2006*. 2006: Wellington: Ministry of Health
7. Forouhi N, Sattar N, Tillin T et al. Do known risk factors explain the higher coronary heart disease mortality in South Asian compared with European men? Prospective follow-up of the Southall and Brent studies, UK. *Diabetologia*, 2006;49(11):2580-2588.
8. Eriksen A, Tillin T, O'Connor L et al. The impact of health behaviours on incident cardiovascular disease in Europeans and South Asians—a prospective analysis in the UK SABRE study. *PLoS one*, 2015;1:15.
9. de Munter JS, Agyemang C, Stronks K et al, Association of physical activity, smoking, and alcohol intake with CVD-related hospital discharge in people of European, South Asian, or African descent. *Eur J Prev Cardiol* 2013;20(1):80-8.
10. Ranganathan M and Bhopal R. Exclusion and inclusion of nonwhite ethnic minority groups in 72 North American and European cardiovascular cohort studies. *PLoS medicine*, 2006;3(3):e44.
11. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet* 2004;364(9438):937-52.
12. O'Donnell MJ, Xavier D, Liu L et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. *Lancet* 2010;376(9735):112-23.
13. Joshi P, Islam S, Pais P et al, Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. *Jama* 2007;297(3):286-94
14. Perumal L, Wells S, Ameratunga S et al. Markedly different clustering of CVD risk factors in New Zealand Indian and European people but similar risk scores (PREDICT-14). *Aust N Z J Public Health* 2012;36(2):141-4.
15. Jenun A, Diep LM, Holmboe-Ottesen G et al. Diabetes susceptibility in ethnic minority groups from Turkey, Vietnam, Sri Lanka and Pakistan compared with Norwegians - the association with adiposity is strongest for ethnic minority women. *BMC Public Health* 2012;12(1):150.
16. Rabanal KS, Lindman AS, Selmer RM et al. Ethnic differences in risk factors and total risk of cardiovascular disease based on the Norwegian CONOR study. *Eur J Prev Cardiol* 2013;20(6):1013-1021.

- 1
- 2
- 3
- 4
- 5 17. Kumar B, Selmer R, Lindman AS et al. Ethnic differences in SCORE cardiovascular risk in Oslo, Norway. *Eur J Cardiovasc Prev Rehabil* 2009;16:229 -
- 6 234.
- 7 18. Bannink L, Wells S, Broad J et al. Web-based assessment of cardiovascular disease risk in routine primary care practice in New Zealand: the first
- 8 18,000 patients (PREDICT CVD-1). *N Z Med J* 2006; 119(1245):U2313.
- 9 19. Wells S, Riddell T, Kerr A et al. Cohort Profile: The PREDICT Cardiovascular Disease Cohort in New Zealand Primary Care (PREDICT-CVD 19). *Int J*
- 10 *Epidemiol* 2015:dyy312.
- 11 20. Statistics New Zealand. Subnational population estimates tables. Wellington: Statistics New Zealand. 2014.
- 12 21. New Zealand Guideline Group. The assessment and Management of Cardiovascular Risk. 2003: Wellington, New Zealand
- 13 22. Anderson KM, Odell PM, Wilson PW et al. Cardiovascular disease risk profiles. *Am Heart J* 1991;121(1):293-298.
- 14 23. Næss Ø, Sjøgaard AJ, Arnesen et al. Cohort Profile: Cohort of Norway (CONOR). *Int J Epidemiol* 2008; 37(3):481-485.
- 15 24. Sulo G, Iglund J, Vollset SE et al. Cardiovascular disease and diabetes mellitus in Norway during 1994-2009 CVDNOR - a nationwide research project.
- 16 *Norsk epidemiologi* 2013;23(1).
- 17 25. Sulo G, Iglund J, Nygård O et al. Favourable trends in incidence of AMI in Norway during 2001–2009 do not include younger adults: a CVDNOR
- 18 project. *Eur J Prev Cardiol* 2014;21.11:1358-64.
- 19 26. Ministry of Health. ICD-10-AM/ACHI/ACS. Wellington: Ministry of Health. September 25 2015]; Available from: [http://www.health.govt.nz/nz-](http://www.health.govt.nz/nz-health-statistics/classification-and-terminology/icd-10-am-achi-acs)
- 20 [health-statistics/classification-and-terminology/icd-10-am-achi-acs](http://www.health.govt.nz/nz-health-statistics/classification-and-terminology/icd-10-am-achi-acs).
- 21 27. Statistics New Zealand. Tauranga Aotearoa. 2013 Census. Ethnic group profile: Indian. Retrived 11.09.2015 from:
- 22 [http://www.stats.govt.nz/Census/2013-census/profile-and-summary-reports/ethnic-](http://www.stats.govt.nz/Census/2013-census/profile-and-summary-reports/ethnic-profiles.aspx?request_value=24743&parent_id=24726&tabname=#)
- 23 [profiles.aspx?request_value=24743&parent_id=24726&tabname=#](http://www.stats.govt.nz/Census/2013-census/profile-and-summary-reports/ethnic-profiles.aspx?request_value=24743&parent_id=24726&tabname=#) 2013.
- 24 28. Norwegian Institute of Public Health. Documentation of the CONOR file. Version 02.07.2012. 14.12.2016]; Available from:
- 25 <https://www.fhi.no/globalassets/migrering/dokumenter/pdf/documentation-of-the-conor-file.pdf>
- 26 29. Kumar B, Grøtvedt L, Meyer H et al. The Oslo immigrant health profile, in Rapport 2008:7. Oslo: Norwegian Institute of Public Health 2008.
- 27 30. Schoenfeld D. Partial residuals for the proportional hazards regression model. *Biometrika*. 1982;69(1)239-41.
- 28 31. Sogaard A. Cohort Norway (CONOR): Materials and methods: Norwegian Institute of Public Health; 2007. Available from:
- 29 <http://www.fhi.no/studier/cohort-of-norway>.
- 30 32. Sogaard A, Selmer R, Bjertness E et al. The Oslo Health Study: The impact of self-selection in a large population-based survey. *Int J Equity Health*.
- 31 2004;3(3):1-12.
- 32 33. Ministry of Health. How is my PHO performing? 2014/15 Quarter 3 (January to March) results. Wellington: Ministry of Health 2015 [February 5
- 33 2015]. Available from: <http://www.health.govt.nz/new-zealand-health-system/health-targets/how-my-pho-performing>.
- 34 34. Tolonen H, Koponen P, Naska A et al. Challenges in standardization of blood pressure measurement at the population level. *BMC Med Res Methodol*
- 35 2015;15:33.
- 36 35. Pais P, Pogue J, Gerstein H et al. Risk factors for acute myocardial infarction in Indians: a case-control study. *Lancet*. 1996;348(9024):358-63.
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49

- 1
2
3
4
5 36. Williams ED, Stamatakis E, Chandola T et al. Physical activity behaviour and coronary heart disease mortality among South Asian people in the UK: an observational longitudinal study. *Heart*. 2011;97(8):655-9.
- 6
7 37. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation*. 2009;120(16):1640-5.
- 8
9 38. Misra A and Khurana L. The metabolic syndrome in South Asians: epidemiology, determinants, and prevention. *Metab Syndr Relat Disord* 2009;7(6):497-514.
- 10
11 39. McKeigue P, Shah B, Marmot M. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. *Lancet*. 1991;337(8738):382-6..
- 12
13 40. Hjellset VT, Bjorge B, Eriksen HR et al, Risk factors for type 2 diabetes among female Pakistani immigrants: the InvaDiab-DEPLAN study on Pakistani immigrant women living in Oslo, Norway. *J Immigr Minor Health*, 2011;13(1):101-10.
- 14
15 41. Ahmed E, El-Menyar A. South Asian Ethnicity and Cardiovascular Risk The Known, the Unknown, and the Paradox. *Angiology* 2015;66(5):405-15.
- 16
17 42. Nair M, Prabhakaran D. Why Do South Asians Have High Risk for CAD? *Glob Heart*. 2012;7(4):307-14.
- 18
19 43. MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. *Lancet*. 1990;335(8692):765-74.
- 20
21 44. Kumar B, Meyer H, Wandel M et al. Ethnic differences in obesity among immigrants from developing countries, in Oslo, Norway. *Int J Obes*. 2006;30:684-90.
- 22
23 45. Telle-Hjellset V, Raberg Kjollesdal MK, Bjorge B et al. The InnvaDiab-DE-PLAN study: a randomised controlled trial with a culturally adapted education programme improved the risk profile for type 2 diabetes in Pakistani immigrant women. *Br J Nutr*. 2013;109(3):529-38.
- 24
25 46. Andersen E, Hostmark AT, Holme I, Anderssen SA. Intervention effects on physical activity and insulin levels in men of Pakistani origin living in Oslo: a randomised controlled trial. *J Immigr Minor Health*. 2013;15(1):101-10.
- 26
27 47. Rush EC, Chandu V, Plank LD. Reduction of abdominal fat and chronic disease factors by lifestyle change in migrant Asian Indians older than 50 years. *Asia Pac J Clin Nutr*. 2007; 16(4):671-676.
- 28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Appendix

Table A1. Crude rates and age-adjusted HR of CVD by risk factors, Norwegian and South Asian men from the Norwegian cohort.

	Norwegian				South Asian			
	No. of persons	No. of CVD events	Crude rate/100 000 person-years (95% CI)	HR (95% CI)	No. of persons	No. of CVD events	Crude rate/100 000 person-years (95% CI)	HR (95% CI)
Total	6385	379	703 (636-778)		1239	79	833 (668-1039)	
Diabetes								
No	6167	339	649 (583-721)	1.00	1088	59	704 (545-908)	1.00
Yes	101	28	3936 (2718-5701)	3.15 (2.14-4.65)	103	16	2166 (1327-3536)	1.61 (0.90-2.86)
Missing	117	12	539 (298-973)		48	4	1110 (416-2956)	
SBP								
<140	4701	198	493 (429-566)	1.00	1068	56	682 (525-886)	1.00
140-159	1373	130	1150 (969-1366)	1.39 (1.10-1.74)	150	19	1681 (1072-2636)	1.44 (0.83-2.49)
>160	296	51	2228 (1693-2932)	1.76 (1.28-2.42)	21	4	2865 (1075-7634)	1.51 (0.53-4.28)
Missing	15	0			0	0		
TC/HDL ratio								
<5	4284	207	568 (495-650)	1.00	538	21	499 (325-765)	1.00
≥ 5	2090	170	980 (843-1139)	1.64 (1.34-2.00)	698	58	1105 (854-1430)	2.14 (1.30-3.52)
Missing	11	2	2328 (582-9307)		3	0		
TC								
< 5 mmol/L	1930	68	410 (324-520)	1.00	407	19	609 (389-955)	1.00
≥ 5 mmol/L	4444	309	830 (742-927)	1.17 (0.90-1.53)	830	60	945 (734-1217)	1.49 (0.89-2.49)
Missing	11	2	2328 (582-9307)		2	0		
HDL								
< 1.00 mmol/L	1032	78	915 (733-1142)	1.00	525	34	855 (611-1197)	1.00
≥ 1.00 mmol/L	5343	299	660 (589-739)	0.61 (0.47-0.78)	711	45	821 (613-1099)	0.99 (0.63-1.55)
Missing	10	2	2608 (652-10427)		3	0		
Current daily smokers								
No	4706	231	578 (508-657)	1.00	905	52	749 (571-983)	1.00
Yes	1660	146	1062 (903-1248)	1.86 (1.51-2.29)	302	25	1088 (735-1610)	1.43 (0.88-2.30)
Missing	19	2	1236 (309-4941)		32	2	831 (208-3323)	

CI, confidence interval; CVD, cardiovascular disease; HDL, high density lipoprotein; HR, hazard ratio; TC, total cholesterol; SBP, systolic blood pressure

APPENDIX

Table A2. Crude rates and age-adjusted HR of CVD by risk factors, Norwegian and South Asian women from the Norwegian cohort.

	Norwegian				South Asian			
	No. of persons	No. of CVD events	Crude rate/100 000 person-years (95% CI)	HR (95% CI)	No. of persons	No. of CVD events	Crude rate/100 000 person-years (95% CI)	HR (95% CI)
Total	8015	259	378 (335-427)		967	26	341 (232-501)	
Diabetes								
No	7657	237	361 (318-410)	1.00	816	17	262 (163-422)	1.00
Yes	105	11	1305 (723-2356)	2.79 (1.52-5.11)	100	9	1212 (630-2329)	2.74 (1.21-6.22)
Missing	253	11	539 (298-973)		51	0		
SBP								
<140	6823	151	257 (219-302)	1.00	876	18	260 (164-412)	1.00
140-159	920	76	999 (798-1251)	1.82 (1.37-2.43)	67	4	774 (291-2062)	1.45 (0.48-4.34)
>160	266	31	1450 (1020-2062)	2.11 (1.42-3.15)	23	4	2378 (892-6335)	2.42 (0.76-7.71)
Missing	6	1	2128 (300-15106)		1	0		
TC/HDL ratio								
<5	7225	203	328 (286-376)	1.00	749	17	287 (178-462)	1.00
≥ 5	781	54	833 (638-1088)	1.79 (1.33-2.42)	215	9	537 (279-1032)	1.46 (0.65-3.30)
Missing	9	2	3122 (781-12483)			0		
TC								
< 5 mmol/L	3004	44	169 (125-227)	1.00	524	8	193 (97-386)	1.00
≥ 5 mmol/L	5002	213	503 (440-576)	1.40 (1.00-1.97)	440	18	521 (328-826)	1.54 (0.65-3.64)
Missing	9	2	3122 (781-12483)		3	0		
HDL								
< 1.2 mmol/L	1057	52	587 (447-770)	1.00	465	12	329 (187-578)	1.00
≥1.2 mmol/L	6949	205	344 (300-395)	0.55 (0.40-0.74)	499	14	354 (210-598)	0.77 (0.36-1.69)
Missing	9	2	3122 (781-12483)		3	0		
Current daily smokers								
No	5461	134	285 (241-338)	1.00	883	24	344 (231-514)	1.00
Yes	2510	119	564 (471-675)	2.22 (1.73-2.84)	13	0		
Missing	44	6	1759 (790-3916)		71	2	365 (91-1461)	

CI, confidence interval; CVD, cardiovascular disease; HDL, high density lipoprotein; HR, hazard ratio; TC, total cholesterol; SBP, systolic blood pressure

APPENDIX

Table A3. Crude rates and age-adjusted HR of CVD by risk factors, European and Indian New Zealand men from the New Zealand cohort.

	European				Indian			
	No. of persons	No. of CVD events	Crude rate/100 000 person-years (95% CI)	HR (95% CI)	No. of persons	No. of CVD events	Crude rate/100 000 person-years (95% CI)	HR (95% CI)
Total	63 319	1 518	815 (775-857)		9 997	273	933 (828-1050)	
Type 2 diabetes								
No	57 760	1 241	728 (689-770)	1.00	7 641	158	712 (610-833)	1.00
Yes	5 559	277	1739 (1546-1957)	1.92 (1.68-2.19)	2 356	115	1622 (1351-1947)	1.72 (1.34-2.20)
Missing	0				0			
SBP								
<140	42 666	776	632 (589-678)	1.00	7 888	188	805 (698-929)	1.00
140-159	16 417	514	1030 (945-1123)	1.35 (1.20-1.51)	1 723	68	1431 (1128-1814)	1.37 (1.03-1.81)
>160	4 236	228	1675 (1471-1908)	2.03 (1.75-2.36)	386	17	1462 (909-2352)	1.22 (0.74-2.02)
Missing	0				0			
TC/HDL ratio								
<5	45 177	994	756 (711-805)	1.00	6 379	178	926 (799-1072)	1.00
≥ 5	18 139	524	955 (876-1040)	1.58 (1.42-1.76)	3 617	95	946 (774-1157)	1.28 (1.00-1.65)
Missing*	3	0			1	0		
TC								
< 5 mmol/L	20 226	395	879 (797-970)	1.00	4 450	103	841 (693-1020)	1.00
≥ 5 mmol/L	36 071	684	756 (702-815)	1.01 (0.89-1.14)	5 130	137	974 (824-1152)	1.36 (1.05-1.76)
Missing*	7 022	439	861 (785-946)		417	33	1114 (792-1567)	
HDL								
< 1.00 mmol/L	2 325	55	986 (757-1284)	1.00	561	15	1327 (800-2202)	1.00
≥1.00 mmol/L	10 920	323	891 (799-993)	0.87 (0.66-1.17)	1 231	39	1140 (833-1561)	0.62 (0.33-1.14)
Missing*	50 074	1 140	789 (744-836)		8 205	219	886 (776-1011)	
Current daily smokers								
No	55 587	1 197	733 (692-776)	1.00	9 105	242	913 (805-1035)	1.00
Yes	7 731	321	1396 (1252-1558)	2.29 (2.02-2.59)	892	31	1123 (790-1597)	1.45 (0.99-2.11)
Missing	1	0			0			

CI, confidence interval; CVD, cardiovascular disease; HDL, high density lipoprotein; HR, hazard ratio; TC, total cholesterol; SBP, systolic blood pressure. *The number of missing information is different for TC/HDL ratio than for TC and HDL separately. This is because the risk factors included in the PREDICT risk assessment (age, gender, smoking, diabetes, systolic BP and total cholesterol/HDL ratio) was compulsory for assessing risk. Risk factors not compulsory for risk assessment consequently have more missing information (e.g. the HDL and TC)

APPENDIX

Table A4. Crude rates and age-adjusted HR of CVD by risk factors, European and Indian New Zealand women from the New Zealand cohort.

	European				Indian			
	No. of persons	No. of CVD events	Crude rate/100 000 person-years (95% CI)	HR	No. of persons	No. of CVD events	Crude rate/100 000 person-years (95% CI)	HR
Total	49 094	757	528 (492-567)		7 039	106	531 (439-643)	
Type 2 diabetes								
No	44 880	635	485 (448-524)	1.00	5 010	50	358 (271-472)	1.00
Yes	4 214	122	994 (832-1187)	1.93 (1.59-2.35)	2 029	56	936 (720-1216)	2.29 (1.55-3.38)
Missing	0				0			
SBP								
<140	32 178	395	436 (395-481)	1.00	5 370	56	371 (285-482)	1.00
140-159	13 019	258	646 (572-730)	1.22 (1.04-1.44)	1 281	34	919 (656-1286)	2.11 (1.37-3.25)
>160	3 896	104	813 (671-985)	1.42 (1.14-1.77)	388	16	1388 (851-2266)	2.99 (1.70-5.29)
Missing	1	0			0			
TC/HDL ratio								
<5	42 800	626	507 (469-549)	1.00	5 895	89	527 (428-648)	1.00
≥ 5	6 289	131	658 (555-781)	1.42 (1.17-1.71)	1 143	17	559 (347-898)	1.11 (0.66-1.88)
Missing*	5	0			1	0		
TC								
< 5 mmol/L	10 940	127	515 (433-613)	1.00	3 277	57	639 (493-828)	1.00
≥ 5 mmol/L	32 974	415	516 (469-569)	0.96 (0.79-1.17)	3 515	37	398 (289-550)	0.62 (0.41-0.95)
Missing*	5 180	215	561 (491-641)		247	12	689 (391-1212)	
HDL								
< 1.2 mmol/L	1 852	26	529 (360-776)	1.00	568	9	781 (406-1501)	1.00
≥1.2 mmol/L	7 985	149	578 (492-678)	0.97 (0.64-1.47)	866	14	600 (355-1013)	0.75 (0.32-1.77)
Missing*	39 257	582	517 (477-561)		5 605	83	504 (406-625)	
Current daily smokers								
No	43 994	595	466 (430-505)	1.00	6 973	104	526 (434-638)	1.00
Yes	5 100	162	1038 (890-1211)	2.74 (2.30-3.27)	66	2	1090 (272-4357)	2.60 (0.64-10.0)
Missing	0				0			

CI, confidence interval; CVD, cardiovascular disease; HDL, high density lipoprotein; HR, hazard ratio; TC, total cholesterol; SBP, systolic blood pressure. *The number of missing information is different for TC/HDL ratio than for TC and HDL separately. This is because the risk factors included in the PREDICT risk assessment (age, gender, smoking, diabetes, systolic BP and total cholesterol/HDL ratio) was compulsory for assessing risk. Risk factors not compulsory for risk assessment consequently have more missing information (e.g. the HDL and TC).

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cohort studies

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1,2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-8
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6-8
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-9
Bias	9	Describe any efforts to address potential sources of bias	10
Study size	10	Explain how the study size was arrived at	6-8,11
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9-10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9-10
		(b) Describe any methods used to examine subgroups and interactions	9-10
		(c) Explain how missing data were addressed	10
		(d) If applicable, explain how loss to follow-up was addressed	10
		(e) Describe any sensitivity analyses	10
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	11
		(b) Give reasons for non-participation at each stage	We did not have information about reasons for non-participation in CONOR, but participation rates are given on page 7 and the possibility of self-selection bias is discussed on page 17. This was not relevant for the PREDICT cohort since it was based on contact with the primary health care.
		(c) Consider use of a flow diagram	Different persons were involved in the exclusion of participants, so it was easier to describe this process in text.
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	11-14
		(b) Indicate number of participants with missing data for each variable of interest	27-30 (Tables A1-A4 in the appendices)
		(c) Summarise follow-up time (eg, average and total amount)	12-13 (Table 1)
Outcome data	15*	Report numbers of outcome events or summary measures over time	14

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	15-16
		(b) Report category boundaries when continuous variables were categorized	13 (in table legend) and 26-29
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Sensitivity analyses are reported on page 15,17.
Discussion			
Key results	18	Summarise key results with reference to study objectives	17
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	17-22
Generalisability	21	Discuss the generalisability (external validity) of the study results	18
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	23

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Can traditional risk factors explain the higher risk of cardiovascular disease in South Asians compared to Europeans in Norway and New Zealand? Two cohort studies

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-016819.R1
Article Type:	Research
Date Submitted by the Author:	09-Jun-2017
Complete List of Authors:	Rabanal, Kjersti; Nasjonalt folkehelseinstitutt, Domain for Mental and Physical Health Meyer, Haakon; Norwegian Institute of Public Health, Epidemiology Tell, Grethe; University of Bergen, Department of Global Public Health and Primary Care Igland, Jannicke; Faculty of Medicine and Dentistry, University of Bergen, Global Public Health and Primary Care Pylypchuk, Romana; University of Auckland, Epidemiology and Biostatistics, School of Population Health Mehta, Suneela; University of Auckland, Epidemiology and Biostatistics, School of Population Health Kumar, Bernadette; Oslo University Hospital, Norwegian Center for Minority Health Research Jenum, Anne; University of Oslo, Selmer, Randi; Norwegian Institute of Public Health, Department of Pharmacoepidemiology Jackson, Rod; University of Auckland, Epidemiology and Biostatistics
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Cardiovascular medicine, Public health
Keywords:	cardiovascular disease, risk factors, South Asians, ethnicity, prospective, cohort

SCHOLARONE™
Manuscripts

1
2
3
4 **Can traditional risk factors explain the higher risk of cardiovascular disease in South Asians**
5 **compared to Europeans in Norway and New Zealand? Two cohort studies**
6

7 Kjersti S Rabanal^a, Haakon E Meyer^{a, b}, Grethe S Tell^{c, d}, Jannicke Igland^d, Romana Pylypchuk^e,
8 Suneela Mehta^e, Bernadette Kumar^f, Anne Karen Jenum^g, Randi M Selmer^a, Rod Jackson^e
9

10
11 ^a Domain for Mental and Physical Health, Norwegian Institute of Public Health, Oslo, Norway
12

13 ^b Department of Community Medicine, Institute of Health and Society, University of Oslo,
14 Oslo, Norway
15

16 ^c Domain for Health Data and Digitalisation, Norwegian Institute of Public Health, Bergen,
17 Norway
18

19 ^d Department of Global Public Health and Primary Care, University of Bergen, Norway
20

21 ^e School of Population Health, University of Auckland, Auckland, New Zealand
22

23 ^f Norwegian Center for Minority Health Research, Oslo, Norway
24

25 ^g Institute of Health and Society, Faculty of Health and Society, University of Oslo, Oslo,
26 Norway
27
28
29

30 **Corresponding author**

31 Kjersti S Rabanal

32 Address: Norwegian Institute of Public Health, P.O. Box 4404, Nydalen, 0403 Oslo, Norway

33 Telephone number: +47 22078118

34 E-mail: kjersti.stormark.rabanal@fhi.no, kjersti.rabanal@hotmail.com
35
36

37 Wordcount, abstract: 298

38 Wordcount, manuscript text: 4615
39
40

41 Keywords: cardiovascular disease, risk factors, South Asians, ethnicity, prospective, cohort
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives The objective was to prospectively examine potential differences in the risk of first cardiovascular disease (CVD) events between South Asians and Europeans living in Norway and New Zealand, and to investigate whether traditional risk factors could explain any differences.

Methods We included participants (30-74 years) without prior CVD in a Norwegian (n=16 606) and a New Zealand (n=129 449) cohort. Ethnicity and cardiovascular risk factor information was linked with hospital registry data and cause of death registries to identify subsequent CVD events. We used Cox proportional hazards regression to investigate the relationship between risk factors and subsequent CVD for South Asians and Europeans, and to calculate age-adjusted hazard ratios (HRs) for CVD in South Asians versus Europeans in the two cohorts separately. We sequentially added the major CVD risk factors (blood pressure, lipids, diabetes and smoking) to study their explanatory role in observed ethnic CVD risk differences.

Results South Asians had higher total cholesterol (TC)/high density lipoprotein (HDL) ratio and more diabetes at baseline than Europeans, but lower blood pressure and smoking levels. South Asians had increased age-adjusted risk of CVD compared to Europeans (87-92% higher in the Norwegian cohort and 42-75% higher in the New Zealand cohort) and remained with significantly increased risk after adjusting for all major CVD risk factors. Adjusted HRs for South Asians versus Europeans in the Norwegian cohort were 1.57; 95% CI 1.19-2.07 in men and 1.76; 95% CI 1.09-2.82 in women. Corresponding figures for the New Zealand cohort were 1.64; 95% CI 1.43-1.88 in men and 1.39; 95% CI 1.11-1.73 in women.

1
2
3 **Conclusion** Differences in TC/HDL ratio and diabetes appear to explain some of the excess
4
5 risk of CVD in South Asians compared to Europeans. Preventing dyslipidaemia and diabetes
6
7 in South Asians may therefore help reduce their excess risk of CVD.
8
9

10 11 12 13 **Strengths and limitations of this study**

- 14
15 • This is one of few prospective investigations of cardiovascular disease and its risk factors
16 in South Asian populations living in Western countries.
17
- 18
19 • A special feature is the inclusion of prospective data from two different countries
20 enhancing the external validity of the findings.
21
- 22
23 • The two cohorts differed in how participants were recruited and how information about
24 risk factor levels was collected at baseline.
25
- 26
27 • A limited number of South Asians in the Norwegian cohort and short follow up time in
28 the New Zealand cohort restricted the statistical power in our analyses.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Immigrants from South Asia (countries in the Indian subcontinent such as India, Pakistan, Sri Lanka and Bangladesh) who have settled in Western countries have increased risk of cardiovascular disease (CVD) compared to their host populations of European origin[1]. This excess risk has been documented in several countries, especially the increased risk of coronary heart disease (CHD)[2-4]. We recently found that South Asian immigrants in Norway had more than two-fold higher risk of acute myocardial infarction (AMI) than ethnic Norwegians and an increased risk of stroke (26% higher in men and 58% higher in women)[5]. Collaborators in New Zealand found a higher risk of CVD in Indians compared to the European New Zealand population[6].

The mechanisms underlying the increased risk of CVD in South Asian populations are mostly unknown[1]. Few studies have examined the prospective relationship between CVD risk factors and subsequent CVD among South Asians[4, 7-9], despite the urgent need for such studies being addressed for more than ten years ago[10]. The two large and multinational case-control studies, Interheart[11] and Interstroke,[12] indicate that different populations share the same risk factors and that the relationship between risk factors and CVD is similar in different populations around the world. The Interheart study also concluded that the earlier age of AMI in South Asians can be largely attributed to higher risk factor levels at younger ages[13]. However, the Interheart and Interstroke studies are both case-control studies. In both Norway and New Zealand, South Asians have been found to have similar or higher mean total cholesterol (TC) to high density lipoprotein (HDL) ratio and higher prevalence of diabetes compared to the European majority populations[14-17]. However, they also have lower levels of smoking (especially women) and mean systolic blood pressure (SBP) than the European majority populations. Whether the higher risk of CVD among South

1
2
3 Asians in Norway and New Zealand is due to higher levels of certain risk factors have not
4
5 previously been studied.
6
7

8
9 Due to the dearth of prospective data on the relationship between risk factors and CVD
10
11 among South Asians, we aimed to prospectively examine possible differences in the risk of a
12
13 first CVD event between South Asians and Europeans using cohort studies from Norway and
14
15 New Zealand, and to examine whether traditional CVD risk factors could explain such
16
17 differences. Since the two cohorts differ in several aspects we do not intend to compare the
18
19 two cohorts directly, but mainly focus on within-country comparisons.
20
21
22

23 **MATERIAL AND METHODS**

24 **The New Zealand PREDICT-CVD cohort**

25
26 We used data from the PREDICT-CVD cohort, collected through use of the PREDICT web-
27
28 based decision support program in New Zealand for the assessment and management of
29
30 CVD risk during primary health care consultations[18]. The study methods and data
31
32 definitions are described in detail elsewhere[18, 19]. In short, the software has been
33
34 integrated with commonly used primary care management systems, and allows
35
36 systematically coded CVD risk data to be automatically and anonymously extracted from
37
38 patients' electronic medical records and augmented where required by primary care
39
40 staff[18, 19]. The cardiovascular profile data was subsequently linked, using an encrypted
41
42 national health identifier number to national and regional health datasets with information
43
44 about hospitalisations, deaths, publicly funded drug dispensing and laboratory test claims
45
46 and results[19].
47
48
49
50
51
52

53
54 The PREDICT software is used in around 35% of New Zealand primary care practices mainly
55
56 in the Auckland and Northland regions,[19] which serve around 1.7 million people,
57
58
59
60

1
2
3 representing around 37 % of the New Zealand population[20]. Any patient with their CVD
4
5 risk assessed by a general practitioner (GP) or practice nurse into online PREDICT-CVD forms
6
7 are included in the PREDICT cohort.
8
9

10
11 New Zealand CVD risk management guidelines recommend that all men over 45 years and all
12
13 women over 55 years have a regular CVD risk assessment[21]. Specified high-CVD risk
14
15 groups, including those of South Asian ethnicity, are recommended to undergo a risk
16
17 assessment ten years earlier than the general population.
18
19

20
21 We used PREDICT data from August 2002 until September 2012. Members of the cohort
22
23 were enrolled and examined continuously throughout this period via their contact with the
24
25 primary health care. We included individuals aged 30 to 74 years since the dataset was
26
27 comprised of people undergoing a risk assessment based on a Framingham risk score
28
29 intended for people in this age group[22]. Using information from the GP, hospital
30
31 discharges and medication dispensing, we excluded persons with a history of CVD (CHD
32
33 (including angina), stroke, TIA, peripheral vascular disease (PVD), percutaneous coronary
34
35 intervention (PCI) or coronary artery bypass grafting (CABG)), or atrial fibrillation at baseline
36
37 (n=24 537), and people with overt renal disease, those who had eGFR \leq 29 and those with
38
39 prior hospitalisations for congestive heart failure or who were on loop diuretics at baseline
40
41 (n=1582). Only subjects with European or Indian background were included. The risk factor
42
43 measurements in the PREDICT cohort were extracted from a standardised electronic
44
45 template that primary care practitioners completed. The SBP was based on the mean of the
46
47 last two recordings done by the GP or practice nurse, in most cases with a manual mercury
48
49 sphygmomanometer. Blood lipid and glucose or HbA1c measurements were carried out in
50
51 the community laboratories routinely used by general practitioners and smoking status and
52
53
54
55
56
57
58
59
60

1
2
3 other risk factor data was measured using a standard questionnaire completed by a primary
4
5 care practitioner.
6
7

8 **Cohort of Norway**

9
10 We included participants from three surveys conducted during 2000-2002 in Oslo, Norway;
11
12 The Oslo Health Study (HUBRO), The Oslo Immigrant Health Study (I-HUBRO) and The
13
14 Romsås in Motion study (MoRo II) (n=26 709), which are part of the Cohort of Norway
15
16 (CONOR)[23]; a collection of health data and blood samples from several Norwegian health
17
18 surveys. Participation rates for the three studies were 40-46%[23].
19
20
21

22
23 All CONOR surveys followed the same standard procedure for collection of data from self-
24
25 administered questionnaires, physical measurements and blood samples. The CONOR
26
27 questionnaire provided information on self-reported diabetes, smoking, use of blood
28
29 pressure and/or lipid lowering medication and family history of CVD. All participants
30
31 attended a clinical examination and non-fasting venous blood samples were drawn. SBP was
32
33 measured by an automatic device (DINAMAP, Criticon, Tampa, FL,USA) after 2 minutes of
34
35 seated resting. Three recordings were made at 1-min intervals. For the analyses we used the
36
37 average of the second and third SBP measurements. The blood samples were subsequently
38
39 measured for total cholesterol (TC) and HDL cholesterol[23].
40
41
42
43
44

45
46 Using an 11-digit personal identifier, CONOR data were linked to hospitalizations and deaths
47
48 in the Cardiovascular Disease in Norway (CVDNOR) project, 1994-2009[24,25]. This enabled
49
50 us to follow CONOR participants for CVD outcomes (hospitalizations or deaths) occurring
51
52 after CONOR examination through December 31st 2009.
53
54

55
56 We included participants aged 30-74 years old at baseline (n=3 871 excluded) to ensure
57
58 comparable samples between the Norwegian and New Zealand data. We excluded
59
60

1
2
3 participants not born in Norway or South Asia (n=5 651 excluded), pregnant women (n=197),
4
5 and participants with prior CVD ((coronary heart disease (CHD), cerebrovascular disease,
6
7 atherosclerotic disease, transient ischemic attack (TIA) and heart failure (HF)) (n=353) or
8
9 atrial fibrillation (n=31) registered in the hospital data before screening.
10
11

12 13 **Outcomes**

14
15 In both cohorts, we identified the first CVD event (non-fatal and fatal) using main or
16
17 secondary diagnoses from hospital discharge data or the underlying cause of death from
18
19 national mortality statistics. The International Classification of Diseases (ICD) codes
20
21 (versions 9 and/or 10) were used to define outcome variables. New Zealand hospitals used
22
23 an Australian modification of the ICD-10 classification called ICD10-AM[26].
24
25
26

27
28 CVD in both cohorts included the following conditions: CHD; HF; cerebrovascular disease
29
30 including TIA; diseases of arteries, arterioles and capillaries including atherosclerosis,
31
32 aneurysm and dissection as well as embolism and thrombosis. For the Norwegian cohort this
33
34 included the codes: ICD9: 410-414, 428, 430-438, 440, 441 except 441.7, 442, 443.9, 444;
35
36 ICD10:I20-I25, I50, I60-I69, I70-I79, G45. The CVD variable in the New Zealand PREDICT
37
38 cohort included the same ICD10 codes as just listed, and also some additional ICD10-codes
39
40 (I469, J81, G460-G468, Z951, Z955, Z958, Z959) plus a list of procedure codes (too many to
41
42 be listed here). The PREDICT CVD outcome has been described elsewhere[19].
43
44
45
46

47 48 **Ethnicity**

49
50 Ethnicity in the New Zealand PREDICT data was based on two sources: 1) the PREDICT
51
52 template filled in by the GP and 2) the National Health Index dataset, both according to pre-
53
54 defined categories. A prioritising algorithm was used to agree on one ethnicity in case of
55
56 multiple ethnicities recorded (details can be found in a supplementary file entitled the VIEW
57
58
59
60

1
2
3 Ethnicity Protocol). The system for coding ethnicity in New Zealand enables identification of
4
5 Indian people, who account for approximately 90% of South Asian people living in New
6
7 Zealand. The remaining South Asian ethnic groups are classified as part of the “Other Asian”
8
9 ethnic group in national health data and so could not be included here. Indian people can
10
11 include both immigrants and individuals who have been born in New Zealand with parents
12
13 (or older generations) who have immigrated. The majority of this group are immigrants since
14
15 76.5% of the people who identified themselves with the Indian ethnic group in New Zealand
16
17 in 2013 were born overseas[27].
18
19
20
21

22
23 For the Norwegian cohort, we used country of birth merged into larger world regions to
24
25 define ethnicity[28]. We defined South Asians as individuals who migrated to Norway from
26
27 Bangladesh, Myanmar, Sri Lanka, Pakistan, India or Nepal[28]. The largest share of South
28
29 Asians in this dataset (95%) came from the HUBRO or the I-HUBRO study. HUBRO and I-
30
31 HUBRO combined included 1145 Sri Lankans and 780 Pakistanis,[29] indicating that about
32
33 50% of the South Asian group (n=2206) in the present study are Sri Lankans and 35% are
34
35 Pakistanis.
36
37
38
39

40
41 In general, we refer to the ethnic groups as South Asians (South Asians in Norway and/or
42
43 Indians in New Zealand) and Europeans (ethnic Norwegians and/or New-Zealanders with
44
45 ethnic European origin). Most European New Zealanders are of British and Irish ancestry, of
46
47 whom about three quarters were born in New Zealand.
48
49

50 **Statistical analysis**

51
52 Baseline characteristics are reported as mean values with standard deviations for continuous
53
54 variables and fractions for categorical variables. We tested the differences between the
55
56 ethnic groups adjusted for age by analysis of covariance. We used Cox regression models to
57
58
59
60

1
2
3 examine the prospective relationship between baseline risk factors (blood pressure, lipids,
4 diabetes and smoking) and time until subsequent first CVD event. People were censored if
5 they died from other causes (n=961 in PREDICT and n=276 in CONOR). Cox regression was
6 also used to calculate hazard ratios (HRs) for CVD in South Asians versus Europeans using
7 ethnicity as the exposure variable and adjusting for risk factors. The order we added the risk
8 factors to the model was based on the distribution of risk factors in the subpopulations. This
9 meant that we first introduced the risk factors that were more prevalent among South
10 Asians compared to Europeans (diabetes and TC/HDL ratio) and then added the two less
11 prevalent risk factors (SBP and smoking). Additional analyses where we added the risk
12 factors in different orders and looked at each risk factor in separate models with only age as
13 covariate did not change the conclusions. Proportional hazards assumptions were tested
14 using scaled Schoenfeld residuals[30]. All analyses were stratified by sex and ethnicity,
15 except for the analyses where ethnicity was the exposure variable in which we only stratified
16 by sex. Only complete cases were included in the analyses. Stata 14 was used for analyses in
17 the Norwegian data and Stata 11 for analysis in the New Zealand data.

18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39 To check whether the use of BP medication at baseline would impact the analyses where
40 SBP were included, we repeated the Cox regression analyses excluding people using
41 antihypertensive medication at baseline. Correspondingly, we also repeated the Cox-
42 regression analyses for TC/HDL ratio without people using lipid lowering medication at
43 baseline. In addition, since excluding those at highest risk could potentially impact the
44 sensitivity analyses, we also adjusted for medication use without excluding anyone from the
45 analyses.

Ethics

The current project was approved by the Regional Committee for Medical Research Ethics, Health Region West. The PREDICT study was approved by the Northern Region Ethics Committee Y in 2003 (AKY/03/12/134), and later annually approved by the National Multi Region Ethics Committee since 2007 (MEC07/19/EXP)[19]. Each individual CONOR study was approved by the Norwegian Data Inspectorate and evaluated by the Regional Committee for Medical Research ethics[31]. Both datasets contained anonymized data.

RESULTS

Baseline characteristics

The final study sample from the New Zealand cohort consisted of 129 449 individuals (43% women) of European (87%) or Indian ethnicity (13%) with no history of CVD, atrial fibrillation or renal disease. Correspondingly for the Norwegian cohort, the final study sample consisted of 16 606 individuals (54% women) born in either Norway (87%) or South Asia (13%) with no history of CVD or atrial fibrillation.

At baseline, the Norwegian cohort was younger than the New Zealand cohort, and New Zealand women were older than New Zealand men (Table 1). In both cohorts, South Asians were younger than Europeans.

Table 1. Baseline characteristics (unadjusted) of the Norwegian and New Zealand participants. Participants free of prior CVD.

	<i>New Zealand cohort</i>			
	Men		Women	
	European	Indian	European	Indian
<i>N</i>	63 319	9 997	49 094	7 039
Age (years)	55.0 (9.3)	47.4 (9.7)	58.7 (8.7)	52.9 (8.5)
Age range	30.0 - 74.0	30.0 - 74.0	30.0 - 74.0	30.0 - 74.0
TC (mmol/L)	5.36 (1.1)	5.09 (1.1)	5.68 (1.1)	5.04 (1.0)
HDL cholesterol (mmol/L)	1.29 (0.4)	1.14 (0.3)	1.59 (0.5)	1.30 (0.3)
LDL cholesterol (mmol/L)	3.3 (1.0)	2.9 (1.0)	3.4 (1.1)	2.8 (0.9)
TC/HDL ratio	4.35 (1.3)	4.60 (1.3)	3.68 (1.1)	3.93 (1.1)
SBP (mmHg)	131.5 (16.3)	125.3 (16.1)	131.6 (17.4)	126.1 (17.4)
Diastolic blood pressure (mmHg)	80.5 (10.0)	79.1 (10.4)	78.8 (9.7)	77.4 (9.8)
Hypertension [†] (%)	40	34	44	39
Type 2 diabetes [§] (%)	9	24	9	29
Former smokers (%)	19	6	16	1
Current smokers (%)	12	9	10	1
Family history of CVD [§] (%)	12	8	15	10
Antihypertensive treatment (%)	24	26	30	32
Lipid lowering treatment (%)	18	27	18	27
Follow-up time (years)	2.94 (2.3)	2.93 (2.0)	2.92 (2.3)	2.83 (1.9)
	<i>Norwegian cohort</i>			
	Men		Women	
	Norwegian	South Asian	Norwegian	South Asian
<i>N</i>	6 385	1 239	8 015	967
Age (years)	43.7 (11.2)	41.4 (7.8)	43.9 (10.9)	40.3 (7.9)
Age range	30.0 - 70.1	30.0 - 67.8	30.0 - 74.9	30.0 - 65.5
TC (mmol/L)	5.60 (1.1)	5.48 (1.0)	5.41 (1.0)	4.98 (0.9)
HDL cholesterol (mmol/L)	1.31 (0.3)	1.07 (0.2)	1.62 (0.4)	1.24 (0.3)
TC/HDL ratio	4.55 (1.4)	5.33 (1.4)	3.52 (1.1)	4.22 (1.2)
SBP (mmHg)	132.6 (14.4)	126.6 (13.2)	124.0 (15.7)	119.1 (15.6)
Diastolic blood pressure (mmHg)	77.6 (10.8)	76.9 (9.8)	71.5 (10.3)	70.0 (10.1)
Hypertension [†] (%)	30	22	19	16
Diabetes (%)	1.6	8.6	1.4	10.9
Former smokers (%)	28	16	26	2
Current smokers (%)	26	25	31	1
Family history of heart disease* (%)	33	24	37	27
Family history of stroke [#] (%)	11	3	13	4
Antihypertensive treatment (%)	6	8	6	9
Lipid lowering treatment (%)	4	6	3	6
Follow-up time (years)	8.44 (1.4)	7.65 (1.4)	8.54 (1.2)	7.88 (1.1)

Data are mean values (SD) for continuous variables and prevalence (%) for categorical variables. [†] Hypertension is defined as having systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg or using blood pressure medication. HDL, high density lipoprotein; LDL, low density lipoprotein; SBP, systolic blood pressure, TC, total cholesterol. *Parents or siblings have had heart attack or angina pectoris (self-report). [#]Parents or siblings have had stroke (self-report). [§]The diabetes variable in the New Zealand data includes people with diabetes of unknown type (5%) and type 2 diabetes (95%), while in the Norwegian data we could not differentiate between different types of diabetes. [§]Family history of CVD in the New Zealand data: self-reported familial history of ischemic heart disease or ischemic stroke occurring in a father or brother <55 years of age, or a mother or sister <65 years of age

1
2
3 South Asians had lower levels of TC and HDL and higher mean levels of TC/HDL ratios than
4
5 Europeans in both Norway and New Zealand. South Asians also had the lowest SBP levels
6
7 (Table 1). These differences persisted after adjustment for age ($p < 0.05$ for differences
8
9 between ethnic groups – results not shown).
10

11
12
13 The diabetes baseline prevalence was higher among South Asians compared to Europeans in
14
15 both cohorts (Table 1). The difference in diabetes were the same after adjustment for age
16
17 ($p < 0.001$). Antihypertensive and lipid lowering treatments were generally more prevalent
18
19 among South Asians than Europeans, and more prevalent in the New Zealand cohort
20
21 compared to the Norwegian cohort. Cigarette smoking was more common among
22
23 Europeans than South Asians, and practically none of the South Asian women smoked.
24
25 Mean follow up time was significantly longer in the Norwegian cohort than in the New
26
27 Zealand cohort (Table 1).
28
29
30
31

32 **CVD events**

33
34 During follow-up, we observed 2 654 CVD events among 129 446 individuals in the New
35
36 Zealand cohort (378 874 person-years) and 743 new CVD events among the 16 606
37
38 individuals in the Norwegian cohort (139 470 person-years). The overall crude rates were
39
40 700 per 100 000 person-years in the New Zealand cohort and 533 per 100 000 person-years
41
42 in the Norwegian cohort. Ethnic specific rates for men and women in the two cohorts are
43
44 shown in table 2 and in the Appendices (tables A1-A4). Also crude rates and age-adjusted
45
46 HRs of CVD by risk factors, ethnic groups, cohort and gender can be found in the Appendices.
47
48
49
50

51 **Prospective associations between risk factors and CVD**

52
53 Increasing age was significantly associated with risk of CVD in both ethnic groups in both
54
55 cohorts (Table 2). The age effect was very similar within the countries for both ethnic groups
56
57
58
59
60

1
2
3 and gender, but was stronger in the Norwegian cohort compared to the New Zealand
4
5 cohort. After adjustment for age, the traditional CVD risk factors were positively associated
6
7 with CVD in both ethnic groups, across gender and country. Whereas all the risk factor-CVD
8
9 event associations were statistically significant in Europeans, the 95% CIs were wider and the
10
11 results not always statistically significant among South Asians. The relationship between SBP,
12
13 TC/HDL ratio, smoking and subsequent CVD appeared to be weaker in Indian men compared
14
15 to European men in the New Zealand cohort. The prospective association between the risk
16
17 factors and CVD changed little after adjusting for the other risk factors in addition to age
18
19 (results not shown). In the sensitivity analyses where we either adjusted for medication use
20
21 or excluded people using BP- and lipid lowering medication at baseline, the estimates for the
22
23 prospective associations between risk factors and CVD were similar as in the main analyses.
24
25 However, for women in the New Zealand cohort, after excluding people on lipid-lowering
26
27 medication, the HR for TC/HDL ratio changed to 1.12; 95% CI 0.91-1.39 for Indian women
28
29 and to 1.20; 95% CI 1.12-1.27 for European women.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2. Age-adjusted hazard ratios for first CVD event after baseline for selected risk factors in men and women aged 30-74 years with no history of CVD, stratified by cohort, ethnicity and gender.

MEN	N events/N [‡]	Crude rate/100 000 person-years (95% CI)	Age (one year) HR (95%CI)	SBP (10 mm/Hg) HR (95%CI)	DBP (10 mm/Hg) HR (95%CI)	TC/HDL ratio (one unit) HR (95%CI)	Diabetes (yes/no) HR (95%CI)	Current smoking (yes/no) HR (95%CI)
<i>New Zealand cohort</i>								
European men	1518/63316	815 (775-857)	1.07 (1.06-1.07)	1.15 (1.12-1.18)	1.16 (1.10-1.22)	1.20 (1.16-1.23)	1.92 (1.68-2.19)	2.29 (2.02-2.59)
Indian men	273/9997	933 (828-1050)	1.06 (1.05-1.07)	1.05 (0.98-1.13)	1.02 (0.91-1.14)	1.08 (0.98-1.19)	1.72 (1.34-2.20)	1.45 (0.99-2.11)
<i>Norwegian cohort</i>								
Norwegian men	379/6385	703 (636-778)	1.10 (1.09-1.11)	1.15 (1.08-1.22)	1.19 (1.08-1.30)	1.22 (1.15-1.30)	3.15 (2.14-4.65)	1.86 (1.51-2.29)
South Asian men	79/1239	833 (668-1039)	1.11 (1.08-1.14)	1.17 (1.01-1.35)	1.21 (0.97-1.51)	1.23 (1.05-1.42)	1.61 (0.90-2.86)	1.43 (0.88-2.30)
WOMEN	N events/N [‡]	Crude rate/100 000 person-years (95% CI)	Age (one year) HR (95%CI)	SBP(10 mm/Hg) HR (95%CI)	DBP (10 mm/Hg) HR (95%CI)	TC/HDL ratio (one unit) HR (95%CI)	Diabetes (yes/no) HR (95%CI)	Current smoking (yes/no) HR (95%CI)
<i>New Zealand cohort</i>								
European women	757/49094	528 (492-567)	1.06 (1.05-1.07)	1.09 (1.05-1.13)	1.13 (1.05-1.22)	1.14 (1.09-1.21)	1.93 (1.59-2.35)	2.74 (2.30-3.27)
Indian women	106/7039	531 (439-643)	1.06 (1.03-1.08)	1.27 (1.16-1.39)	1.25 (1.03-1.50)	1.21 (1.03-1.41)	2.29 (1.55-3.37)	2.60 (0.64-10.59)
<i>Norwegian cohort</i>								
Norwegian women	259/8015	378 (335-427)	1.10 (1.09-1.12)	1.20 (1.12-1.28)	1.32 (1.18-1.47)	1.30 (1.19-1.43)	2.79 (1.52-5.11)	2.22 (1.73-2.84)
South Asian women	26/967	341 (232-501)	1.14 (1.09-1.19)	1.06 (0.86-1.30)	1.07 (0.74-1.55)	1.04 (0.77-1.39)	2.74 (1.21-6.22)	†

[‡]The numbers of events and people included in the analyses may differ due to missing risk factor data. Few were missing in the NZ cohort. [†] Not calculated due to no exposed cases.

DBP, diastolic blood pressure; HDL, high density lipoprotein; SBP, systolic blood pressure; TC, total cholesterol.

Ethnic difference in CVD

South Asians of both genders in Norway and New Zealand had increased risk of CVD compared to the European majority populations (Table 3), with age-adjusted HRs ranging from 1.42-1.92. After adjustment for TC/HDL ratio and diabetes, the HRs for South Asians versus Europeans were reduced and no longer significant in women. Additional adjustments for SBP and smoking increased the hazard ratios again so that South Asians in both countries had significantly increased risk of CVD compared to Europeans. After adjustment for age, TC/HDL ratio, diabetes, SBP and smoking, the HRs for the excess risk in South Asians compared to Europeans varied from 1.39-1.76. The largest reduction in risk estimate after full adjustment was seen in South Asian men in the Norwegian cohort where the HR was lowered by approximately 38% after adjusting for the four major risk factors. The smallest

reduction in risk estimate after adjustment was among South Asian women in the New Zealand cohort where the risk estimate was only reduced by 7 % (from 1.42 – 1.39).

Table 3. Hazard ratios (95% CI) for first CVD event in South Asian groups compared to ethnic European groups in New Zealand and Norway.

	Men		Women	
	Indian vs. European NZ	South Asians vs. Norwegians	Indian NZ vs. European NZ	South Asians vs. Norwegians
<i>N events/N</i>	1791/73308	436/7387	863/56126	264/8558
<i>Adjusted for</i>				
Age	1.75 (1.53-2.00)	1.92 (1.48-2.49)	1.42 (1.16-1.75)	1.87 (1.21-2.87)
Age, TC/HDL ratio	1.77 (1.55-2.02)	1.66 (1.27-2.16)	1.41 (1.14-1.73)	1.52 (0.98-2.36)
Age, TC/HDL ratio, diabetes	1.49 (1.30-1.71)	1.42 (1.08-1.87)	1.15 (0.92-1.42)	1.30 (0.82-2.04)
Age, TC/HDL ratio, diabetes, SBP	1.57 (1.37-1.80)	1.53 (1.16-2.01)	1.19 (0.96-1.47)	1.31 (0.83-2.07)
Age, TC/HDL ratio, diabetes, SBP, smoking	1.64 (1.43-1.88)	1.57 (1.19-2.07)	1.39 (1.11-1.73)	1.76 (1.09-2.82)

HDL, high density lipoprotein; NZ, New Zealand; SBP, systolic blood pressure; TC, Total cholesterol.

All had complete information on the risk factors

Additional analyses showed that the excess risk in South Asians was particularly high for CHD. The full-adjusted HRs for CHD (corresponding to the analyses in the last row of Table 3) were 2.07; 95% CI 1.76-2.44 in South Asian men and 1.60; 95% CI 1.20-2.13 in South Asian women in New Zealand. In the Norwegian cohort, the full-adjusted HRs for CHD were 1.86; 95% CI 1.36-2.55 in South Asian men and 2.84; 95% CI 1.61-5.03 in South Asian women. In the sensitivity analyses for table 3 where we excluded people using BP- or lipid lowering medication at baseline, the patterns according to the risk factor adjustments remained the same as in the main analysis.

DISCUSSION

This study confirmed that the traditional risk factors SBP, TC/HDL ratio, diabetes and smoking are all positively associated with risk of CVD in South Asians as well as in Europeans. The present study also confirmed that South Asians had an increased risk of CVD compared

1
2
3 to Europeans and that ethnic differences in the distribution of TC/HDL ratio and type 2
4
5 diabetes appear to explain some of this excess risk.
6
7

8
9 The main strengths of this study are the prospective study design, and inclusion of data from
10
11 two countries. Unfortunately, we lacked information about duration of stay for the
12
13 immigrants and the ethnic groups that we studied are heterogeneous.
14

15
16 Strengths of the PREDICT cohort are the large sample size and the completeness of risk
17
18 factors included in the risk-assessment. Only 0.01% were missing on any of the four major
19
20 risk factors because they were part of the prediction algorithm and thereby compulsory to
21
22 fill in to the PREDICT template. Furthermore, comprehensive national health registers were
23
24 used to identify and exclude people with prior CVD and to determine cardiovascular
25
26 outcomes. In the New Zealand cohort, some recruitment bias is likely since risk assessment
27
28 was initially prioritized for high-risk patients. Indian patients are therefore over-represented
29
30 in the cohort together with Maoris and Pacifics[19]. The representativeness of the source
31
32 population is, however, improving as PREDICTs coverage increases. In this study, follow-up
33
34 extended to 2012 when PREDICT included 50% of guideline-eligible patients in the practices
35
36 where the PREDICT software is used[32]. We did not assume that the cohorts were
37
38 representative of the general populations in the two countries, but that the ethnic groups
39
40 within the two cohorts should be comparable. Adjusting for age was therefore particularly
41
42 important in the New Zealand cohort since South Asians were around seven years younger
43
44 than Europeans. Results from the two cohorts showed approximately the same regarding
45
46 ethnic differences, which is a strength concerning the external validity of these results. A
47
48 limitation in the New Zealand data is short follow-up time restricting the statistical power.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Another limitation is the lack of standardized BP measurements since recorded BP can easily
4
5 be affected by a range of factors including the type of device used[33].
6
7

8
9 Strengths of CONOR data are the standardized measurements of risk factors, the linkage
10
11 with disease outcomes from comprehensive national health registers and the standardized
12
13 way of defining ethnicity using country of birth. A validation study examining the Oslo Health
14
15 study, showed that participants with a non-western background had a lower participation
16
17 rate than others[34]. This may reflect self-selection which can work both ways; healthy and
18
19 resourceful people have the energy and motivation to participate or less healthy people who
20
21 think their health could benefit from participating do so. Self-selection is unlikely to
22
23 influence associations between risk factors and subsequent disease, but could influence the
24
25 ethnic comparisons if the mechanisms were systematically different for the ethnic groups.
26
27

28
29 The South Asian group in the Norwegian cohort was relatively small, which reduced the
30
31 precision of the estimates and limited the statistical power. Another limitation in the CONOR
32
33 data is missing information on some of the risk factors (see tables A1-A2 in the appendices
34
35 for numbers of missing). However, the extent of missing was small. The risk factor with most
36
37 missing in CONOR was diabetes (3% for the total cohort).
38
39

40
41 In both cohorts, the endpoints are based on register data, including both hospital and
42
43 mortality data, which enables almost complete ascertainment of CVD events. In New
44
45 Zealand, more than 95% of patients with an acute CVD event are managed by government-
46
47 funded health services[19]. However, CVD events occurring among participants who
48
49 travelled outside of New Zealand, those who emigrated after the index CVD risk assessment
50
51 or among participants treated in private hospitals would not be captured in the national
52
53 hospital and mortality registers[19]. We have no information about possible emigration for
54
55
56
57
58
59
60

1
2
3 the New Zealand cohort, but for the Norwegian cohort we know that few people have
4
5 emigrated (about 1% of the ethnic Norwegians and <3% of the South Asians who
6
7 participated in the Oslo health studies had emigrated by the end of follow-up). A limitation
8
9 for both cohorts is also the lack of medication data during follow-up. However, adjustment
10
11 for baseline medication did not change the estimates (results not shown), and Table 1 shows
12
13 that South Asians used more antihypertensives and lipid lowering drugs at baseline than
14
15 Europeans. Both countries have universal health care and South Asians should have the
16
17 same access to cardiovascular medication as Europeans. It is therefore not likely that lack of
18
19 treatment explains the differences in risk of CVD between the two ethnic groups.
20
21
22
23

24
25 Our finding that the traditional major CVD risk factors contribute to the development of CVD
26
27 in South Asians as in Europeans was an expected, yet important, finding since most
28
29 knowledge about CVD prevention is based on studies in populations of European descent,
30
31 and some have questioned whether these risk factors apply worldwide[11, 35]. This finding
32
33 is in line with the large INTERHEART and INTERSTROKE case-control studies[11, 12], which
34
35 reported that 90% of the population attributable risk for AMI and stroke worldwide was
36
37 accounted for by respectively nine and ten (similar) risk factors, including those included in
38
39 the present study. We are only aware of two other prospective studies reporting HRs for the
40
41 prospective relationship between major CVD risk factors and subsequent CVD in South
42
43 Asians[7, 36]. One of these studies included only men,[7] and the other showed estimates
44
45 for men and women combined and did not include blood lipids[36]. These studies generally
46
47 agree with our findings that traditional risk factors contribute to the development of CVD in
48
49 South Asians as in Europeans[7, 36]. Also, consistent with previous reports[5, 6], we found
50
51 that South Asians in both Norway and New Zealand have a higher risk of CVD compared to
52
53 the European majority populations. By including all the measured risk factors (BP, TC/HDL
54
55
56
57
58
59
60

1
2
3 ratio, diabetes and smoking) as adjustment variables in one statistical model, we could not
4
5 explain the higher risk of CVD in South Asians. However, the increased risk was attenuated
6
7 when we only included the risk factors more prevalent in South Asians than in Europeans
8
9 (TC/HDL ratio and diabetes).
10

11
12
13 The excess risk of CVD among South Asians compared to Europeans in the Norwegian cohort
14
15 was almost two-fold. This is comparable to what we reported previously when studying the
16
17 total Norwegian population[5]. The South Asians in the New Zealand cohort had 42-75%
18
19 higher risk of CVD compared to European New Zealanders which also agrees with previous
20
21 New Zealand studies [6]. In both the Norwegian and New Zealand data, South Asians had
22
23 higher baseline levels of dyslipidemia indicated by the TC/HDL ratio and higher diabetes
24
25 prevalence compared to the European majority populations, which is in general agreement
26
27 with previous knowledge from these countries[14-16]. Attenuation of the excess risk in
28
29 South Asians versus Europeans was best achieved in the Cox model only including diabetes
30
31 and TC/HDL ratio as covariates in addition to age. The same was found in both cohorts,
32
33 clearly indicating that the unfavorable distribution of blood lipids and type 2 diabetes
34
35 explains some of the higher risk of CVD in South Asians. South Asians generally have a high
36
37 prevalence of metabolic risk factors related to insulin resistance, often clustered so that they
38
39 match the concept of the metabolic syndrome[37-40]. A British cohort study that tested
40
41 whether traditional risk factors could account for the high mortality of CHD among South
42
43 Asian men compared to European men, reported that adjusting for insulin resistance,
44
45 dyslipidemia and hyperglycemia in South Asians did not explain their higher risk[7].
46
47 However, they also adjusted for smoking and total cholesterol, which were both less
48
49 prevalent/lower among South Asian men compared to European men.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 It is unclear why the traditional risk factors do not completely explain the excess risk of CVD
4
5 in South Asians. This could be related to incomplete adjustments; due to either imprecise
6
7 measurement of risk factors or that other important risk factors were not included (e.g.
8
9 waist measurement, length of time since diabetes diagnosis). A number of non-conventional
10
11 risk factors are also thought to partially account for the high risk of CVD in South Asians,
12
13 including dysfunctional HDL, C-Reactive Protein, thrombogenic risk factors, telomere length,
14
15 high homocysteine levels and low birth weight[41, 42]. Socioeconomic factors could
16
17 probably also explain some of the differences in risk between the ethnic groups, but we did
18
19 not have such variables. Another possibility is that risk factors work cumulatively over time
20
21 in the development of atherosclerosis, and some risk factors may also work at specific and
22
23 crucial time points during the life course. Measurements taken on single occasions may also
24
25 lead to an underestimation of the strength between the *usual* levels of the risk factors and
26
27 later disease, known as the regression dilution bias[43]. Consequently, it is unlikely that the
28
29 ethnic differences would disappear completely by adjusting for selected risk factors
30
31 measured once in midlife.
32
33
34
35
36
37
38

39 Although South Asians seem to have an underlying susceptibility for metabolic diseases,
40
41 traditional and modifiable risk factors are important for preventing disease. Our analyses
42
43 indicate that it is important to focus on the prevention of type 2 diabetes and dyslipidaemia
44
45 when aiming to reduce the burden of CVD among South Asians. The additional effect of
46
47 abdominal obesity for the risk of CVD among South Asians in Norway and New Zealand has,
48
49 however, not yet been studied although we know that the prevalence is high in this ethnic
50
51 group[38, 44]. In both Norway[45, 46] and New Zealand,[47] intervention studies targeting
52
53 immigrants from South Asia have been carried out with some promising results. A UK-study
54
55 that prospectively examined the influence from four health behaviors on the risk of CVD in
56
57
58
59
60

1
2
3 South Asian immigrants and UK Europeans found an important potential for disease
4
5 prevention among South Asians if they adhered to healthy behaviors[8].
6
7
8
9

10 **CONCLUSION**

11
12 Ethnic differences in distribution of TC/HDL ratio and type 2 diabetes explained some, but
13 not all, the excess risk of CVD in South Asians compared to Europeans in Norway and New
14 Zealand. Smoking and elevated BP were less prevalent among South Asians and thus could
15 not explain any of the observed differences in risk of CVD. Targeted diabetes and
16
17 dyslipidaemia management among South Asians, including support for healthy lifestyle
18
19 choices, should be a priority if the high burden of CVD in these ethnic populations is to be
20
21 reduced.
22
23
24
25
26
27
28
29
30
31
32

33 **Acknowledgements**

34
35 The authors thank Tomislav Dimoski at the Norwegian Knowledge Centre for Health Services,
36 Oslo, Norway for his contribution by developing software necessary for obtaining data from
37 Norwegian hospitals, conducting the data collection and quality assurance of data in this
38 project. We also wish to thank Dr. Geeta Gala and Dr Roshini Peiris-John, members of the
39 South Asian governance group for the University of Auckland VIEW research team, for
40 reviewing the paper and giving us their feedback.
41
42
43
44
45
46
47
48
49

50 **Competing interests:** All authors have completed the ICMJE uniform disclosure form at
51 www.icmje.org/coi_disclosure.pdf. Dr. Jackson and Dr. Mehta both report grants from
52 Health Research Council of New Zealand. All other co-authors declare to have no competing
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

1
2
3 **Funding:** This work was supported by the Norwegian Extra-Foundation for Health and
4
5 Rehabilitation (grant number 2012-2-0129).
6
7

8 **Contributors:** HEM, RJ and GST contributed to the conception and design of the work. RJ, BK,
9
10 AKJ and GST contributed to the collection of data. JI, RP and SM contributed to data
11
12 preparations and definition of endpoints. KRS drafted the paper and carried out the data
13
14 analyses. All authors contributed to the interpretation of data as well as critical reading and
15
16 revision of the draft.
17
18
19

20
21 **Data sharing statement:** No additional data are available.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Zaman MJ, Bhopal RS. New answers to three questions on the epidemic of coronary mortality in south Asians: incidence or case fatality? Biology or environment? Will the next generation be affected? *Heart* 2013;99(3):154-8.
2. Bo A, Zinckernagel L, Krasnik A et al. Coronary heart disease incidence among non-Western immigrants compared to Danish-born people: effect of country of birth, migrant status, and income. *Eur J Prev Cardiol* 2015;22(10):1281-9
3. Hedlund E, Lange A, Hammar N. Acute myocardial infarction incidence in immigrants to Sweden. Country of birth, time since immigration, and time trends over 20 years. *Eur J Epidemiol* 2007;22(8):493-503.
4. Tillin T, Hughes AD, Mayet J, et al. The Relationship Between Metabolic Risk Factors and Incident Cardiovascular Disease in Europeans, South Asians, and African Caribbeans: SABRE (Southall and Brent Revisited)—A Prospective Population-Based Study. *J Am Coll Cardiol*. 2013;61(17):1777-1786.
5. Rabanal KS, Selmer RM, Iglund J et al. Ethnic inequalities in acute myocardial infarction and stroke rates in Norway 1994-2009: a nationwide cohort study (CVDNOR). *BMC Public Health* 2015;15:1073.
6. Ministry of Health, *Asian Health Chart Book 2006*. 2006: Wellington: Ministry of Health
7. Forouhi N, Sattar N, Tillin T et al. Do known risk factors explain the higher coronary heart disease mortality in South Asian compared with European men? Prospective follow-up of the Southall and Brent studies, UK. *Diabetologia*, 2006;49(11):2580-2588.
8. Eriksen A, Tillin T, O'Connor L et al. The impact of health behaviours on incident cardiovascular disease in Europeans and South Asians—a prospective analysis in the UK SABRE study. *PLoS one*, 2015;1:15.
9. de Munter JS, Agyemang C, Stronks K et al, Association of physical activity, smoking, and alcohol intake with CVD-related hospital discharge in people of European, South Asian, or African descent. *Eur J Prev Cardiol* 2013;20(1):80-8.
10. Ranganathan M and Bhopal R. Exclusion and inclusion of nonwhite ethnic minority groups in 72 North American and European cardiovascular cohort studies. *PLoS medicine*, 2006;3(3):e44.
11. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet* 2004;364(9438):937-52.
12. O'Donnell MJ, Xavier D, Liu L et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. *Lancet* 2010;376(9735):112-23.
13. Joshi P, Islam S, Pais P et al, Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. *Jama* 2007;297(3):286-94
14. Perumal L, Wells S, Ameratunga S et al. Markedly different clustering of CVD risk factors in New Zealand Indian and European people but similar risk scores (PREDICT-14). *Aust N Z J Public Health* 2012;36(2):141-4.
15. Jenum A, Diep LM, Holmboe-Ottesen G et al. Diabetes susceptibility in ethnic minority groups from Turkey, Vietnam, Sri Lanka and Pakistan compared with Norwegians - the association with adiposity is strongest for ethnic minority women. *BMC Public Health* 2012;12(1):150.
16. Rabanal KS, Lindman AS, Selmer RM et al. Ethnic differences in risk factors and total risk of cardiovascular disease based on the Norwegian CONOR study. *Eur J Prev Cardiol* 2013;20(6):1013-1021.
17. Kumar B, Selmer R, Lindman AS et al. Ethnic differences in SCORE cardiovascular risk in Oslo, Norway. *Eur J Cardiovasc Prev Rehabil* 2009;16:229 - 234.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
18. Bannink L, Wells S, Broad J et al. Web-based assessment of cardiovascular disease risk in routine primary care practice in New Zealand: the first 18,000 patients (PREDICT CVD-1). *N Z Med J* 2006; 119(1245):U2313.
19. Wells S, Riddell T, Kerr A et al. Cohort Profile: The PREDICT Cardiovascular Disease Cohort in New Zealand Primary Care (PREDICT-CVD 19). *Int J Epidemiol* 2015:dyv312.
20. Statistics New Zealand. Subnational population estimates tables. Wellington: Statistics New Zealand. 2014.
21. New Zealand Guideline Group. The assessment and Management of Cardiovascular Risk. 2003: Wellington, New Zealand
22. Anderson KM, Odell PM, Wilson PW et al. Cardiovascular disease risk profiles. *Am Heart J* 1991;121(1):293-298.
23. Næss Ø, Sjøgaard AJ, Arnese et al. Cohort Profile: Cohort of Norway (CONOR). *Int J Epidemiol* 2008; 37(3):481-485.
24. Sulo G, Igland J, Vollset SE et al. Cardiovascular disease and diabetes mellitus in Norway during 1994-2009 CVDNOR - a nationwide research project. *Norsk epidemiologi* 2013;23(1).
25. Sulo G, Igland J, Nygård O et al. Favourable trends in incidence of AMI in Norway during 2001-2009 do not include younger adults: a CVDNOR project. *Eur J Prev Cardiol* 2014;21.11:1358-64.
26. Ministry of Health. ICD-10-AM/ACHI/ACS. Wellington: Ministry of Health. September 25 2015]; Available from: <http://www.health.govt.nz/nz-health-statistics/classification-and-terminology/icd-10-am-achi-acs>.
27. Statistics New Zealand. Tatauranga Aotearoa. 2013 Census. Ethnic group profile: Indian. Retrived 11.09.2015 from: http://www.stats.govt.nz/Census/2013-census/profile-and-summary-reports/ethnic-profiles.aspx?request_value=24743&parent_id=24726&tabname=#2013.
28. Norwegian Institute of Public Health. Documentation of the CONOR file. Version 02.07.2012. 14.12.2016]; Available from: <https://www.fhi.no/globalassets/migrering/dokumenter/pdf/documentation-of-the-conor-file.pdf>
29. Kumar B, Grøtvedt L, Meyer H et al. The Oslo immigrant health profile, in Rapport 2008:7. Oslo: Norwegian Institute of Public Health 2008.
30. Schoenfeld D. Partial residuals for the proportional hazards regression model. *Biometrika*. 1982;69(1)239-41.
31. Sogaard A. Cohort Norway (CONOR): Materials and methods: Norwegian Institute of Public Health; 2007. Available from: <http://www.fhi.no/studier/cohort-of-norway>.
32. Ministry of Health. How is my PHO performing? 2014/15 Quarter 3 (January to March) results. Wellington: Ministry of Health 2015 [February 5 2015]. Available from: <http://www.health.govt.nz/new-zealand-health-system/health-targets/how-my-pho-performing>.
33. Tolonen H, Koponen P, Naska A et al. Challenges in standardization of blood pressure measurement at the population level. *BMC Med Res Methodol* 2015;15:33.
34. Sogaard A, Selmer R, Bjertness E et al. The Oslo Health Study: The impact of self-selection in a large population-based survey. *Int J Equity Health*. 2004;3(3):1-12.
35. Pais P, Pogue J, Gerstein H et al. Risk factors for acute myocardial infarction in Indians: a case-control study. *Lancet*. 1996;348(9024):358-63.
36. Williams ED, Stamatakis E, Chandola T et al. Physical activity behaviour and coronary heart disease mortality among South Asian people in the UK: an observational longitudinal study. *Heart*. 2011;97(8):655-9.
37. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American

- 1
2
3 Heart Association; World Heart Federation; International Atherosclerosis Society; and
4 International Association for the Study of Obesity. *Circulation*. 2009;120(16):1640-5.
5 38. Misra A and Khurana L. The metabolic syndrome in South Asians: epidemiology,
6 determinants, and prevention. *Metab Syndr Relat Disord* 2009;7(6):497-514.
7 39. McKeigue P, Shah B, Marmot M. Relation of central obesity and insulin resistance with high
8 diabetes prevalence and cardiovascular risk in South Asians. *Lancet*. 1991;337(8738):382-6..
9 40. Hjellset VT, Bjorge B, Eriksen HR et al, Risk factors for type 2 diabetes among female Pakistani
10 immigrants: the InvaDiab-DEPLAN study on Pakistani immigrant women living in Oslo,
11 Norway. *J Immigr Minor Health*, 2011;13(1):101-10.
12 41. Ahmed E, El-Menyar A. South Asian Ethnicity and Cardiovascular Risk The Known, the
13 Unknown, and the Paradox. *Angiology* 2015;66(5):405-15.
14 42. Nair M, Prabhakaran D. Why Do South Asians Have High Risk for CAD? *Glob Heart*.
15 2012;7(4):307-14.
16 43. MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part
17 1, Prolonged differences in blood pressure: prospective observational studies corrected for
18 the regression dilution bias. *Lancet*. 1990;335(8692):765-74.
19 44. Kumar B, Meyer H, Wandel M et al. Ethnic differences in obesity among immigrants from
20 developing countries, in Oslo, Norway. *Int J Obes*. 2006;30:684-90.
21 45. Telle-Hjellset V, Raberg Kjollesdal MK, Bjorge B et al. The InnvaDiab-DE-PLAN study: a
22 randomised controlled trial with a culturally adapted education programme improved the
23 risk profile for type 2 diabetes in Pakistani immigrant women. *Br J Nutr*. 2013;109(3):529-38.
24 46. Andersen E, Hostmark AT, Holme I, Anderssen SA. Intervention effects on physical activity
25 and insulin levels in men of Pakistani origin living in Oslo: a randomised controlled trial. *J*
26 *Immigr Minor Health*. 2013;15(1):101-10.
27 47. Rush EC, Chandu V, Plank LD. Reduction of abdominal fat and chronic disease factors by
28 lifestyle change in migrant Asian Indians older than 50 years. *Asia Pac J Clin Nutr*. 2007;
29 16(4):671-676.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

VIEW Ethnicity Protocol

Ethnicity is assigned to an individual based on a prioritisation output. The prioritisation ethnicity protocol adopted by VIEW is based on the Statistics New Zealand ethnicity prioritisation method, and is the most frequently used output method in Ministry of Health statistics. The table below shows level 2 ethnicity codes and their corresponding priority. More information on prioritised output can be found in Appendix A

Table 1

Level 2 ethnic codes

Ethnic Group code	Ethnic Group code description	Ethnic Group priority	Revised VIEW priority
10	European not further defined	21	
11	NZ European	22	
12	Other European	20	
21	NZ Maori	1	
30	Pacific Island not further defined	9	
31	Samoan	7	
32	Cook Island Maori	6	
33	Tongan	5	
34	Niuean	4	
35	Tokelauan	2	
36	Fijian	3	
37	Other Pacific Island	8	
40	Asian not further defined	14	
41	Southeast Asian	10	12
42	Chinese	12	11
43	Indian	11	10
44	Other Asian	13	
51	Middle Eastern	17	
52	Latin American / Hispanic	15	
53	African	16	
54	Other (retired on 1/07/2009)	19	
61	Other ethnicity	18	
94	Don't know	94	
95	Refused to answer	95	
97	Response unidentifiable	97	
99	Not stated	99	

PREDICT 2015 baseline data – Unique ethnicity codes

Ethnicity data used in VIEW comes from two sources – PREDICT and Ministry of Health. When patients are enrolled into PREDICT, their ethnicity are recorded across three ethnicity inputs fields (allowing for the self-identification of up to 3 ethnicity responses). In addition, the Ministry of Health has provided us with a 2015 update of the NHI Demographic Lookup table, containing the demographic data for 7.7 million unique eNHI. Similarly, up to three ethnicity codes are provided (allowing for the self-identification of up to three ethnicity responses). In total, each patient has up to 6 codes that represent their ethnicity.

All unique responses provided from each of the ethnicity fields in the PREDICT 2015 Baseline Data

Source	Variable name	Ethnicity Codes
PREDICT 2015	pt_ethnic_group_1	10 11 12 21 30 31 32 33 34 35 36 37 40 41 42 43 44 51 52 53 54 441 442 443 444 44411 44412 44413 44414 44415 NA
	pt_ethnic_group_2	10 11 12 21 30 31 32 33 34 35 36 37 40 41 42 43 44 51 52 53 54 99 441 443 44411 44412 44414 NA
	pt_ethnic_group_3	10 11 12 21 30 31 32 33 34 35 36 37 40 41 42 43 44 51 52 53 54 99 441 44411 44414 NA
Ministry of Health 2015	nhi_ethnicg1	10 11 12 21 30 31 32 33 34 35 36 37 40 41 42 43 44 51 52 53 54 61 94 95 97 99
	nhi_ethnicg2	10 11 12 21 30 31 32 33 34 35 36 37 40 41 42 43 44 51 52 53 54 61 94 95 97 99 NA
	nhi_ethnicg3	10 11 12 21 30 31 32 33 34 35 36 37 40 41 42 43 44 51 52 53 61 97 99 NA

NB: There are no NAs in “nhi_ethnicg1”

Procedure for Ethnicity Allocation

The procedure assigns one single ethnicity to each individual. The ethnicity response (there are 6 in total) of each individual is read by the programme using the prioritisation protocol. The programme checks each of the 6 ethnicity fields of a person, and determines which single ethnicity will be assigned. The programme checks each row of data and executes the following command in this order:

- 1) Is this person Maori? If yes, write "NZMaori", otherwise next question.
- 2) Is this person Pacific? If yes, write "Pacific", otherwise next question.
- 3) Is this person Indian? If yes, write "Indian", otherwise next question.
- 4) Is this person Chinese? If yes, write "Chinese", otherwise next question.
- 5) Is this person Asian? If yes, write "Asian", otherwise next question.
- 6) Is this person MELAA? If yes, write "MELAA", otherwise next question.
- 7) Is this person Other? If yes, write "Other", otherwise next question.
- 8) Is this person European? If yes, write "European", otherwise next question.
- 9) Is the ethnicity unknown, not answered, not identifiable? If yes, write "No_not_stated".

NB: MELAA = Middle Eastern, Latin American, African

VIEW REVISED Procedure for Ethnicity Allocation

- 1) Is this person Maori? If yes, write "NZMaori", otherwise next question.
- 2) Is this person Pacific? If yes, write "Pacific", otherwise next question.
- 3) Is this person Indian? If yes, write "Indian", otherwise next question.
- 4) Is this person Chinese? If yes, write "Chinese", otherwise next question.
- 5) Is this person Asian? If yes, write "Asian", otherwise next question.
- 6) Is this person European? If yes, write "European", otherwise next question.
- 7) Is this person MELAA? If yes, write "MELAA", otherwise next question.
- 8) Is this person Other? If yes, write "Other", otherwise next question.
- 9) Is the ethnicity unknown, not answered, not identifiable? If yes, write "No_not_stated".

Multiple Ethnicities

Any individuals with multiple ethnicity responses will be assigned the higher priority of ethnicity.

Example 1 – If a patient is recorded as Maori (21) and Samoan (31), then they are recorded as “Maori”. This is because the programme asks whether this person is “Maori” first. With the answer being yes, “Maori” is recorded. The programme then moves onto the next person instead of asking whether or not they are Pacific.

Example 2 – If a person is recorded as Chinese (42), Southeast Asian (41), and NZ European (11), then they are recorded as Chinese. With Chinese being the highest priority, the person is assigned “Chinese” and the programme moves onto the next person.

NB: “Asian” contains Southeast Asian (41) which has a higher priority compared to Indian and Chinese (see Table 1). However, due to its relatively small population, the Southeast Asian group will be included in the “Asian” group, and thus not prioritised over Indian or Chinese. This is the ONLY exception to the prioritisation order!

The use of “OTHER” Ethnicity

This classification should be clearly defined. The term “Other” does in fact have its own ethnicity coding. It should not be used as a category for which miscellaneous or small populations are assigned as a matter of convenience. Previously, Middle Eastern (51), Latin American/Hispanic (52), and African (53), were frequently included in the OTHER ethnic group. Since 2009 (I think), Statistics New Zealand and the MOH have adopted a new category called MELAA which incorporates codes 51-53. A distinction between MELAA and Other is therefore created. There are two codes (and there should only be two codes), for Other Ethnicity – 54 (pre-2009) and 61 (post-2009).

Original “ag_eth” Classification

Label	Code
Maori	21
Pacific	30, 31, 32, 33, 34, 35, 36, 37
Indian	43, (36 & 43)
Asian	40, 41, 42, 44, 441, 442, 443, 444, 44411, 44412, 44414
Other	51, 52, 53, 54
European	10, 11, 12, 94, 95, 96, 99, " ", ""

Problems with above coding convention:

- “44415” is missing from Asian group
- MELAA codes (51-53) are recorded as “Other Ethnicity”
- “Other Ethnicity” code (61) missing
- European group contains residual codes (94, 95, 96, 99, " ", "")
- “Chinese” are not represented clearly

Distribution of original “ag_eth” (all unique individuals at baseline)

Frequency

Asian	European	Indian	NZMaori	Other	Pacific	<NA>
45308	276933	39205	62181	8907	59305	306

NB: There should be no NA values since `nhi_ethnicg1` contains no NAs

Proportion

Asian	European	Indian	NZMaori	Other	Pacific	<NA>
0.092	0.563	0.080	0.126	0.018	0.121	0.001

NEW “view_ag_eth” Classification

Label	Code
Maori	21
Pacific	30, 31, 32, 33, 34, 35, 36, 37
Indian	43, (36 & 43)
Chinese	42
Asian	40, 41, 44, 441, 442, 443, 444, 44411, 44412, 44414, 44415
MELAA	51, 52, 53
Other	54, 61
European	10, 11, 12
No_not_stated	94, 95, 96, 99, " ", ""

“Other” includes individuals who write “Klingon” or “Martian” as their response.

This list of ethnic groups can be combined as suited to the individual study, however the default coding for VIEW should be that “MELAA” and “Other” will be combined into “Other”. As this is a very heterogeneous group, it may be left out of analyses that focus on ethnic-specific analyses.

“No_not_stated” is defined rather than the default “NA”. The reason is that the MOH have codes precisely for these situation, ranging from “Don’t know” (94), “Refused to Answer” (95), to “Not Stated” (99). If you’re reporting the status of everyone in your cohort of interest, this should be stated as being missing data on ethnicity and not combined with “Other”, as they represent two different types of data.

In previous merges, the European group included “Other” and “NA”. The new coding allows European to be more clearly defined.

Distribution of proposed new “ag_eth2” (all unique individuals at baseline)**Frequency**

Asian	Chinese	European	Indian	MELAA	No_not_stated	NZMaori
18745	26563	276433	39205	6797	654	62181
Other	Pacific	<NA>				
2262	59305	0				

Proportion

Asian	Chinese	European	Indian	MELAA	No_not_stated	NZMaori
0.038	0.054	0.562	0.080	0.014	0.001	0.126
Other	Pacific	<NA>				
0.005	0.121	0.000				

Appendix A

Prioritisation Output for Ethnicity

In prioritised output, each respondent is allocated to a single ethnic group using the priority system (Māori, Pacific peoples, Asian, other groups except NZ European; and NZ European). The aim of prioritisation is to ensure that where some need exists to assign people to a single ethnic group, ethnic groups of policy importance, or of small size, are not swamped by the NZ European ethnic group.

This output type is the one most frequently used in Ministry of Health statistics and is also widely used in the health and disability sector for funding calculations, monitoring changes in the ethnic composition of service utilisation, and so on. Its advantage is that it produces data that are easy to work with as each individual appears only once so the sum of the ethnic group populations will add up to the total New Zealand population.

When ethnicity data is to be output to the Ministry of Health National Systems and more than three ethnicities are available to send, the prioritisation method described in the protocols must be used. This will ensure consistency within the national collections.

Limitations are that prioritised output:

- places people in specific (high priority because of policy importance) ethnic groups which simplifies yet biases the resulting statistics
- over-represents some groups at the expense of others – for example, Māori gain at the expense of Pacific peoples (approximately 31,542) and Pacific peoples gain at the expense of other groups (34,602) of which most are Pacific/European (30,018)
- goes against the principle of self-identification.

One of the main criteria stipulated in the definition of ethnicity is that a person can belong to more than one ethnic group. The ethnicity question caters for multiple responses. However, the question does not ask people to indicate the ethnic group with which they identify the most strongly; instead, prioritisation makes this choice for them. The question is to remain the same for the 2006 census so, to ensure numerator and denominator consistency (see Section 1.5), asking people to state the ethnicity with which they identify the 'most strongly' is not an option.

Appendix

Table A1. Crude rates and age-adjusted HR of CVD by risk factors, Norwegian and South Asian men from the Norwegian cohort.

	Norwegian				South Asian			
	No. of persons	No. of CVD events	Crude rate/100 000 person-years (95% CI)	HR (95% CI)	No. of persons	No. of CVD events	Crude rate/100 000 person-years (95% CI)	HR (95% CI)
Total	6385	379	703 (636-778)		1239	79	833 (668-1039)	
Diabetes								
No	6167	339	649 (583-721)	1.00	1088	59	704 (545-908)	1.00
Yes	101	28	3936 (2718-5701)	3.15 (2.14-4.65)	103	16	2166 (1327-3536)	1.61 (0.90-2.86)
Missing	117	12	539 (298-973)		48	4	1110 (416-2956)	
SBP								
<140	4701	198	493 (429-566)	1.00	1068	56	682 (525-886)	1.00
140-159	1373	130	1150 (969-1366)	1.39 (1.10-1.74)	150	19	1681 (1072-2636)	1.44 (0.83-2.49)
>160	296	51	2228 (1693-2932)	1.76 (1.28-2.42)	21	4	2865 (1075-7634)	1.51 (0.53-4.28)
Missing	15	0			0	0		
TC/HDL ratio								
<5	4284	207	568 (495-650)	1.00	538	21	499 (325-765)	1.00
≥ 5	2090	170	980 (843-1139)	1.64 (1.34-2.00)	698	58	1105 (854-1430)	2.14 (1.30-3.52)
Missing	11	2	2328 (582-9307)		3	0		
TC								
< 5 mmol/L	1930	68	410 (324-520)	1.00	407	19	609 (389-955)	1.00
≥ 5 mmol/L	4444	309	830 (742-927)	1.17 (0.90-1.53)	830	60	945 (734-1217)	1.49 (0.89-2.49)
Missing	11	2	2328 (582-9307)		2	0		
HDL								
< 1.00 mmol/L	1032	78	915 (733-1142)	1.00	525	34	855 (611-1197)	1.00
≥1.00 mmol/L	5343	299	660 (589-739)	0.61 (0.47-0.78)	711	45	821 (613-1099)	0.99 (0.63-1.55)
Missing	10	2	2608 (652-10427)		3	0		
Current daily smokers								
No	4706	231	578 (508-657)	1.00	905	52	749 (571-983)	1.00
Yes	1660	146	1062 (903-1248)	1.86 (1.51-2.29)	302	25	1088 (735-1610)	1.43 (0.88-2.30)
Missing	19	2	1236 (309-4941)		32	2	831 (208-3323)	

CI, confidence interval; CVD, cardiovascular disease; HDL, high density lipoprotein; HR, hazard ratio; TC, total cholesterol; SBP, systolic blood pressure

APPENDIX

Table A2. Crude rates and age-adjusted HR of CVD by risk factors, Norwegian and South Asian women from the Norwegian cohort.

	Norwegian				South Asian			
	No. of persons	No. of CVD events	Crude rate/100 000 person-years (95% CI)	HR (95% CI)	No. of persons	No. of CVD events	Crude rate/100 000 person-years (95% CI)	HR (95% CI)
Total	8015	259	378 (335-427)		967	26	341 (232-501)	
Diabetes								
No	7657	237	361 (318-410)	1.00	816	17	262 (163-422)	1.00
Yes	105	11	1305 (723-2356)	2.79 (1.52-5.11)	100	9	1212 (630-2329)	2.74 (1.21-6.22)
Missing	253	11	539 (298-973)		51	0		
SBP								
<140	6823	151	257 (219-302)	1.00	876	18	260 (164-412)	1.00
140-159	920	76	999 (798-1251)	1.82 (1.37-2.43)	67	4	774 (291-2062)	1.45 (0.48-4.34)
>160	266	31	1450 (1020-2062)	2.11 (1.42-3.15)	23	4	2378 (892-6335)	2.42 (0.76-7.71)
Missing	6	1	2128 (300-15106)		1	0		
TC/HDL ratio								
<5	7225	203	328 (286-376)	1.00	749	17	287 (178-462)	1.00
≥ 5	781	54	833 (638-1088)	1.79 (1.33-2.42)	215	9	537 (279-1032)	1.46 (0.65-3.30)
Missing	9	2	3122 (781-12483)			0		
TC								
< 5 mmol/L	3004	44	169 (125-227)	1.00	524	8	193 (97-386)	1.00
≥ 5 mmol/L	5002	213	503 (440-576)	1.40 (1.00-1.97)	440	18	521 (328-826)	1.54 (0.65-3.64)
Missing	9	2	3122 (781-12483)		3	0		
HDL								
< 1.2 mmol/L	1057	52	587 (447-770)	1.00	465	12	329 (187-578)	1.00
≥1.2 mmol/L	6949	205	344 (300-395)	0.55 (0.40-0.74)	499	14	354 (210-598)	0.77 (0.36-1.69)
Missing	9	2	3122 (781-12483)		3	0		
Current daily smokers								
No	5461	134	285 (241-338)	1.00	883	24	344 (231-514)	1.00
Yes	2510	119	564 (471-675)	2.22 (1.73-2.84)	13	0		
Missing	44	6	1759 (790-3916)		71	2	365 (91-1461)	

CI, confidence interval; CVD, cardiovascular disease; HDL, high density lipoprotein; HR, hazard ratio; TC, total cholesterol; SBP, systolic blood pressure

APPENDIX

Table A3. Crude rates and age-adjusted HR of CVD by risk factors, European and Indian New Zealand men from the New Zealand cohort.

	European				Indian			
	No. of persons	No. of CVD events	Crude rate/100 000 person-years (95% CI)	HR (95% CI)	No. of persons	No. of CVD events	Crude rate/100 000 person-years (95% CI)	HR (95% CI)
Total	63 319	1 518	815 (775-857)		9 997	273	933 (828-1050)	
Type 2 diabetes								
No	57 760	1 241	728 (689-770)	1.00	7 641	158	712 (610-833)	1.00
Yes	5 559	277	1739 (1546-1957)	1.92 (1.68-2.19)	2 356	115	1622 (1351-1947)	1.72 (1.34-2.20)
Missing	0				0			
SBP								
<140	42 666	776	632 (589-678)	1.00	7 888	188	805 (698-929)	1.00
140-159	16 417	514	1030 (945-1123)	1.35 (1.20-1.51)	1 723	68	1431 (1128-1814)	1.37 (1.03-1.81)
>160	4 236	228	1675 (1471-1908)	2.03 (1.75-2.36)	386	17	1462 (909-2352)	1.22 (0.74-2.02)
Missing	0				0			
TC/HDL ratio								
<5	45 177	994	756 (711-805)	1.00	6 379	178	926 (799-1072)	1.00
≥ 5	18 139	524	955 (876-1040)	1.58 (1.42-1.76)	3 617	95	946 (774-1157)	1.28 (1.00-1.65)
Missing*	3	0			1	0		
TC								
< 5 mmol/L	20 226	395	879 (797-970)	1.00	4 450	103	841 (693-1020)	1.00
≥ 5 mmol/L	36 071	684	756 (702-815)	1.01 (0.89-1.14)	5 130	137	974 (824-1152)	1.36 (1.05-1.76)
Missing*	7 022	439	861 (785-946)		417	33	1114 (792-1567)	
HDL								
< 1.00 mmol/L	2 325	55	986 (757-1284)	1.00	561	15	1327 (800-2202)	1.00
≥1.00 mmol/L	10 920	323	891 (799-993)	0.87 (0.66-1.17)	1 231	39	1140 (833-1561)	0.62 (0.33-1.14)
Missing*	50 074	1 140	789 (744-836)		8 205	219	886 (776-1011)	
Current daily smokers								
No	55 587	1 197	733 (692-776)	1.00	9 105	242	913 (805-1035)	1.00
Yes	7 731	321	1396 (1252-1558)	2.29 (2.02-2.59)	892	31	1123 (790-1597)	1.45 (0.99-2.11)
Missing	1	0			0			

CI, confidence interval; CVD, cardiovascular disease; HDL, high density lipoprotein; HR, hazard ratio; TC, total cholesterol; SBP, systolic blood pressure. *The number of missing information is different for TC/HDL ratio than for TC and HDL separately. This is because the risk factors included in the PREDICT risk assessment (age, gender, smoking, diabetes, systolic BP and total cholesterol/HDL ratio) was compulsory for assessing risk. Risk factors not compulsory for risk assessment consequently have more missing information (e.g. the HDL and TC)

APPENDIX

Table A4. Crude rates and age-adjusted HR of CVD by risk factors, European and Indian New Zealand women from the New Zealand cohort.

	European				Indian			
	No. of persons	No. of CVD events	Crude rate/100 000 person-years (95% CI)	HR	No. of persons	No. of CVD events	Crude rate/100 000 person-years (95% CI)	HR
Total	49 094	757	528 (492-567)		7 039	106	531 (439-643)	
Type 2 diabetes								
No	44 880	635	485 (448-524)	1.00	5 010	50	358 (271-472)	1.00
Yes	4 214	122	994 (832-1187)	1.93 (1.59-2.35)	2 029	56	936 (720-1216)	2.29 (1.55-3.37)
Missing	0				0			
SBP								
<140	32 178	395	436 (395-481)	1.00	5 370	56	371 (285-482)	1.00
140-159	13 019	258	646 (572-730)	1.22 (1.04-1.44)	1 281	34	919 (656-1286)	2.11 (1.37-3.26)
>160	3 896	104	813 (671-985)	1.42 (1.14-1.77)	388	16	1388 (851-2266)	2.99 (1.70-5.27)
Missing	1	0			0			
TC/HDL ratio								
<5	42 800	626	507 (469-549)	1.00	5 895	89	527 (428-648)	1.00
≥ 5	6 289	131	658 (555-781)	1.42 (1.17-1.71)	1 143	17	559 (347-898)	1.11 (0.66-1.86)
Missing*	5	0			1	0		
TC								
< 5 mmol/L	10 940	127	515 (433-613)	1.00	3 277	57	639 (493-828)	1.00
≥ 5 mmol/L	32 974	415	516 (469-569)	0.96 (0.79-1.17)	3 515	37	398 (289-550)	0.62 (0.41-0.94)
Missing*	5 180	215	561 (491-641)		247	12	689 (391-1212)	
HDL								
< 1.2 mmol/L	1 852	26	529 (360-776)	1.00	568	9	781 (406-1501)	1.00
≥1.2 mmol/L	7 985	149	578 (492-678)	0.97 (0.64-1.47)	866	14	600 (355-1013)	0.75 (0.32-1.77)
Missing*	39 257	582	517 (477-561)		5 605	83	504 (406-625)	
Current daily smokers								
No	43 994	595	466 (430-505)	1.00	6 973	104	526 (434-638)	1.00
Yes	5 100	162	1038 (890-1211)	2.74 (2.30-3.27)	66	2	1090 (272-4357)	2.60 (0.64-10.5)
Missing	0				0			

CI, confidence interval; CVD, cardiovascular disease; HDL, high density lipoprotein; HR, hazard ratio; TC, total cholesterol; SBP, systolic blood pressure. *The number of missing information is different for TC/HDL ratio than for TC and HDL separately. This is because the risk factors included in the PREDICT risk assessment (age, gender, smoking, diabetes, systolic BP and total cholesterol/HDL ratio) was compulsory for assessing risk. Risk factors not compulsory for risk assessment consequently have more missing information (e.g. the HDL and TC).

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1,2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-8
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6-8
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-9
Bias	9	Describe any efforts to address potential sources of bias	10
Study size	10	Explain how the study size was arrived at	6-8,11
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9-10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9-10
		(b) Describe any methods used to examine subgroups and interactions	9-10
		(c) Explain how missing data were addressed	10
		(d) If applicable, explain how loss to follow-up was addressed	10
		(e) Describe any sensitivity analyses	10
Results			

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	11
		(b) Give reasons for non-participation at each stage	We did not have information about reasons for non-participation in CONOR, but participation rates are given on page 7 and the possibility of self-selection bias is discussed on page 18. This was not relevant for the PREDICT cohort since it was based on contact with the primary health care.
		(c) Consider use of a flow diagram	Different persons were involved in the exclusion of participants, so it was easier to describe this process in text.
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	11-13
		(b) Indicate number of participants with missing data for each variable of interest	Tables A1-A4 in the appendices
		(c) Summarise follow-up time (eg, average and total amount)	12 (Table 1)
Outcome data	15*	Report numbers of outcome events or summary measures over time	13

1			
2			
3			
4	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included
5			
6			(b) Report category boundaries when continuous variables were categorized
7			
8			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
9			
10	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
11			
12			Sensitivity analyses are reported on page 14, 16
13			
14	Discussion		
15	Key results	18	Summarise key results with reference to study objectives
16	Limitations		
17			
18	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
19			
20	Generalisability	21	Discuss the generalisability (external validity) of the study results
21			
22	Other information		
23	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based
24			
25			
26			

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Can traditional risk factors explain the higher risk of cardiovascular disease in South Asians compared to Europeans in Norway and New Zealand? Two cohort studies

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-016819.R2
Article Type:	Research
Date Submitted by the Author:	08-Aug-2017
Complete List of Authors:	Rabanal, Kjersti; Nasjonalt folkehelseinstitutt, Division for Mental and Physical Health Meyer, Haakon; Norwegian Institute of Public Health, Division for Mental and Physical Health; Universitetet i Oslo Avdeling for samfunnsmedisin Tell, Grethe; University of Bergen, Department of Global Public Health and Primary Care; Nasjonalt folkehelseinstitutt, Division for Health Data and Digitalisation Iglund, Jannicke; Faculty of Medicine and Dentistry, University of Bergen, Global Public Health and Primary Care Pylypchuk, Romana; University of Auckland, Epidemiology and Biostatistic, School of Population Health Mehta, Suneela; University of Auckland, Epidemiology and Biostatistics, School of Population Health Kumar, Bernadette; Oslo University Hospital, Norwegian Center for Minority Health Research Jenum, Anne; University of Oslo, Selmer, Randi; Norwegian Institute of Public Health, Division for Mental and Physical Health Jackson, Rod; University of Auckland, Epidemiology and Biostatistics
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Cardiovascular medicine, Public health
Keywords:	cardiovascular disease, risk factors, South Asians, ethnicity, prospective, cohort

SCHOLARONE™
Manuscripts

1
2
3
4 **Can traditional risk factors explain the higher risk of cardiovascular disease in South Asians**
5 **compared to Europeans in Norway and New Zealand? Two cohort studies**
6

7 Kjersti S Rabanal^a, Haakon E Meyer^{a, b}, Grethe S Tell^{c, d}, Jannicke Igland^d, Romana Pylypchuk^e,
8 Suneela Mehta^e, Bernadette Kumar^f, Anne Karen Jenum^g, Randi M Selmer^a, Rod Jackson^e
9

10
11 ^a Division for Mental and Physical Health, Norwegian Institute of Public Health, Oslo, Norway
12

13 ^b Department of Community Medicine, Institute of Health and Society, University of Oslo,
14 Oslo, Norway
15

16 ^c Division for Health Data and Digitalisation, Norwegian Institute of Public Health, Bergen,
17 Norway
18

19 ^d Department of Global Public Health and Primary Care, University of Bergen, Norway
20

21 ^e School of Population Health, University of Auckland, Auckland, New Zealand
22

23 ^f Norwegian Center for Minority Health Research, Oslo, Norway
24

25 ^g Institute of Health and Society, Faculty of Health and Society, University of Oslo, Oslo,
26 Norway
27
28
29

30 **Corresponding author**

31 Kjersti S Rabanal

32 Address: Norwegian Institute of Public Health, P.O. Box 4404, Nydalen, 0403 Oslo, Norway

33 Telephone number: +47 22078118

34 E-mail: kjersti.stormark.rabanal@fhi.no, kjersti.rabanal@hotmail.com
35
36

37 Wordcount, abstract: 298

38 Wordcount, manuscript text: 4660
39
40

41 Keywords: cardiovascular disease, risk factors, South Asians, ethnicity, prospective, cohort
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives The objective was to prospectively examine potential differences in the risk of first cardiovascular disease (CVD) events between South Asians and Europeans living in Norway and New Zealand, and to investigate whether traditional risk factors could explain any differences.

Methods We included participants (30-74 years) without prior CVD in a Norwegian (n=16 606) and a New Zealand (n=129 449) cohort. Ethnicity and cardiovascular risk factor information was linked with hospital registry data and cause of death registries to identify subsequent CVD events. We used Cox proportional hazards regression to investigate the relationship between risk factors and subsequent CVD for South Asians and Europeans, and to calculate age-adjusted hazard ratios (HRs) for CVD in South Asians versus Europeans in the two cohorts separately. We sequentially added the major CVD risk factors (blood pressure, lipids, diabetes and smoking) to study their explanatory role in observed ethnic CVD risk differences.

Results South Asians had higher total cholesterol (TC)/high density lipoprotein (HDL) ratio and more diabetes at baseline than Europeans, but lower blood pressure and smoking levels. South Asians had increased age-adjusted risk of CVD compared to Europeans (87-92% higher in the Norwegian cohort and 42-75% higher in the New Zealand cohort) and remained with significantly increased risk after adjusting for all major CVD risk factors. Adjusted HRs for South Asians versus Europeans in the Norwegian cohort were 1.57; 95% CI 1.19-2.07 in men and 1.76; 95% CI 1.09-2.82 in women. Corresponding figures for the New Zealand cohort were 1.64; 95% CI 1.43-1.88 in men and 1.39; 95% CI 1.11-1.73 in women.

1
2
3 **Conclusion** Differences in TC/HDL ratio and diabetes appear to explain some of the excess
4
5 risk of CVD in South Asians compared to Europeans. Preventing dyslipidaemia and diabetes
6
7 in South Asians may therefore help reduce their excess risk of CVD.
8
9

10 11 12 13 **Strengths and limitations of this study**

- 14
15 • This is one of few prospective investigations of cardiovascular disease and its risk factors
16 in South Asian populations living in Western countries.
17
- 18
19 • A special feature is the inclusion of prospective data from two different countries
20 enhancing the external validity of the findings.
21
22
- 23
24 • The two cohorts differed in how participants were recruited and how information about
25 risk factor levels was collected at baseline.
26
27
- 28
29 • A limited number of South Asians in the Norwegian cohort and short follow up time in
30 the New Zealand cohort restricted the statistical power in our analyses.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Immigrants from South Asia (countries in the Indian subcontinent such as India, Pakistan, Sri Lanka and Bangladesh) who have settled in Western countries have increased risk of cardiovascular disease (CVD) compared to their host populations of European origin[1]. This excess risk has been documented in several countries, especially the increased risk of coronary heart disease (CHD)[2-4]. We recently found that South Asian immigrants in Norway had more than two-fold higher risk of acute myocardial infarction (AMI) than ethnic Norwegians and an increased risk of stroke (26% higher in men and 58% higher in women)[5]. Collaborators in New Zealand found a higher risk of CVD in Indians compared to the European New Zealand population[6].

The mechanisms underlying the increased risk of CVD in South Asian populations are mostly unknown[1]. Few studies have examined the prospective relationship between CVD risk factors and subsequent CVD among South Asians[4, 7-9], despite the urgent need for such studies being addressed for more than ten years ago[10]. The two large and multinational case-control studies, Interheart[11] and Interstroke,[12] indicate that different populations share the same risk factors and that the relationship between risk factors and CVD is similar in different populations around the world. The Interheart study also concluded that the earlier age of AMI in South Asians can be largely attributed to higher risk factor levels at younger ages[13]. However, the Interheart and Interstroke studies are both case-control studies. In both Norway and New Zealand, South Asians have been found to have similar or higher mean total cholesterol (TC) to high density lipoprotein (HDL) ratio and higher prevalence of diabetes compared to the European majority populations[14-17]. However, they also have lower levels of smoking (especially women) and mean systolic blood pressure (SBP) than the European majority populations. Whether the higher risk of CVD among South

1
2
3 Asians in Norway and New Zealand is due to higher levels of certain risk factors have not
4
5 previously been studied.
6
7

8
9 Due to the dearth of prospective data on the relationship between risk factors and CVD
10
11 among South Asians, we aimed to prospectively examine possible differences in the risk of a
12
13 first CVD event between South Asians and Europeans using cohort studies from Norway and
14
15 New Zealand, and to examine whether traditional CVD risk factors could explain such
16
17 differences. Since the two cohorts differ in several aspects we do not intend to compare the
18
19 two cohorts directly, but mainly focus on within-country comparisons.
20
21
22

23 **MATERIAL AND METHODS**

24 **The New Zealand PREDICT-CVD cohort**

25
26 We used data from the PREDICT-CVD cohort, collected through use of the PREDICT web-
27
28 based decision support program in New Zealand for the assessment and management of
29
30 CVD risk during primary health care consultations[18]. The study methods and data
31
32 definitions are described in detail elsewhere[18, 19]. In short, the software has been
33
34 integrated with commonly used primary care management systems, and allows
35
36 systematically coded CVD risk data to be automatically and anonymously extracted from
37
38 patients' electronic medical records and augmented where required by primary care
39
40 staff[18, 19]. The cardiovascular profile data was subsequently linked, using an encrypted
41
42 national health identifier number to national and regional health datasets with information
43
44 about hospitalisations, deaths, publicly funded drug dispensing and laboratory test claims
45
46 and results[19].
47
48
49
50
51
52

53
54 The PREDICT software is used in around 35% of New Zealand primary care practices mainly
55
56 in the Auckland and Northland regions,[19] which serve around 1.7 million people,
57
58
59
60

1
2
3 representing around 37 % of the New Zealand population[20]. Any patient with their CVD
4
5 risk assessed by a general practitioner (GP) or practice nurse into online PREDICT-CVD forms
6
7 are included in the PREDICT cohort.
8
9

10
11 New Zealand CVD risk management guidelines recommend that all men over 45 years and all
12
13 women over 55 years have a regular CVD risk assessment[21]. Specified high-CVD risk
14
15 groups, including those of South Asian ethnicity, are recommended to undergo a risk
16
17 assessment ten years earlier than the general population.
18
19

20
21 We used PREDICT data from August 2002 until September 2012. Members of the cohort
22
23 were enrolled and examined continuously throughout this period via their contact with the
24
25 primary health care. We included individuals aged 30 to 74 years since the dataset was
26
27 comprised of people undergoing a risk assessment based on a Framingham risk score
28
29 intended for people in this age group[22]. Using information from the GP, hospital
30
31 discharges and medication dispensing, we excluded persons with a history of CVD (CHD
32
33 (including angina), stroke, TIA, peripheral vascular disease (PVD), percutaneous coronary
34
35 intervention (PCI) or coronary artery bypass grafting (CABG)), or atrial fibrillation at baseline
36
37 (n=24 537), and people with overt renal disease, those who had eGFR \leq 29 and those with
38
39 prior hospitalisations for congestive heart failure or who were on loop diuretics at baseline
40
41 (n=1582). Only subjects with European or Indian background were included. The risk factor
42
43 measurements in the PREDICT cohort were extracted from a standardised electronic
44
45 template that primary care practitioners completed. The SBP was based on the mean of the
46
47 last two recordings done by the GP or practice nurse, in most cases with a manual mercury
48
49 sphygmomanometer. Blood lipid and glucose or HbA1c measurements were carried out in
50
51 the community laboratories routinely used by general practitioners and smoking status and
52
53
54
55
56
57
58
59
60

1
2
3 other risk factor data was measured using a standard questionnaire completed by a primary
4
5 care practitioner.
6
7

8 **Cohort of Norway**

9
10 We included participants from three surveys conducted during 2000-2002 in Oslo, Norway;
11
12 The Oslo Health Study (HUBRO), The Oslo Immigrant Health Study (I-HUBRO) and The
13
14 Romsås in Motion study (MoRo II) (n=26 709), which are part of the Cohort of Norway
15
16 (CONOR)[23]; a collection of health data and blood samples from several Norwegian health
17
18 surveys. Participation rates for the three studies were 40-46%[23].
19
20

21
22 All CONOR surveys followed the same standard procedure for collection of data from self-
23
24 administered questionnaires, physical measurements and blood samples. The CONOR
25
26 questionnaire provided information on self-reported diabetes, smoking, use of blood
27
28 pressure and/or lipid lowering medication and family history of CVD. All participants
29
30 attended a clinical examination and non-fasting venous blood samples were drawn. SBP was
31
32 measured by an automatic device (DINAMAP, Criticon, Tampa, FL,USA) after 2 minutes of
33
34 seated resting. Three recordings were made at 1-min intervals. For the analyses we used the
35
36 average of the second and third SBP measurements. The blood samples were subsequently
37
38 measured for total cholesterol (TC) and HDL cholesterol[23].
39
40
41
42
43
44

45 Using an 11-digit personal identifier, CONOR data were linked to hospitalizations and deaths
46
47 in the Cardiovascular Disease in Norway (CVDNOR) project, 1994-2009[24,25]. This enabled
48
49 us to follow CONOR participants for CVD outcomes (hospitalizations or deaths) occurring
50
51 after CONOR examination through December 31st 2009.
52
53
54

55 We included participants aged 30-74 years old at baseline (n=3 871 excluded) to ensure
56
57 comparable samples between the Norwegian and New Zealand data. We excluded
58
59
60

1
2
3 participants not born in Norway or South Asia (n=5 651 excluded), pregnant women (n=197),
4
5 and participants with prior CVD ((coronary heart disease (CHD), cerebrovascular disease,
6
7 atherosclerotic disease, transient ischemic attack (TIA) and heart failure (HF)) (n=353) or
8
9 atrial fibrillation (n=31) registered in the hospital data before screening.
10
11

12 13 **Outcomes**

14
15 In both cohorts, we identified the first CVD event (non-fatal and fatal) using main or
16
17 secondary diagnoses from hospital discharge data or the underlying cause of death from
18
19 national mortality statistics. The International Classification of Diseases (ICD) codes
20
21 (versions 9 and/or 10) were used to define outcome variables. New Zealand hospitals used
22
23 an Australian modification of the ICD-10 classification called ICD10-AM[26].
24
25
26

27
28 CVD in both cohorts included the following conditions: CHD; HF; cerebrovascular disease
29
30 including TIA; diseases of arteries, arterioles and capillaries including atherosclerosis,
31
32 aneurysm and dissection as well as embolism and thrombosis. For the Norwegian cohort this
33
34 included the codes: ICD9: 410-414, 428, 430-438, 440, 441 except 441.7, 442, 443.9, 444;
35
36 ICD10:I20-I25, I50, I60-I69, I70-I79, G45. The CVD variable in the New Zealand PREDICT
37
38 cohort included the same ICD10 codes as just listed, and also some additional ICD10-codes
39
40 (I469, J81, G460-G468, Z951, Z955, Z958, Z959) plus a list of procedure codes (too many to
41
42 be listed here). The PREDICT CVD outcome has been described elsewhere[19].
43
44
45
46

47 **Ethnicity**

48
49 Ethnicity in the New Zealand PREDICT data was based on two sources: 1) the PREDICT
50
51 template filled in by the GP and 2) the National Health Index dataset, both according to pre-
52
53 defined categories. A prioritising algorithm was used to agree on one ethnicity in case of
54
55 multiple ethnicities recorded (details can be found in a supplementary file entitled the VIEW
56
57
58
59
60

1
2
3 Ethnicity Protocol). The system for coding ethnicity in New Zealand enables identification of
4
5 Indian people, who account for approximately 90% of South Asian people living in New
6
7 Zealand. The remaining South Asian ethnic groups are classified as part of the “Other Asian”
8
9 ethnic group in national health data and so could not be included here. Indian people can
10
11 include both immigrants and individuals who have been born in New Zealand with parents
12
13 (or older generations) who have immigrated. The majority of this group are immigrants since
14
15 76.5% of the people who identified themselves with the Indian ethnic group in New Zealand
16
17 in 2013 were born overseas[27].
18
19
20
21

22
23 For the Norwegian cohort, we used country of birth merged into larger world regions to
24
25 define ethnicity[28]. We defined South Asians as individuals who migrated to Norway from
26
27 Bangladesh, Myanmar, Sri Lanka, Pakistan, India or Nepal[28]. The largest share of South
28
29 Asians in this dataset (95%) came from the HUBRO or the I-HUBRO study. HUBRO and I-
30
31 HUBRO combined included 1145 Sri Lankans and 780 Pakistanis,[29] indicating that about
32
33 50% of the South Asian group (n=2206) in the present study are Sri Lankans and 35% are
34
35 Pakistanis.
36
37
38
39

40
41 In general, we refer to the ethnic groups as South Asians (South Asians in Norway and/or
42
43 Indians in New Zealand) and Europeans (ethnic Norwegians and/or New-Zealanders with
44
45 ethnic European origin). Most European New Zealanders are of British and Irish ancestry, of
46
47 whom about three quarters were born in New Zealand.
48
49

50 **Statistical analysis**

51
52 Baseline characteristics are reported as mean values with standard deviations for continuous
53
54 variables and fractions for categorical variables. We tested the differences between the
55
56 ethnic groups adjusted for age by analysis of covariance. We used Cox regression models to
57
58
59
60

1
2
3 examine the prospective relationship between baseline risk factors (blood pressure, lipids,
4 diabetes and smoking) and time until subsequent first CVD event. People were censored if
5 they died from other causes (n=961 in PREDICT and n=276 in CONOR). Cox regression was
6 also used to calculate hazard ratios (HRs) for CVD in South Asians versus Europeans using
7 ethnicity as the exposure variable and adjusting for risk factors. The order we added the risk
8 factors to the model was based on the distribution of risk factors in the subpopulations. This
9 meant that we first introduced the risk factors that were more prevalent among South
10 Asians compared to Europeans (diabetes and TC/HDL ratio) and then added the two less
11 prevalent risk factors (SBP and smoking). Additional analyses where we added the risk
12 factors in different orders and looked at each risk factor in separate models with only age as
13 covariate did not change the conclusions (Tables A1-A2 in the Appendices). Proportional
14 hazards assumptions were tested using scaled Schoenfeld residuals[30]. All analyses were
15 stratified by sex and ethnicity, except for the analyses where ethnicity was the exposure
16 variable in which we only stratified by sex. Only complete cases were included in the
17 analyses. Stata 14 was used for analyses in the Norwegian data and Stata 11 for analysis in
18 the New Zealand data.

19
20
21 To check whether the use of BP medication at baseline would impact the analyses where
22 SBP were included, we repeated the Cox regression analyses excluding people using
23 antihypertensive medication at baseline. Correspondingly, we also repeated the Cox-
24 regression analyses for TC/HDL ratio without people using lipid lowering medication at
25 baseline. In addition, since excluding those at highest risk could potentially impact the
26 sensitivity analyses, we also adjusted for medication use without excluding anyone from the
27 analyses (Tables A3-A4 in the Appendices).

Ethics

The current project was approved by the Regional Committee for Medical Research Ethics, Health Region West. The PREDICT study was approved by the Northern Region Ethics Committee Y in 2003 (AKY/03/12/134), and later annually approved by the National Multi Region Ethics Committee since 2007 (MEC07/19/EXP)[19]. Each individual CONOR study was approved by the Norwegian Data Inspectorate and evaluated by the Regional Committee for Medical Research ethics[31]. Both datasets contained anonymized data.

RESULTS

Baseline characteristics

The final study sample from the New Zealand cohort consisted of 129 449 individuals (43% women) of European (87%) or Indian ethnicity (13%) with no history of CVD, atrial fibrillation or renal disease. Correspondingly for the Norwegian cohort, the final study sample consisted of 16 606 individuals (54% women) born in either Norway (87%) or South Asia (13%) with no history of CVD or atrial fibrillation.

At baseline, the Norwegian cohort was younger than the New Zealand cohort, and New Zealand women were older than New Zealand men (Table 1). In both cohorts, South Asians were younger than Europeans.

Table 1. Baseline characteristics (unadjusted) of the Norwegian and New Zealand participants. Participants free of prior CVD.

	<i>New Zealand cohort</i>			
	Men		Women	
	European	Indian	European	Indian
<i>N</i>	63 319	9 997	49 094	7 039
Age (years)	55.0 (9.3)	47.4 (9.7)	58.7 (8.7)	52.9 (8.5)
Age range	30.0 - 74.0	30.0 - 74.0	30.0 - 74.0	30.0 - 74.0
TC (mmol/L)	5.36 (1.1)	5.09 (1.1)	5.68 (1.1)	5.04 (1.0)
HDL cholesterol (mmol/L)	1.29 (0.4)	1.14 (0.3)	1.59 (0.5)	1.30 (0.3)
LDL cholesterol (mmol/L)	3.3 (1.0)	2.9 (1.0)	3.4 (1.1)	2.8 (0.9)
TC/HDL ratio	4.35 (1.3)	4.60 (1.3)	3.68 (1.1)	3.93 (1.1)
SBP (mmHg)	131.5 (16.3)	125.3 (16.1)	131.6 (17.4)	126.1 (17.4)
Diastolic blood pressure (mmHg)	80.5 (10.0)	79.1 (10.4)	78.8 (9.7)	77.4 (9.8)
Hypertension [†] (%)	40	34	44	39
Type 2 diabetes [§] (%)	9	24	9	29
Former smokers (%)	19	6	16	1
Current smokers (%)	12	9	10	1
Family history of CVD [§] (%)	12	8	15	10
Antihypertensive treatment (%)	24	26	30	32
Lipid lowering treatment (%)	18	27	18	27
Follow-up time (years)	2.94 (2.3)	2.93 (2.0)	2.92 (2.3)	2.83 (1.9)
	<i>Norwegian cohort</i>			
	Men		Women	
	Norwegian	South Asian	Norwegian	South Asian
<i>N</i>	6 385	1 239	8 015	967
Age (years)	43.7 (11.2)	41.4 (7.8)	43.9 (10.9)	40.3 (7.9)
Age range	30.0 - 70.1	30.0 - 67.8	30.0 - 74.9	30.0 - 65.5
TC (mmol/L)	5.60 (1.1)	5.48 (1.0)	5.41 (1.0)	4.98 (0.9)
HDL cholesterol (mmol/L)	1.31 (0.3)	1.07 (0.2)	1.62 (0.4)	1.24 (0.3)
TC/HDL ratio	4.55 (1.4)	5.33 (1.4)	3.52 (1.1)	4.22 (1.2)
SBP (mmHg)	132.6 (14.4)	126.6 (13.2)	124.0 (15.7)	119.1 (15.6)
Diastolic blood pressure (mmHg)	77.6 (10.8)	76.9 (9.8)	71.5 (10.3)	70.0 (10.1)
Hypertension [†] (%)	30	22	19	16
Diabetes (%)	1.6	8.6	1.4	10.9
Former smokers (%)	28	16	26	2
Current smokers (%)	26	25	31	1
Family history of heart disease* (%)	33	24	37	27
Family history of stroke [#] (%)	11	3	13	4
Antihypertensive treatment (%)	6	8	6	9
Lipid lowering treatment (%)	4	6	3	6
Follow-up time (years)	8.44 (1.4)	7.65 (1.4)	8.54 (1.2)	7.88 (1.1)

Data are mean values (SD) for continuous variables and prevalence (%) for categorical variables. HDL, high density lipoprotein; LDL, low density lipoprotein; SBP, systolic blood pressure, TC, total cholesterol. [†]Hypertension is defined as having systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg or using blood pressure medication. [§]The diabetes variable in the New Zealand data includes people with diabetes of unknown type (5%) and type 2 diabetes (95%), while in the Norwegian data we could not differentiate between different types of diabetes. [§]Family history of CVD in the New Zealand data: self-reported familial history of ischemic heart disease or ischemic stroke occurring in a father or brother <55 years of age, or a mother or sister <65 years of age. *Parents or siblings have had heart attack or angina pectoris (self-report). [#]Parents or siblings have had stroke (self-report).

1
2
3 South Asians had lower levels of TC and HDL and higher mean levels of TC/HDL ratios than
4
5 Europeans in both Norway and New Zealand. South Asians also had the lowest SBP levels
6
7 (Table 1). These differences persisted after adjustment for age ($p < 0.05$ for differences
8
9 between ethnic groups – results not shown).
10

11
12
13 The diabetes baseline prevalence was higher among South Asians compared to Europeans in
14
15 both cohorts (Table 1). The difference in diabetes were the same after adjustment for age
16
17 ($p < 0.001$). Antihypertensive and lipid lowering treatments were generally more prevalent
18
19 among South Asians than Europeans, and more prevalent in the New Zealand cohort
20
21 compared to the Norwegian cohort. Cigarette smoking was more common among
22
23 Europeans than South Asians, and practically none of the South Asian women smoked.
24
25 Mean follow up time was significantly longer in the Norwegian cohort than in the New
26
27 Zealand cohort (Table 1).
28
29
30
31

32 **CVD events**

33
34 During follow-up, we observed 2 654 CVD events among 129 446 individuals in the New
35
36 Zealand cohort (378 874 person-years) and 743 new CVD events among the 16 606
37
38 individuals in the Norwegian cohort (139 470 person-years). The overall crude rates were
39
40 700 per 100 000 person-years in the New Zealand cohort and 533 per 100 000 person-years
41
42 in the Norwegian cohort. Ethnic specific rates for men and women in the two cohorts are
43
44 shown in table 2 and in the Appendices (Tables A5-A8). Also crude rates and age-adjusted
45
46 HRs of CVD by risk factors, ethnic groups, cohort and gender can be found in the same tables
47
48 in the Appendices.
49
50
51
52
53
54
55
56
57
58
59
60

Prospective associations between risk factors and CVD

Increasing age was significantly associated with risk of CVD in both ethnic groups in both cohorts (Table 2). The age effect was very similar within the countries for both ethnic groups and gender, but was stronger in the Norwegian cohort compared to the New Zealand cohort. After adjustment for age, the traditional CVD risk factors were positively associated with CVD in both ethnic groups, across gender and country. Whereas all the risk factor-CVD event associations were statistically significant in Europeans, the 95% CIs were wider and the results not always statistically significant among South Asians. The relationship between SBP, TC/HDL ratio, smoking and subsequent CVD appeared to be weaker in Indian men compared to European men in the New Zealand cohort. The prospective association between the risk factors and CVD changed little after adjusting for the other risk factors in addition to age (results not shown). In the sensitivity analyses where we either adjusted for medication use (Table A3 in the Appendices) or excluded people using BP- and lipid lowering medication at baseline (results not shown), the estimates for the prospective associations between risk factors and CVD were similar as in the main analyses. However, for women in the New Zealand cohort, after excluding people on lipid-lowering medication, the HR for TC/HDL ratio changed to 1.12; 95% CI 0.91-1.39 for Indian women and to 1.20; 95% CI 1.12-1.27 for European women.

Table 2. Age-adjusted hazard ratios for first CVD event after baseline for selected risk factors in men and women aged 30-74 years with no history of CVD, stratified by cohort, ethnicity and gender.

MEN								
	N events/N [‡]	Crude rate/100 000 person-years (95% CI)	Age (one year) HR (95%CI)	SBP (10 mm/Hg) HR (95%CI)	DBP (10 mm/Hg) HR (95%CI)	TC/HDL ratio (one unit) HR (95%CI)	Diabetes (yes/no) HR (95%CI)	Current smoking (yes/no) HR (95%CI)
<i>New Zealand cohort</i>								
European men	1518/63316	815 (775-857)	1.07 (1.06-1.07)	1.15 (1.12-1.18)	1.16 (1.10-1.22)	1.20 (1.16-1.23)	1.92 (1.68-2.19)	2.29 (2.02-2.59)
Indian men	273/9997	933 (828-1050)	1.06 (1.05-1.07)	1.05 (0.98-1.13)	1.02 (0.91-1.14)	1.08 (0.98-1.19)	1.72 (1.34-2.20)	1.45 (0.99-2.11)
<i>Norwegian cohort</i>								
Norwegian men	379/6385	703 (636-778)	1.10 (1.09-1.11)	1.15 (1.08-1.22)	1.19 (1.08-1.30)	1.22 (1.15-1.30)	3.15 (2.14-4.65)	1.86 (1.51-2.29)
South Asian men	79/1239	833 (668-1039)	1.11 (1.08-1.14)	1.17 (1.01-1.35)	1.21 (0.97-1.51)	1.23 (1.05-1.42)	1.61 (0.90-2.86)	1.43 (0.88-2.30)
WOMEN								
	N events/N [‡]	Crude rate/100 000 person-years (95% CI)	Age (one year) HR (95%CI)	SBP(10 mm/Hg) HR (95%CI)	DBP (10 mm/Hg) HR (95%CI)	TC/HDL ratio (one unit) HR (95%CI)	Diabetes (yes/no) HR (95%CI)	Current smoking (yes/no) HR (95%CI)
<i>New Zealand cohort</i>								
European women	757/49094	528 (492-567)	1.06 (1.05-1.07)	1.09 (1.05-1.13)	1.13 (1.05-1.22)	1.14 (1.09-1.21)	1.93 (1.59-2.35)	2.74 (2.30-3.27)
Indian women	106/7039	531 (439-643)	1.06 (1.03-1.08)	1.27 (1.16-1.39)	1.25 (1.03-1.50)	1.21 (1.03-1.41)	2.29 (1.55-3.37)	2.60 (0.64-10.59)
<i>Norwegian cohort</i>								
Norwegian women	259/8015	378 (335-427)	1.10 (1.09-1.12)	1.20 (1.12-1.28)	1.32 (1.18-1.47)	1.30 (1.19-1.43)	2.79 (1.52-5.11)	2.22 (1.73-2.84)
South Asian women	26/967	341 (232-501)	1.14 (1.09-1.19)	1.06 (0.86-1.30)	1.07 (0.74-1.55)	1.04 (0.77-1.39)	2.74 (1.21-6.22)	†

[‡]The numbers of events and people included in the analyses may differ due to missing risk factor data. Few were missing in the NZ cohort. [†] Not calculated due to no exposed cases.

DBP, diastolic blood pressure; HDL, high density lipoprotein; SBP, systolic blood pressure; TC, total cholesterol.

Ethnic difference in CVD

South Asians of both genders in Norway and New Zealand had increased risk of CVD compared to the European majority populations (Table 3), with age-adjusted HRs ranging from 1.42-1.92. After adjustment for TC/HDL ratio and diabetes, the HRs for South Asians versus Europeans were reduced and no longer significant in women. Additional adjustments for SBP and smoking increased the hazard ratios again so that South Asians in both countries had significantly increased risk of CVD compared to Europeans. After adjustment for age, TC/HDL ratio, diabetes, SBP and smoking, the HRs for the excess risk in South Asians compared to Europeans varied from 1.39-1.76. The largest reduction in risk estimate after

full adjustment was seen in South Asian men in the Norwegian cohort where the HR was lowered by approximately 38% after adjusting for the four major risk factors. The smallest reduction in risk estimate after adjustment was among South Asian women in the New Zealand cohort where the risk estimate was only reduced by 7 % (from 1.42 – 1.39).

Table 3. Hazard ratios (95% CI) for first CVD event in South Asian groups compared to ethnic European groups in New Zealand and Norway.

	Men		Women	
	Indian vs. European NZ	South Asians vs. Norwegians	Indian NZ vs. European NZ	South Asians vs. Norwegians
<i>N events/N</i>	1791/73308	436/7387	863/56126	264/8558
<i>Adjusted for</i>				
Age	1.75 (1.53-2.00)	1.92 (1.48-2.49)	1.42 (1.16-1.75)	1.87 (1.21-2.87)
Age, TC/HDL ratio	1.77 (1.55-2.02)	1.66 (1.27-2.16)	1.41 (1.14-1.73)	1.52 (0.98-2.36)
Age, TC/HDL ratio, diabetes	1.49 (1.30-1.71)	1.42 (1.08-1.87)	1.15 (0.92-1.42)	1.30 (0.82-2.04)
Age, TC/HDL ratio, diabetes, SBP	1.57 (1.37-1.80)	1.53 (1.16-2.01)	1.19 (0.96-1.47)	1.31 (0.83-2.07)
Age, TC/HDL ratio, diabetes, SBP, smoking	1.64 (1.43-1.88)	1.57 (1.19-2.07)	1.39 (1.11-1.73)	1.76 (1.09-2.82)

HDL, high density lipoprotein; NZ, New Zealand; SBP, systolic blood pressure; TC, Total cholesterol.

All had complete information on the risk factors

Additional analyses showed that the excess risk in South Asians was particularly high for CHD. The full-adjusted HRs for CHD (corresponding to the analyses in the last row of Table 3) were 2.07; 95% CI 1.76-2.44 in South Asian men and 1.60; 95% CI 1.20-2.13 in South Asian women in New Zealand. In the Norwegian cohort, the full-adjusted HRs for CHD were 1.86; 95% CI 1.36-2.55 in South Asian men and 2.84; 95% CI 1.61-5.03 in South Asian women (Table A9 in the Appendices). In the sensitivity analyses for table 3 where we excluded people using BP- or lipid lowering medication at baseline (results not shown) or adjusted for BP- or lipid lowering medication (Table A4 in the Appendices), the patterns according to the risk factor adjustments remained the same as in the main analysis.

DISCUSSION

This study confirmed that the traditional risk factors SBP, TC/HDL ratio, diabetes and smoking are all positively associated with risk of CVD in South Asians as well as in Europeans. The present study also confirmed that South Asians had an increased risk of CVD compared to Europeans and that ethnic differences in the distribution of TC/HDL ratio and type 2 diabetes appear to explain some of this excess risk.

The main strengths of this study are the prospective study design, and inclusion of data from two countries. Unfortunately, we lacked information about duration of stay for the immigrants and the ethnic groups that we studied are heterogeneous.

Strengths of the PREDICT cohort are the large sample size and the completeness of risk factors included in the risk-assessment. Only 0.01% were missing on any of the four major risk factors because they were part of the prediction algorithm and thereby compulsory to fill in to the PREDICT template. Furthermore, comprehensive national health registers were used to identify and exclude people with prior CVD and to determine cardiovascular outcomes. In the New Zealand cohort, some recruitment bias is likely since risk assessment was initially prioritized for high-risk patients. Indian patients are therefore over-represented in the cohort together with Maoris and Pacifics[19]. The representativeness of the source population is, however, improving as PREDICTs coverage increases. In this study, follow-up extended to 2012 when PREDICT included 50% of guideline-eligible patients in the practices where the PREDICT software is used[32]. We did not assume that the cohorts were representative of the general populations in the two countries, but that the ethnic groups within the two cohorts should be comparable. Adjusting for age was therefore particularly

1
2
3 important in the New Zealand cohort since South Asians were around seven years younger
4
5 than Europeans. Results from the two cohorts showed approximately the same regarding
6
7 ethnic differences, which is a strength concerning the external validity of these results. A
8
9 limitation in the New Zealand data is short follow-up time restricting the statistical power.
10
11 Another limitation is the lack of standardized BP measurements since recorded BP can easily
12
13 be affected by a range of factors including the type of device used[33].
14
15

16
17
18 Strengths of CONOR data are the standardized measurements of risk factors, the linkage
19
20 with disease outcomes from comprehensive national health registers and the standardized
21
22 way of defining ethnicity using country of birth. A validation study examining the Oslo Health
23
24 study, showed that participants with a non-western background had a lower participation
25
26 rate than others[34]. This may reflect self-selection which can work both ways; healthy and
27
28 resourceful people have the energy and motivation to participate or less healthy people who
29
30 think their health could benefit from participating do so. Self-selection is unlikely to
31
32 influence associations between risk factors and subsequent disease, but could influence the
33
34 ethnic comparisons if the mechanisms were systematically different for the ethnic groups.
35
36
37 The South Asian group in the Norwegian cohort was relatively small, which reduced the
38
39 precision of the estimates and limited the statistical power. Another limitation in the CONOR
40
41 data is missing information on some of the risk factors (see Tables A3-A6 in the Appendices
42
43 for numbers of missing). However, the extent of missing was small. The risk factor with most
44
45 missing in CONOR was diabetes (3% for the total cohort).
46
47
48
49

50
51 In both cohorts, the endpoints are based on register data, including both hospital and
52
53 mortality data, which enables almost complete ascertainment of CVD events. In New
54
55 Zealand, more than 95% of patients with an acute CVD event are managed by government-
56
57
58
59
60

1
2
3 funded health services[19]. However, CVD events occurring among participants who
4
5 travelled outside of New Zealand, those who emigrated after the index CVD risk assessment
6
7 or among participants treated in private hospitals would not be captured in the national
8
9 hospital and mortality registers[19]. We have no information about possible emigration for
10
11 the New Zealand cohort, but for the Norwegian cohort we know that few people have
12
13 emigrated (about 1% of the ethnic Norwegians and <3% of the South Asians who
14
15 participated in the Oslo health studies had emigrated by the end of follow-up). A limitation
16
17 for both cohorts is also the lack of medication data during follow-up. However, adjustment
18
19 for baseline medication did not change the estimates (Tables A3-A4 in the Appendices), and
20
21 Table 1 shows that South Asians used more antihypertensives and lipid lowering drugs at
22
23 baseline than Europeans. Both countries have universal health care and South Asians should
24
25 have the same access to cardiovascular medication as Europeans. It is therefore not likely
26
27 that lack of treatment explains the differences in risk of CVD between the two ethnic groups.
28
29
30
31
32
33
34 Our finding that the traditional major CVD risk factors contribute to the development of CVD
35
36 in South Asians as in Europeans was an expected, yet important, finding since most
37
38 knowledge about CVD prevention is based on studies in populations of European descent,
39
40 and some have questioned whether these risk factors apply worldwide[11, 35]. This finding
41
42 is in line with the large INTERHEART and INTERSTROKE case-control studies[11, 12], which
43
44 reported that 90% of the population attributable risk for AMI and stroke worldwide was
45
46 accounted for by respectively nine and ten (similar) risk factors, including those included in
47
48 the present study. We are only aware of two other prospective studies reporting HRs for the
49
50 prospective relationship between major CVD risk factors and subsequent CVD in South
51
52 Asians[7, 36]. One of these studies included only men,[7] and the other showed estimates
53
54 for men and women combined and did not include blood lipids[36]. These studies generally
55
56
57
58
59
60

1
2
3 agree with our findings that traditional risk factors contribute to the development of CVD in
4
5 South Asians as in Europeans[7, 36]. Also, consistent with previous reports[5, 6], we found
6
7 that South Asians in both Norway and New Zealand have a higher risk of CVD compared to
8
9 the European majority populations. By including all the measured risk factors (BP, TC/HDL
10
11 ratio, diabetes and smoking) as adjustment variables in one statistical model, we could not
12
13 explain the higher risk of CVD in South Asians. However, the increased risk was attenuated
14
15 when we only included the risk factors more prevalent in South Asians than in Europeans
16
17 (TC/HDL ratio and diabetes).
18
19
20

21
22 The excess risk of CVD among South Asians compared to Europeans in the Norwegian cohort
23
24 was almost two-fold. This is comparable to what we reported previously when studying the
25
26 total Norwegian population[5]. The South Asians in the New Zealand cohort had 42-75%
27
28 higher risk of CVD compared to European New Zealanders which also agrees with previous
29
30 New Zealand studies [6]. In both the Norwegian and New Zealand data, South Asians had
31
32 higher baseline levels of dyslipidemia indicated by the TC/HDL ratio and higher diabetes
33
34 prevalence compared to the European majority populations, which is in general agreement
35
36 with previous knowledge from these countries[14-16]. Attenuation of the excess risk in
37
38 South Asians versus Europeans was best achieved in the Cox model only including diabetes
39
40 and TC/HDL ratio as covariates in addition to age. The same was found in both cohorts,
41
42 clearly indicating that the unfavorable distribution of blood lipids and type 2 diabetes
43
44 explains some of the higher risk of CVD in South Asians. South Asians generally have a high
45
46 prevalence of metabolic risk factors related to insulin resistance, often clustered so that they
47
48 match the concept of the metabolic syndrome[37-40]. A British cohort study that tested
49
50 whether traditional risk factors could account for the high mortality of CHD among South
51
52 Asian men compared to European men, reported that adjusting for insulin resistance,
53
54
55
56
57
58
59
60

1
2
3 dyslipidemia and hyperglycemia in South Asians did not explain their higher risk[7].

4
5 However, they also adjusted for smoking and total cholesterol, which were both less
6
7 prevalent/lower among South Asian men compared to European men.
8
9

10 It is unclear why the traditional risk factors do not completely explain the excess risk of CVD
11
12 in South Asians. This could be related to incomplete adjustments; due to either imprecise
13
14 measurement of risk factors or that other important risk factors were not included (e.g.
15
16 waist measurement, length of time since diabetes diagnosis). A number of non-conventional
17
18 risk factors are also thought to partially account for the high risk of CVD in South Asians,
19
20 including dysfunctional HDL, C-Reactive Protein, thrombogenic risk factors, telomere length,
21
22 high homocysteine levels and low birth weight[41, 42]. Socioeconomic factors could
23
24 probably also explain some of the differences in risk between the ethnic groups, but we did
25
26 not have such variables. Another possibility is that risk factors work cumulatively over time
27
28 in the development of atherosclerosis, and some risk factors may also work at specific and
29
30 crucial time points during the life course. Measurements taken on single occasions may also
31
32 lead to an underestimation of the strength between the *usual* levels of the risk factors and
33
34 later disease, known as the regression dilution bias[43]. Consequently, it is unlikely that the
35
36 ethnic differences would disappear completely by adjusting for selected risk factors
37
38 measured once in midlife.
39
40
41
42
43
44
45

46 Although South Asians seem to have an underlying susceptibility for metabolic diseases,
47
48 traditional and modifiable risk factors are important for preventing disease. Our analyses
49
50 indicate that it is important to focus on the prevention of type 2 diabetes and dyslipidaemia
51
52 when aiming to reduce the burden of CVD among South Asians. The additional effect of
53
54 abdominal obesity for the risk of CVD among South Asians in Norway and New Zealand has,
55
56
57
58
59
60

1
2
3 however, not yet been studied although we know that the prevalence is high in this ethnic
4
5 group[38, 44]. In both Norway[45, 46] and New Zealand,[47] intervention studies targeting
6
7 immigrants from South Asia have been carried out with some promising results. A UK-study
8
9 that prospectively examined the influence from four health behaviors on the risk of CVD in
10
11 South Asian immigrants and UK Europeans found an important potential for disease
12
13 prevention among South Asians if they adhered to healthy behaviors[8].
14
15
16
17
18
19

20 **CONCLUSION**

21
22 Ethnic differences in distribution of TC/HDL ratio and type 2 diabetes explained some, but
23
24 not all, the excess risk of CVD in South Asians compared to Europeans in Norway and New
25
26 Zealand. Smoking and elevated BP were less prevalent among South Asians and thus could
27
28 not explain any of the observed differences in risk of CVD. Targeted diabetes and
29
30 dyslipidaemia management among South Asians, including support for healthy lifestyle
31
32 choices, should be a priority if the high burden of CVD in these ethnic populations is to be
33
34 reduced.
35
36
37
38
39
40
41
42

43 **Acknowledgements**

44
45 The authors thank Tomislav Dimoski at the Norwegian Knowledge Centre for Health Services,
46
47 Oslo, Norway for his contribution by developing software necessary for obtaining data from
48
49 Norwegian hospitals, conducting the data collection and quality assurance of data in this
50
51 project. We also wish to thank Dr. Geeta Gala and Dr Roshini Peiris-John, members of the
52
53 South Asian governance group for the University of Auckland VIEW research team, for
54
55 reviewing the paper and giving us their feedback.
56
57
58
59
60

1
2
3 **Competing interests:** All authors have completed the ICMJE uniform disclosure form at
4
5 www.icmje.org/coi_disclosure.pdf. Dr. Jackson and Dr. Mehta both report grants from
6
7 Health Research Council of New Zealand. All other co-authors declare to have no competing
8
9 interests.
10

11
12
13 **Funding:** This work was supported by the Norwegian Extra-Foundation for Health and
14
15 Rehabilitation (grant number 2012-2-0129).
16

17
18 **Contributors:** HEM, RJ and GST contributed to the conception and design of the work. RJ, BK,
19
20 AKJ and GST contributed to the collection of data. JI, RP and SM contributed to data
21
22 preparations and definition of endpoints. KRS drafted the paper and carried out the data
23
24 analyses. All authors contributed to the interpretation of data as well as critical reading and
25
26 revision of the draft.
27
28

29
30
31 **Data sharing statement:** No additional data are available.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Zaman MJ, Bhopal RS. New answers to three questions on the epidemic of coronary mortality in south Asians: incidence or case fatality? Biology or environment? Will the next generation be affected? *Heart* 2013;99(3):154-8.
2. Bo A, Zinckernagel L, Krasnik A et al. Coronary heart disease incidence among non-Western immigrants compared to Danish-born people: effect of country of birth, migrant status, and income. *Eur J Prev Cardiol* 2015;22(10):1281-9
3. Hedlund E, Lange A, Hammar N. Acute myocardial infarction incidence in immigrants to Sweden. Country of birth, time since immigration, and time trends over 20 years. *Eur J Epidemiol* 2007;22(8):493-503.
4. Tillin T, Hughes AD, Mayet J, et al. The Relationship Between Metabolic Risk Factors and Incident Cardiovascular Disease in Europeans, South Asians, and African Caribbeans: SABRE (Southall and Brent Revisited)—A Prospective Population-Based Study. *J Am Coll Cardiol*. 2013;61(17):1777-1786.
5. Rabanal KS, Selmer RM, Iglund J et al. Ethnic inequalities in acute myocardial infarction and stroke rates in Norway 1994-2009: a nationwide cohort study (CVDNOR). *BMC Public Health* 2015;15:1073.
6. Ministry of Health, *Asian Health Chart Book 2006*. 2006: Wellington: Ministry of Health
7. Forouhi N, Sattar N, Tillin T et al. Do known risk factors explain the higher coronary heart disease mortality in South Asian compared with European men? Prospective follow-up of the Southall and Brent studies, UK. *Diabetologia*, 2006;49(11):2580-2588.
8. Eriksen A, Tillin T, O'Connor L et al. The impact of health behaviours on incident cardiovascular disease in Europeans and South Asians—a prospective analysis in the UK SABRE study. *PLoS one*, 2015;1:15.
9. de Munter JS, Agyemang C, Stronks K et al, Association of physical activity, smoking, and alcohol intake with CVD-related hospital discharge in people of European, South Asian, or African descent. *Eur J Prev Cardiol* 2013;20(1):80-8.
10. Ranganathan M and Bhopal R. Exclusion and inclusion of nonwhite ethnic minority groups in 72 North American and European cardiovascular cohort studies. *PLoS medicine*, 2006;3(3):e44.
11. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet* 2004;364(9438):937-52.
12. O'Donnell MJ, Xavier D, Liu L et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. *Lancet* 2010;376(9735):112-23.
13. Joshi P, Islam S, Pais P et al, Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. *Jama* 2007;297(3):286-94
14. Perumal L, Wells S, Ameratunga S et al. Markedly different clustering of CVD risk factors in New Zealand Indian and European people but similar risk scores (PREDICT-14). *Aust N Z J Public Health* 2012;36(2):141-4.
15. Jenum A, Diep LM, Holmboe-Ottesen G et al. Diabetes susceptibility in ethnic minority groups from Turkey, Vietnam, Sri Lanka and Pakistan compared with Norwegians - the association with adiposity is strongest for ethnic minority women. *BMC Public Health* 2012;12(1):150.
16. Rabanal KS, Lindman AS, Selmer RM et al. Ethnic differences in risk factors and total risk of cardiovascular disease based on the Norwegian CONOR study. *Eur J Prev Cardiol* 2013;20(6):1013-1021.
17. Kumar B, Selmer R, Lindman AS et al. Ethnic differences in SCORE cardiovascular risk in Oslo, Norway. *Eur J Cardiovasc Prev Rehabil* 2009;16:229 - 234.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
18. Bannink L, Wells S, Broad J et al. Web-based assessment of cardiovascular disease risk in routine primary care practice in New Zealand: the first 18,000 patients (PREDICT CVD-1). *N Z Med J* 2006; 119(1245):U2313.
19. Wells S, Riddell T, Kerr A et al. Cohort Profile: The PREDICT Cardiovascular Disease Cohort in New Zealand Primary Care (PREDICT-CVD 19). *Int J Epidemiol* 2015:dyv312.
20. Statistics New Zealand. Subnational population estimates tables. Wellington: Statistics New Zealand. 2014.
21. New Zealand Guideline Group. The assessment and Management of Cardiovascular Risk. 2003: Wellington, New Zealand
22. Anderson KM, Odell PM, Wilson PW et al. Cardiovascular disease risk profiles. *Am Heart J* 1991;121(1):293-298.
23. Næss Ø, Sjøgaard AJ, Arnese et al. Cohort Profile: Cohort of Norway (CONOR). *Int J Epidemiol* 2008; 37(3):481-485.
24. Sulo G, Igland J, Vollset SE et al. Cardiovascular disease and diabetes mellitus in Norway during 1994-2009 CVDNOR - a nationwide research project. *Norsk epidemiologi* 2013;23(1).
25. Sulo G, Igland J, Nygård O et al. Favourable trends in incidence of AMI in Norway during 2001-2009 do not include younger adults: a CVDNOR project. *Eur J Prev Cardiol* 2014;21.11:1358-64.
26. Ministry of Health. ICD-10-AM/ACHI/ACS. Wellington: Ministry of Health. September 25 2015]; Available from: <http://www.health.govt.nz/nz-health-statistics/classification-and-terminology/icd-10-am-achi-acs>.
27. Statistics New Zealand. Tatauranga Aotearoa. 2013 Census. Ethnic group profile: Indian. Retrived 11.09.2015 from: http://www.stats.govt.nz/Census/2013-census/profile-and-summary-reports/ethnic-profiles.aspx?request_value=24743&parent_id=24726&tabname=#2013.
28. Norwegian Institute of Public Health. Documentation of the CONOR file. Version 02.07.2012. 14.12.2016]; Available from: <https://www.fhi.no/globalassets/migrering/dokumenter/pdf/documentation-of-the-conor-file.pdf>
29. Kumar B, Grøtvedt L, Meyer H et al. The Oslo immigrant health profile, in Rapport 2008:7. Oslo: Norwegian Institute of Public Health 2008.
30. Schoenfeld D. Partial residuals for the proportional hazards regression model. *Biometrika*. 1982;69(1)239-41.
31. Sogaard A. Cohort Norway (CONOR): Materials and methods: Norwegian Institute of Public Health; 2007. Available from: <http://www.fhi.no/studier/cohort-of-norway>.
32. Ministry of Health. How is my PHO performing? 2014/15 Quarter 3 (January to March) results. Wellington: Ministry of Health 2015 [February 5 2015]. Available from: <http://www.health.govt.nz/new-zealand-health-system/health-targets/how-my-pho-performing>.
33. Tolonen H, Koponen P, Naska A et al. Challenges in standardization of blood pressure measurement at the population level. *BMC Med Res Methodol* 2015;15:33.
34. Sogaard A, Selmer R, Bjertness E et al. The Oslo Health Study: The impact of self-selection in a large population-based survey. *Int J Equity Health*. 2004;3(3):1-12.
35. Pais P, Pogue J, Gerstein H et al. Risk factors for acute myocardial infarction in Indians: a case-control study. *Lancet*. 1996;348(9024):358-63.
36. Williams ED, Stamatakis E, Chandola T et al. Physical activity behaviour and coronary heart disease mortality among South Asian people in the UK: an observational longitudinal study. *Heart*. 2011;97(8):655-9.
37. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American

- 1
2
3 Heart Association; World Heart Federation; International Atherosclerosis Society; and
4 International Association for the Study of Obesity. *Circulation*. 2009;120(16):1640-5.
5 38. Misra A and Khurana L. The metabolic syndrome in South Asians: epidemiology,
6 determinants, and prevention. *Metab Syndr Relat Disord* 2009;7(6):497-514.
7 39. McKeigue P, Shah B, Marmot M. Relation of central obesity and insulin resistance with high
8 diabetes prevalence and cardiovascular risk in South Asians. *Lancet*. 1991;337(8738):382-6..
9 40. Hjellset VT, Bjorge B, Eriksen HR et al, Risk factors for type 2 diabetes among female Pakistani
10 immigrants: the InvaDiab-DEPLAN study on Pakistani immigrant women living in Oslo,
11 Norway. *J Immigr Minor Health*, 2011;13(1):101-10.
12 41. Ahmed E, El-Menyar A. South Asian Ethnicity and Cardiovascular Risk The Known, the
13 Unknown, and the Paradox. *Angiology* 2015;66(5):405-15.
14 42. Nair M, Prabhakaran D. Why Do South Asians Have High Risk for CAD? *Glob Heart*.
15 2012;7(4):307-14.
16 43. MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part
17 1, Prolonged differences in blood pressure: prospective observational studies corrected for
18 the regression dilution bias. *Lancet*. 1990;335(8692):765-74.
19 44. Kumar B, Meyer H, Wandel M et al. Ethnic differences in obesity among immigrants from
20 developing countries, in Oslo, Norway. *Int J Obes*. 2006;30:684-90.
21 45. Telle-Hjellset V, Raberg Kjollesdal MK, Bjorge B et al. The InnvaDiab-DE-PLAN study: a
22 randomised controlled trial with a culturally adapted education programme improved the
23 risk profile for type 2 diabetes in Pakistani immigrant women. *Br J Nutr*. 2013;109(3):529-38.
24 46. Andersen E, Hostmark AT, Holme I, Anderssen SA. Intervention effects on physical activity
25 and insulin levels in men of Pakistani origin living in Oslo: a randomised controlled trial. *J*
26 *Immigr Minor Health*. 2013;15(1):101-10.
27 47. Rush EC, Chandu V, Plank LD. Reduction of abdominal fat and chronic disease factors by
28 lifestyle change in migrant Asian Indians older than 50 years. *Asia Pac J Clin Nutr*. 2007;
29 16(4):671-676.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

VIEW Ethnicity Protocol

Ethnicity is assigned to an individual based on a prioritisation output. The prioritisation ethnicity protocol adopted by VIEW is based on the Statistics New Zealand ethnicity prioritisation method, and is the most frequently used output method in Ministry of Health statistics. The table below shows level 2 ethnicity codes and their corresponding priority. More information on prioritised output can be found in Appendix A

Table 1

Level 2 ethnic codes

Ethnic Group code	Ethnic Group code description	Ethnic Group priority	Revised VIEW priority
10	European not further defined	21	
11	NZ European	22	
12	Other European	20	
21	NZ Maori	1	
30	Pacific Island not further defined	9	
31	Samoan	7	
32	Cook Island Maori	6	
33	Tongan	5	
34	Niuean	4	
35	Tokelauan	2	
36	Fijian	3	
37	Other Pacific Island	8	
40	Asian not further defined	14	
41	Southeast Asian	10	12
42	Chinese	12	11
43	Indian	11	10
44	Other Asian	13	
51	Middle Eastern	17	
52	Latin American / Hispanic	15	
53	African	16	
54	Other (retired on 1/07/2009)	19	
61	Other ethnicity	18	
94	Don't know	94	
95	Refused to answer	95	
97	Response unidentifiable	97	
99	Not stated	99	

PREDICT 2015 baseline data – Unique ethnicity codes

Ethnicity data used in VIEW comes from two sources – PREDICT and Ministry of Health. When patients are enrolled into PREDICT, their ethnicity are recorded across three ethnicity inputs fields (allowing for the self-identification of up to 3 ethnicity responses). In addition, the Ministry of Health has provided us with a 2015 update of the NHI Demographic Lookup table, containing the demographic data for 7.7 million unique eNHI. Similarly, up to three ethnicity codes are provided (allowing for the self-identification of up to three ethnicity responses). In total, each patient has up to 6 codes that represent their ethnicity.

All unique responses provided from each of the ethnicity fields in the PREDICT 2015 Baseline Data

Source	Variable name	Ethnicity Codes
PREDICT 2015	pt_ethnic_group_1	10 11 12 21 30 31 32 33 34 35 36 37 40 41 42 43 44 51 52 53 54 441 442 443 444 44411 44412 44413 44414 44415 NA
	pt_ethnic_group_2	10 11 12 21 30 31 32 33 34 35 36 37 40 41 42 43 44 51 52 53 54 99 441 443 44411 44412 44414 NA
	pt_ethnic_group_3	10 11 12 21 30 31 32 33 34 35 36 37 40 41 42 43 44 51 52 53 54 99 441 44411 44414 NA
Ministry of Health 2015	nhi_ethnicg1	10 11 12 21 30 31 32 33 34 35 36 37 40 41 42 43 44 51 52 53 54 61 94 95 97 99
	nhi_ethnicg2	10 11 12 21 30 31 32 33 34 35 36 37 40 41 42 43 44 51 52 53 54 61 94 95 97 99 NA
	nhi_ethnicg3	10 11 12 21 30 31 32 33 34 35 36 37 40 41 42 43 44 51 52 53 61 97 99 NA

NB: There are no NAs in “nhi_ethnicg1”

Procedure for Ethnicity Allocation

The procedure assigns one single ethnicity to each individual. The ethnicity response (there are 6 in total) of each individual is read by the programme using the prioritisation protocol. The programme checks each of the 6 ethnicity fields of a person, and determines which single ethnicity will be assigned. The programme checks each row of data and executes the following command in this order:

- 1) Is this person Maori? If yes, write "NZMaori", otherwise next question.
- 2) Is this person Pacific? If yes, write "Pacific", otherwise next question.
- 3) Is this person Indian? If yes, write "Indian", otherwise next question.
- 4) Is this person Chinese? If yes, write "Chinese", otherwise next question.
- 5) Is this person Asian? If yes, write "Asian", otherwise next question.
- 6) Is this person MELAA? If yes, write "MELAA", otherwise next question.
- 7) Is this person Other? If yes, write "Other", otherwise next question.
- 8) Is this person European? If yes, write "European", otherwise next question.
- 9) Is the ethnicity unknown, not answered, not identifiable? If yes, write "No_not_stated".

NB: MELAA = Middle Eastern, Latin American, African

VIEW REVISED Procedure for Ethnicity Allocation

- 1) Is this person Maori? If yes, write "NZMaori", otherwise next question.
- 2) Is this person Pacific? If yes, write "Pacific", otherwise next question.
- 3) Is this person Indian? If yes, write "Indian", otherwise next question.
- 4) Is this person Chinese? If yes, write "Chinese", otherwise next question.
- 5) Is this person Asian? If yes, write "Asian", otherwise next question.
- 6) Is this person European? If yes, write "European", otherwise next question.
- 7) Is this person MELAA? If yes, write "MELAA", otherwise next question.
- 8) Is this person Other? If yes, write "Other", otherwise next question.
- 9) Is the ethnicity unknown, not answered, not identifiable? If yes, write "No_not_stated".

Multiple Ethnicities

Any individuals with multiple ethnicity responses will be assigned the higher priority of ethnicity.

Example 1 – If a patient is recorded as Maori (21) and Samoan (31), then they are recorded as “Maori”. This is because the programme asks whether this person is “Maori” first. With the answer being yes, “Maori” is recorded. The programme then moves onto the next person instead of asking whether or not they are Pacific.

Example 2 – If a person is recorded as Chinese (42), Southeast Asian (41), and NZ European (11), then they are recorded as Chinese. With Chinese being the highest priority, the person is assigned “Chinese” and the programme moves onto the next person.

NB: “Asian” contains Southeast Asian (41) which has a higher priority compared to Indian and Chinese (see Table 1). However, due to its relatively small population, the Southeast Asian group will be included in the “Asian” group, and thus not prioritised over Indian or Chinese. This is the ONLY exception to the prioritisation order!

The use of “OTHER” Ethnicity

This classification should be clearly defined. The term “Other” does in fact have its own ethnicity coding. It should not be used as a category for which miscellaneous or small populations are assigned as a matter of convenience. Previously, Middle Eastern (51), Latin American/Hispanic (52), and African (53), were frequently included in the OTHER ethnic group. Since 2009 (I think), Statistics New Zealand and the MOH have adopted a new category called MELAA which incorporates codes 51-53. A distinction between MELAA and Other is therefore created. There are two codes (and there should only be two codes), for Other Ethnicity – 54 (pre-2009) and 61 (post-2009).

Original “ag_eth” Classification

Label	Code
Maori	21
Pacific	30, 31, 32, 33, 34, 35, 36, 37
Indian	43, (36 & 43)
Asian	40, 41, 42, 44, 441, 442, 443, 444, 44411, 44412, 44414
Other	51, 52, 53, 54
European	10, 11, 12, 94, 95, 96, 99, " ", ""

Problems with above coding convention:

- “44415” is missing from Asian group
- MELAA codes (51-53) are recorded as “Other Ethnicity”
- “Other Ethnicity” code (61) missing
- European group contains residual codes (94, 95, 96, 99, " ", "")
- “Chinese” are not represented clearly

Distribution of original “ag_eth” (all unique individuals at baseline)

Frequency

Asian	European	Indian	NZMaori	Other	Pacific	<NA>
45308	276933	39205	62181	8907	59305	306

NB: There should be no NA values since `nhi_ethnicg1` contains no NAs

Proportion

Asian	European	Indian	NZMaori	Other	Pacific	<NA>
0.092	0.563	0.080	0.126	0.018	0.121	0.001

NEW “view_ag_eth” Classification

Label	Code
Maori	21
Pacific	30, 31, 32, 33, 34, 35, 36, 37
Indian	43, (36 & 43)
Chinese	42
Asian	40, 41, 44, 441, 442, 443, 444, 44411, 44412, 44414, 44415
MELAA	51, 52, 53
Other	54, 61
European	10, 11, 12
No_not_stated	94, 95, 96, 99, " ", ""

“Other” includes individuals who write “Klingon” or “Martian” as their response.

This list of ethnic groups can be combined as suited to the individual study, however the default coding for VIEW should be that “MELAA” and “Other” will be combined into “Other”. As this is a very heterogeneous group, it may be left out of analyses that focus on ethnic-specific analyses.

“No_not_stated” is defined rather than the default “NA”. The reason is that the MOH have codes precisely for these situation, ranging from “Don’t know” (94), “Refused to Answer” (95), to “Not Stated” (99). If you’re reporting the status of everyone in your cohort of interest, this should be stated as being missing data on ethnicity and not combined with “Other”, as they represent two different types of data.

In previous merges, the European group included “Other” and “NA”. The new coding allows European to be more clearly defined.

Distribution of proposed new “ag_eth2” (all unique individuals at baseline)**Frequency**

Asian	Chinese	European	Indian	MELAA	No_not_stated	NZMaori
18745	26563	276433	39205	6797	654	62181
Other	Pacific	<NA>				
2262	59305	0				

Proportion

Asian	Chinese	European	Indian	MELAA	No_not_stated	NZMaori
0.038	0.054	0.562	0.080	0.014	0.001	0.126
Other	Pacific	<NA>				
0.005	0.121	0.000				

Appendix A

Prioritisation Output for Ethnicity

In prioritised output, each respondent is allocated to a single ethnic group using the priority system (Māori, Pacific peoples, Asian, other groups except NZ European; and NZ European). The aim of prioritisation is to ensure that where some need exists to assign people to a single ethnic group, ethnic groups of policy importance, or of small size, are not swamped by the NZ European ethnic group.

This output type is the one most frequently used in Ministry of Health statistics and is also widely used in the health and disability sector for funding calculations, monitoring changes in the ethnic composition of service utilisation, and so on. Its advantage is that it produces data that are easy to work with as each individual appears only once so the sum of the ethnic group populations will add up to the total New Zealand population.

When ethnicity data is to be output to the Ministry of Health National Systems and more than three ethnicities are available to send, the prioritisation method described in the protocols must be used. This will ensure consistency within the national collections.

Limitations are that prioritised output:

- places people in specific (high priority because of policy importance) ethnic groups which simplifies yet biases the resulting statistics
- over-represents some groups at the expense of others – for example, Māori gain at the expense of Pacific peoples (approximately 31,542) and Pacific peoples gain at the expense of other groups (34,602) of which most are Pacific/European (30,018)
- goes against the principle of self-identification.

One of the main criteria stipulated in the definition of ethnicity is that a person can belong to more than one ethnic group. The ethnicity question caters for multiple responses. However, the question does not ask people to indicate the ethnic group with which they identify the most strongly; instead, prioritisation makes this choice for them. The question is to remain the same for the 2006 census so, to ensure numerator and denominator consistency (see Section 1.5), asking people to state the ethnicity with which they identify the 'most strongly' is not an option.

Appendix

Table A1. Hazard ratios (95% CI) for first CVD event in South Asian groups compared to ethnic European groups in New Zealand and Norway- risk factors introduced in a different order than in the main analyses.

	Men		Women	
	Indian vs. European NZ	South Asians vs. Norwegians	Indian NZ vs. European NZ	South Asians vs. Norwegians
<i>N events/N</i>	1791/73308	436/7387	863/56126	264/8558
<i>Adjusted for</i>				
Age	1.75 (1.53-2.00)	1.92 (1.48-2.49)	1.42 (1.16-1.75)	1.87 (1.21-2.87)
Age, diabetes	1.48 (1.29-1.70)	1.64 (1.25-2.15)	1.15 (0.93-1.43)	1.52 (0.96-2.39)
Age, diabetes, SBP	1.56 (1.36-1.79)	1.76 (1.34-2.31)	1.19 (0.96-1.48)	1.49 (0.94-2.36)
Age, diabetes, SBP, smoking	1.63 (1.42-1.87)	1.78 (1.35-2.33)	1.39 (1.12-1.74)	2.00 (1.25-3.20)
Age, diabetes, SBP, smoking, TC/HDL ratio	1.64 (1.43-1.88)	1.57 (1.19-2.07)	1.39 (1.11-1.73)	1.76 (1.09-2.82)

Table A2. Hazard ratios (95% CI) for first CVD event in South Asian groups compared to ethnic European groups in New Zealand and Norway – adjusting for each risk factor in separate models with only age as covariate.

	Men		Women	
	Indian vs. European NZ	South Asians vs. Norwegians	Indian NZ vs. European NZ	South Asians vs. Norwegians
<i>N events/N</i>	1791/73308	436/7387	863/56126	264/8558
<i>Adjusted for</i>				
Age only	1.75 (1.53-2.00)	1.92 (1.48-2.49)	1.42 (1.16-1.75)	1.87 (1.21-2.87)
Age and diabetes only	1.48 (1.29-1.70)	1.64 (1.25-2.15)	1.15 (0.93-1.43)	1.52 (0.96-2.39)
Age and TC/HDL ratio only	1.77 (1.55-2.02)	1.66 (1.27-2.16)	1.41 (1.14-1.73)	1.52 (0.98-2.36)
Age and SBP only	1.84 (1.61-2.10)	2.04 (1.57-2.65)	1.47 (1.20-1.82)	1.84 (1.20-2.82)
Age and smoking only	1.84 (1.61-2.10)	2.46 (1.58-3.84)	1.67 (1.35-2.07)	1.94 (1.49-2.51)

Table A3. Age-adjusted hazard ratios for first CVD event after baseline for selected risk factors in men and women aged 30-74 years with no history of CVD, stratified by cohort, ethnicity and gender – with and without adjustment for medication at baseline.

MEN	N events/N*	SBP (10 mm/Hg)	SBP (10 mm/Hg) adjusted for BP medication	TC/HDL ratio (one unit)	TC/HDL ratio (one unit) adjusted for lipid lowering medication
<i>New Zealand cohort</i>		HR (95%CI)		HR (95%CI)	
European men	1518/63316	1.15 (1.12-1.18)	1.14 (1.11-1.17)	1.20 (1.16-1.23)	1.20 (1.16-1.24)
Indian men	273/9997	1.05 (0.98-1.13)	1.03 (0.96-1.11)	1.08 (0.98-1.19)	1.10 (1.00-1.20)
<i>Norwegian cohort</i>		HR (95%CI)		HR (95%CI)	
Norwegian men	379/6385	1.15 (1.08-1.22)	1.13 (1.06-1.20)	1.22 (1.15-1.30)	1.23 (1.16-1.31)
South Asian men	79/1239	1.17 (1.01-1.35)	1.14 (0.98-1.32)	1.23 (1.05-1.42)	1.21 (1.04-1.42)
WOMEN	N events/N*	SBP(10 mm/Hg)	SBP (10 mm/Hg) adjusted for BP medication	TC/HDL ratio (one unit)	TC/HDL ratio (one unit) adjusted for lipid lowering medication
<i>New Zealand cohort</i>		HR (95%CI)		HR (95%CI)	
European women	757/49094	1.09 (1.05-1.13)	1.07 (1.03-1.12)	1.14 (1.09-1.21)	1.15 (1.09-1.21)
Indian women	106/7039	1.27 (1.16-1.39)	1.23 (1.12-1.36)	1.21 (1.03-1.41)	1.22 (1.04-1.42)
<i>Norwegian cohort</i>		HR (95%CI)		HR (95%CI)	
Norwegian women	259/8015	1.20 (1.12-1.28)	1.18 (1.11-1.26)	1.30 (1.19-1.43)	1.33 (1.21-1.46)
South Asian women	26/967	1.06 (0.86-1.30)	1.06 (0.85-1.31)	1.04 (0.77-1.39)	1.01 (0.75-1.37)

*The numbers of events and people included in the analyses may differ due to missing risk factor data. Few were missing in the NZ cohort. SBP, systolic blood pressure; TC, total cholesterol; HDL, high density lipoprotein.

Table A4. Hazard ratios (95% CI) for first CVD event in South Asian groups compared to ethnic European groups in New Zealand and Norway – with and without adjustment for medication at baseline.

	Men	Women
	Indian vs. European NZ	South Asians vs. Norwegians
	Indian NZ vs. European NZ	South Asians vs. Norwegians
N events/N	1791/73308	436/7387
Adjusted for		
Age, TC/HDL ratio, diabetes, SBP, smoking	1.64 (1.43-1.88)	1.57 (1.19-2.07)
Age, TC/HDL ratio, diabetes, SBP, smoking + medication use at baseline (antihypertensives and lipid lowering drugs)	1.62 (1.41-1.86)	1.53 (1.16-2.03)

HDL, high density lipoprotein; NZ, New Zealand; SBP, systolic blood pressure; TC, Total cholesterol. All had complete information on the risk factors

Table A5. Crude rates and age-adjusted HR of CVD by risk factors, Norwegian and South Asian men from the Norwegian cohort.

	Norwegian				South Asian			
	No. of persons	No. of CVD events	Crude rate/100 000 person-years (95% CI)	HR (95% CI)	No. of persons	No. of CVD events	Crude rate/100 000 person-years (95% CI)	HR (95% CI)
Total	6385	379	703 (636-778)		1239	79	833 (668-1039)	
Diabetes								
No	6167	339	649 (583-721)	1.00	1088	59	704 (545-908)	1.00
Yes	101	28	3936 (2718-5701)	3.15 (2.14-4.65)	103	16	2166 (1327-3536)	1.61 (0.90-2.86)
Missing	117	12	539 (298-973)		48	4	1110 (416-2956)	
SBP								
<140	4701	198	493 (429-566)	1.00	1068	56	682 (525-886)	1.00
140-159	1373	130	1150 (969-1366)	1.39 (1.10-1.74)	150	19	1681 (1072-2636)	1.44 (0.83-2.49)
>160	296	51	2228 (1693-2932)	1.76 (1.28-2.42)	21	4	2865 (1075-7634)	1.51 (0.53-4.28)
Missing	15	0			0	0		
TC/HDL ratio								
<5	4284	207	568 (495-650)	1.00	538	21	499 (325-765)	1.00
≥ 5	2090	170	980 (843-1139)	1.64 (1.34-2.00)	698	58	1105 (854-1430)	2.14 (1.30-3.52)
Missing	11	2	2328 (582-9307)		3	0		
TC								
< 5 mmol/L	1930	68	410 (324-520)	1.00	407	19	609 (389-955)	1.00
≥ 5 mmol/L	4444	309	830 (742-927)	1.17 (0.90-1.53)	830	60	945 (734-1217)	1.49 (0.89-2.49)
Missing	11	2	2328 (582-9307)		2	0		
HDL								
< 1.00 mmol/L	1032	78	915 (733-1142)	1.00	525	34	855 (611-1197)	1.00
≥1.00 mmol/L	5343	299	660 (589-739)	0.61 (0.47-0.78)	711	45	821 (613-1099)	0.99 (0.63-1.55)
Missing	10	2	2608 (652-10427)		3	0		
Current daily smokers								
No	4706	231	578 (508-657)	1.00	905	52	749 (571-983)	1.00
Yes	1660	146	1062 (903-1248)	1.86 (1.51-2.29)	302	25	1088 (735-1610)	1.43 (0.88-2.30)
Missing	19	2	1236 (309-4941)		32	2	831 (208-3323)	

CI, confidence interval; CVD, cardiovascular disease; HDL, high density lipoprotein; HR, hazard ratio; TC, total cholesterol; SBP, systolic blood pressure

Table A6. Crude rates and age-adjusted HR of CVD by risk factors, Norwegian and South Asian women from the Norwegian cohort.

	Norwegian				South Asian			
	No. of persons	No. of CVD events	Crude rate/100 000 person-years (95% CI)	HR (95% CI)	No. of persons	No. of CVD events	Crude rate/100 000 person-years (95% CI)	HR (95% CI)
Total	8015	259	378 (335-427)		967	26	341 (232-501)	
Diabetes								
No	7657	237	361 (318-410)	1.00	816	17	262 (163-422)	1.00
Yes	105	11	1305 (723-2356)	2.79 (1.52-5.11)	100	9	1212 (630-2329)	2.74 (1.21-6.22)
Missing	253	11	539 (298-973)		51	0		
SBP								
<140	6823	151	257 (219-302)	1.00	876	18	260 (164-412)	1.00
140-159	920	76	999 (798-1251)	1.82 (1.37-2.43)	67	4	774 (291-2062)	1.45 (0.48-4.34)
>160	266	31	1450 (1020-2062)	2.11 (1.42-3.15)	23	4	2378 (892-6335)	2.42 (0.76-7.71)
Missing	6	1	2128 (300-15106)		1	0		
TC/HDL ratio								
<5	7225	203	328 (286-376)	1.00	749	17	287 (178-462)	1.00
≥ 5	781	54	833 (638-1088)	1.79 (1.33-2.42)	215	9	537 (279-1032)	1.46 (0.65-3.30)
Missing	9	2	3122 (781-12483)			0		
TC								
< 5 mmol/L	3004	44	169 (125-227)	1.00	524	8	193 (97-386)	1.00
≥ 5 mmol/L	5002	213	503 (440-576)	1.40 (1.00-1.97)	440	18	521 (328-826)	1.54 (0.65-3.64)
Missing	9	2	3122 (781-12483)		3	0		
HDL								
< 1.2 mmol/L	1057	52	587 (447-770)	1.00	465	12	329 (187-578)	1.00
≥1.2 mmol/L	6949	205	344 (300-395)	0.55 (0.40-0.74)	499	14	354 (210-598)	0.77 (0.36-1.69)
Missing	9	2	3122 (781-12483)		3	0		
Current daily smokers								
No	5461	134	285 (241-338)	1.00	883	24	344 (231-514)	1.00
Yes	2510	119	564 (471-675)	2.22 (1.73-2.84)	13	0		
Missing	44	6	1759 (790-3916)		71	2	365 (91-1461)	

CI, confidence interval; CVD, cardiovascular disease; HDL, high density lipoprotein; HR, hazard ratio; TC, total cholesterol; SBP, systolic blood pressure

Table A7. Crude rates and age-adjusted HR of CVD by risk factors, European and Indian New Zealand men from the New Zealand cohort.

	European				Indian			
	No. of persons	No. of CVD events	Crude rate/100 000 person-years (95% CI)	HR (95% CI)	No. of persons	No. of CVD events	Crude rate/100 000 person-years (95% CI)	HR (95% CI)
Total	63 319	1 518	815 (775-857)		9 997	273	933 (828-1050)	
Type 2 diabetes								
No	57 760	1 241	728 (689-770)	1.00	7 641	158	712 (610-833)	1.00
Yes	5 559	277	1739 (1546-1957)	1.92 (1.68-2.19)	2 356	115	1622 (1351-1947)	1.72 (1.34-2.20)
Missing	0				0			
SBP								
<140	42 666	776	632 (589-678)	1.00	7 888	188	805 (698-929)	1.00
140-159	16 417	514	1030 (945-1123)	1.35 (1.20-1.51)	1 723	68	1431 (1128-1814)	1.37 (1.03-1.81)
>160	4 236	228	1675 (1471-1908)	2.03 (1.75-2.36)	386	17	1462 (909-2352)	1.22 (0.74-2.02)
Missing	0				0			
TC/HDL ratio								
<5	45 177	994	756 (711-805)	1.00	6 379	178	926 (799-1072)	1.00
≥ 5	18 139	524	955 (876-1040)	1.58 (1.42-1.76)	3 617	95	946 (774-1157)	1.28 (1.00-1.65)
Missing*	3	0			1	0		
TC								
< 5 mmol/L	20 226	395	879 (797-970)	1.00	4 450	103	841 (693-1020)	1.00
≥ 5 mmol/L	36 071	684	756 (702-815)	1.01 (0.89-1.14)	5 130	137	974 (824-1152)	1.36 (1.05-1.76)
Missing*	7 022	439	861 (785-946)		417	33	1114 (792-1567)	
HDL								
< 1.00 mmol/L	2 325	55	986 (757-1284)	1.00	561	15	1327 (800-2202)	1.00
≥1.00 mmol/L	10 920	323	891 (799-993)	0.87 (0.66-1.17)	1 231	39	1140 (833-1561)	0.62 (0.33-1.14)
Missing*	50 074	1 140	789 (744-836)		8 205	219	886 (776-1011)	
Current daily smokers								
No	55 587	1 197	733 (692-776)	1.00	9 105	242	913 (805-1035)	1.00
Yes	7 731	321	1396 (1252-1558)	2.29 (2.02-2.59)	892	31	1123 (790-1597)	1.45 (0.99-2.11)
Missing	1	0			0			

CI, confidence interval; CVD, cardiovascular disease; HDL, high density lipoprotein; HR, hazard ratio; TC, total cholesterol; SBP, systolic blood pressure. *The number of missing information is different for TC/HDL ratio than for TC and HDL separately. This is because the risk factors included in the PREDICT risk assessment (age, gender, smoking, diabetes, systolic BP and total cholesterol/HDL ratio) was compulsory for assessing risk. Risk factors not compulsory for risk assessment consequently have more missing information (e.g. the HDL and TC)

Table A8. Crude rates and age-adjusted HR of CVD by risk factors, European and Indian New Zealand women from the New Zealand cohort.

	European				Indian			
	No. of persons	No. of CVD events	Crude rate/100 000 person-years (95% CI)	HR	No. of persons	No. of CVD events	Crude rate/100 000 person-years (95% CI)	HR
Total	49 094	757	528 (492-567)		7 039	106	531 (439-643)	
Type 2 diabetes								
No	44 880	635	485 (448-524)	1.00	5 010	50	358 (271-472)	1.00
Yes	4 214	122	994 (832-1187)	1.93 (1.59-2.35)	2 029	56	936 (720-1216)	2.29 (1.55-3.37)
Missing	0				0			
SBP								
<140	32 178	395	436 (395-481)	1.00	5 370	56	371 (285-482)	1.00
140-159	13 019	258	646 (572-730)	1.22 (1.04-1.44)	1 281	34	919 (656-1286)	2.11 (1.37-3.26)
>160	3 896	104	813 (671-985)	1.42 (1.14-1.77)	388	16	1388 (851-2266)	2.99 (1.70-5.27)
Missing	1	0			0			
TC/HDL ratio								
<5	42 800	626	507 (469-549)	1.00	5 895	89	527 (428-648)	1.00
≥ 5	6 289	131	658 (555-781)	1.42 (1.17-1.71)	1 143	17	559 (347-898)	1.11 (0.66-1.86)
Missing*	5	0			1	0		
TC								
< 5 mmol/L	10 940	127	515 (433-613)	1.00	3 277	57	639 (493-828)	1.00
≥ 5 mmol/L	32 974	415	516 (469-569)	0.96 (0.79-1.17)	3 515	37	398 (289-550)	0.62 (0.41-0.94)
Missing*	5 180	215	561 (491-641)		247	12	689 (391-1212)	
HDL								
< 1.2 mmol/L	1 852	26	529 (360-776)	1.00	568	9	781 (406-1501)	1.00
≥1.2 mmol/L	7 985	149	578 (492-678)	0.97 (0.64-1.47)	866	14	600 (355-1013)	0.75 (0.32-1.77)
Missing*	39 257	582	517 (477-561)		5 605	83	504 (406-625)	
Current daily smokers								
No	43 994	595	466 (430-505)	1.00	6 973	104	526 (434-638)	1.00
Yes	5 100	162	1038 (890-1211)	2.74 (2.30-3.27)	66	2	1090 (272-4357)	2.60 (0.64-10.59)
Missing	0				0			

CI, confidence interval; CVD, cardiovascular disease; HDL, high density lipoprotein; HR, hazard ratio; TC, total cholesterol; SBP, systolic blood pressure. *The number of missing information is different for TC/HDL ratio than for TC and HDL separately. This is because the risk factors included in the PREDICT risk assessment (age, gender, smoking, diabetes, systolic BP and total cholesterol/HDL ratio) was compulsory for assessing risk. Risk factors not compulsory for risk assessment consequently have more missing information (e.g. the HDL and TC).

Table A9. Hazard ratios for first **CHD** event in South Asian groups compared to ethnic European groups in New Zealand and Norway.

	Men		Women	
	Indian NZ vs. European NZ	South Asians vs. Norwegians	Indian NZ vs. European NZ	South Asians vs. Norwegians
<i>Adjusted for</i>				
Age	2.10 (1.79-2.46)	2.45 (1.82-3.30)	1.60 (1.22-2.10)	3.23 (1.95-5.34)
Age, TC/HDL ratio	2.13 (1.81-2.50)	2.04 (1.51-2.76)	1.58 (1.20-2.07)	2.71 (1.61-4.54)
Age, TC/HDL ratio, diabetes	1.92 (1.63-2.26)	1.68 (1.23-2.30)	1.31 (0.99-1.74)	2.24 (1.30-3.86)
Age, TC/HDL ratio, diabetes, systolic BP	2.00 (1.70-2.36)	1.81 (1.32-2.48)	1.36 (1.02-1.80)	2.26 (1.31-3.90)
Age, TC/HDL ratio, diabetes, systolic BP, smoking	2.07 (1.76-2.44)	1.86 (1.36-2.55)	1.60 (1.20-2.13)	2.84 (1.61-5.03)

HDL, high density lipoprotein; NZ, New Zealand; SBP, systolic blood pressure; TC, Total cholesterol.

All had complete information on the risk factors

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1,2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-8
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6-8
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-9
Bias	9	Describe any efforts to address potential sources of bias	10
Study size	10	Explain how the study size was arrived at	6-8,11
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9-10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9-10
		(b) Describe any methods used to examine subgroups and interactions	9-10
		(c) Explain how missing data were addressed	10
		(d) If applicable, explain how loss to follow-up was addressed	10
		(e) Describe any sensitivity analyses	10
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	11
		(b) Give reasons for non-participation at each stage	We did not have information about reasons for non-participation in CONOR, but participation rates are given on page 7 and the possibility of self-selection bias is discussed on page 18. This was not relevant for the PREDICT cohort since it was based on contact with the primary health care.
		(c) Consider use of a flow diagram	Different persons were involved in the exclusion of participants, so it was easier to describe this process in text.
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	11-13
		(b) Indicate number of participants with missing data for each variable of interest	Tables A3-A6 in the appendices
		(c) Summarise follow-up time (eg, average and total amount)	12 (Table 1)
Outcome data	15*	Report numbers of outcome events or summary measures over time	13

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	15-16
		(b) Report category boundaries when continuous variables were categorized	12 (in table legend) and 26-29
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Sensitivity analyses are reported on page 14, 16
Discussion			
Key results	18	Summarise key results with reference to study objectives	17
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	17-22
Generalisability	21	Discuss the generalisability (external validity) of the study results	17
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	23

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.